var title_f4_33_4624="Inflammatory arthritis xray";
var content_f4_33_4624=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F53662&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F53662&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Inflammatory arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 275px; height: 368px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This plain film demonstrates erosive changes at the distal interphalangeal (DIP) joints (synovial thickening or pannus eroding the adjacent bone), as well as juxtaarticular osteoporosis of the metacarpophalangeal joints (hyperemia).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_33_4624=[""].join("\n");
var outline_f4_33_4624=null;
var title_f4_33_4625="Bilateral ovarian cancers";
var content_f4_33_4625=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F64042&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F64042&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Uterus with bilateral ovarian malignancies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 295px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of William Mann, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_33_4625=[""].join("\n");
var outline_f4_33_4625=null;
var title_f4_33_4626="Rams horn toenails";
var content_f4_33_4626=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F76809&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F76809&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Markedly thickened, curved, ram's horn type of toenails",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Atlas of Office Procedures 1999; 2:97. Copyright 1999 WB Saunders.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_33_4626=[""].join("\n");
var outline_f4_33_4626=null;
var title_f4_33_4627="Wrist flexion examination";
var content_f4_33_4627=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F75033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F75033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Examination of wrist flexion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 338px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pain with resisted wrist flexion with the elbow in full extension is characteristic of medial epicondylitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Neeru Jayanthi, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_33_4627=[""].join("\n");
var outline_f4_33_4627=null;
var title_f4_33_4628="Ceftaroline: Drug information";
var content_f4_33_4628=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ceftaroline: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?25/56/26499?source=see_link\">",
"    see \"Ceftaroline: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F11390165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Teflaro&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F10953358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Cephalosporin (Fifth Generation)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F11426126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Usual dosage range:",
"     </b>",
"     I.V.: 600 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Indication-specific dosage:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Pneumonia, community-acquired: 600 mg every 12 hours for 5-7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Skin and skin structure, complicated: 600 mg every 12 hours for 5-14 days",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F11426127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F11426124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     31-50 mL/minute: Administer 400 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     15-30 mL/minute: Administer 300 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;15mL/minute and ESRD patients receiving hemodialysis: Administer 200 mg every 12 hours; should be given after hemodialysis, if applicable",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied). However, ceftaroline is primarily renally eliminated.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F11390166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Teflaro&trade;: 600 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F11426096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F11426128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer by slow I.V. infusion over 60 minutes.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F11426113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      2.5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10953360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of",
"     <i>",
"      Staphylococcus aureus",
"     </i>",
"     (including methicillin-susceptible and -resistant isolates),",
"     <i>",
"      Streptococcus pyogenes, Streptococcus agalactiae, Escherichia coli, Klebsiella pneumoniae",
"     </i>",
"     , and",
"     <i>",
"      Klebsiella oxytoca,",
"     </i>",
"     and community-acquired pneumonia (CAP) caused by",
"     <i>",
"      Streptococcus pneumoniae",
"     </i>",
"     (including cases with concurrent bacteremia),",
"     <i>",
"      Staphylococcus aureus",
"     </i>",
"     (methicillin-susceptible isolates only),",
"     <i>",
"      Haemophilus influenzae, Klebsiella pneumoniae, Klebsiella oxytoca,",
"     </i>",
"     and",
"     <i>",
"      Escherichia coli",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F11426104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Hematologic: Positive Coombs&rsquo; test without hemolysis (~11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (3% to 5%), insomnia (3% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Pruritus (3% to 4%), rash (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypokalemia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (5%), nausea (4%), constipation (2%), vomiting (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Transaminases increased (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Phlebitis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;2% (Limited to important or life-threatening): Abdominal pain, anaphylaxis, anemia, bradycardia, dizziness,",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD), eosinophilia, fever, hepatitis, hyperglycemia, hyperkalemia, hypersensitivity, neutropenia, palpitation, seizures, renal failure, thrombocytopenia, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F11426100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ceftaroline, other cephalosporins, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F11426101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Penicillin allergy: Use with caution in patients with a history of penicillin allergy, especially IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;50 mL/minute); dosage adjustments recommended.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F11429548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Cephalosporins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F11426097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F11426098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Skeletal abnormalities have been observed in some but not all animal studies using maternally toxic doses. There are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F11426099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Teflaro Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (1): $55.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mg (1): $55.28",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F11426132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Obtain specimen for culture and susceptibility prior to the first dose. Monitor for signs of anaphylaxis during first dose. Monitor renal function.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F11426114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) 1 through 3. This action blocks the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls and inhibits cell wall biosynthesis.Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysis and murein hydrolases) while cell wall assembly is arrested. Ceftaroline has a strong affinity for PBP2a, a modified PBP in MRSA, and PBP2x in",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     , contributing to its spectrum of activity against these bacteria.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F11426116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 18.3-21.6 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: ~20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Ceftaroline fosamil (inactive prodrug) undergoes rapid conversion to bioactive ceftaroline in plasma by phosphatase enzyme; ceftaroline is hydrolyzed to form inactive ceftaroline M-1 metabolite",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Normal renal function: 2.4 hours; Moderate renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute): 4.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (~88%); feces (~6%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Biek D, Critchley IA, Riccobene TA, et al, \"Ceftaroline Fosamil: A Novel Broad-Spectrum Cephalosporin With Expanded Anti-Gram-Positive Activity,\"",
"      <i>",
"       J Antimicrob Chemother,",
"      </i>",
"      2010, 65(Suppl 4):iv9-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/33/4628/abstract-text/21115457/pubmed\" id=\"21115457\" target=\"_blank\">",
"        21115457",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Corey GR, Wilcox M, Talbot GH, et al, \"Integrated Analysis of CANVAS 1 and 2: Phase 3,Multicenter, Randomized, Double-Blind Studies to Evaluate the Safety and Efficacy of Ceftaroline Versus Vancomycin Plus Aztreonam in Complicated Skin and Skin-Structure Infection,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2010, 51(6):641-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/33/4628/abstract-text/20695801/pubmed\" id=\"20695801\" target=\"_blank\">",
"        20695801",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      File TM Jr, Low DE, Eckburg PB, et al, \"Integrated Analysis of FOCUS 1and FOCUS 2: Randomized, Double-Blinded, Multicenter Phase 3 Trials of the Efficacy and Safety of Ceftaroline Fosamil Versus Ceftriaxone in Patients With Community-Acquired Pneumonia,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2010, 51(12):1395-405.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/33/4628/abstract-text/21067350/pubmed\" id=\"21067350\" target=\"_blank\">",
"        21067350",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steed ME and Rybak MJ, \"Ceftaroline: A New Cephalosporin With Activity Against Resistant Gram-Positive Pathogens,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2010 30(4):375-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/33/4628/abstract-text/20334458/pubmed\" id=\"20334458\" target=\"_blank\">",
"        20334458",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16088 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-D4E9CFABE8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_33_4628=[""].join("\n");
var outline_f4_33_4628=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390165\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10953358\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11426126\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11426127\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11426124\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682548\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390166\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11426096\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11426128\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11426113\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10953360\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11426104\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11426100\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11426101\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298995\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11429548\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11426097\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11426098\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11426099\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322874\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11426132\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11426114\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11426116\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16088\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16088|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/56/26499?source=related_link\">",
"      Ceftaroline: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_33_4629="Ospemifene: Drug information";
var content_f4_33_4629=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ospemifene: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?24/58/25508?source=see_link\">",
"    see \"Ospemifene: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F16255099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F16255541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Selective Estrogen Receptor Modulator (SERM)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F16338124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Dyspareunia, moderate-to-severe:",
"     </b>",
"     Postmenopausal females: Oral: 60 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F16338125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16338126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16338127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild or moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe impairment (Child-Pugh class C): No dosage adjustment provided in manufacturer's labeling (has not been studied). Use is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F16255098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Osphena&trade;: FDA approved February 2013; anticipated availability is June 2013. Consult prescribing information for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F16338128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with food.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F16255083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of moderate-to-severe dyspareunia due to vulvar and vaginal atrophy (VVA) of menopause",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F16337718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Ospemifene may be confused with raloxifene, toremifene",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F16337735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Hyperhidrosis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hot flashes (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Vaginal discharge (4%), genital discharge (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Muscle spasm (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening: DVT, hemorrhagic stroke, thromboembolic stroke",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F16337724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Undiagnosed abnormal vaginal bleeding; DVT or PE (current or history of); active or history of arterial thromboembolic disease (eg, stroke, MI); estrogen-dependent tumor (known or suspected); women who are or may become pregnant",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F16337725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Breast cancer: Ospemifene was not studied in women with breast cancer. Use is not currently recommended in women with carcinoma of the breast (known, suspected or history of) and use is contraindicated with an estrogen-dependent tumor.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Endometrial carcinoma:",
"     <b>",
"      [U.S. Boxed Warning]: The use of unopposed estrogen in women with an intact uterus is associated with an increased risk of endometrial cancer. The addition of a progestin to estrogen therapy may decrease the risk of endometrial hyperplasia, a precursor to endometrial cancer. Adequate diagnostic measures, including endometrial sampling if indicated, should be performed to rule out malignancy in postmenopausal women with undiagnosed abnormal vaginal bleeding. Ospemifene is an estrogen agonist/antagonist with agonistic effects on the endometrium.",
"     </b>",
"     For women with an intact uterus using an estrogen without a progestin, the risk of endometrial cancer is dependent upon dose and duration of therapy. Endometrial cancer was not reported in clinical studies of ospemifene (duration &le;52 weeks) and the use of progestins was not evaluated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cardiovascular disease:",
"     <b>",
"      [U.S. Boxed Warning]: Using data from the Women&rsquo;s Health Initiative (WHI) studies, an increased risk of deep vein thrombosis (DVT) and stroke has been reported with oral conjugated estrogens. The following were reported with ospemifene in clinical trials lasting &le;15 months duration: thromboembolic stroke 0.72/1000 women (placebo 1.04/1000 women); hemorrhagic stroke 1.45/1000 women (placebo 0/1000 women); DVT 1.45/1000 women (placebo 1.04/1000 women).",
"     </b>",
"     Risk factors for cardiovascular disorders, arterial vascular disorders and /or venous thromboembolism (VTE) should be managed appropriately. Risk factors include diabetes mellitus, hypercholesterolemia, hypertension, SLE, obesity, tobacco use, and/or history of VTE. Discontinue immediately if a VTE, thromboembolic or hemorrhagic stroke occur or are suspected.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic dysfunction: Has not been studied in patients with severe hepatic impairment; use is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Surgical patients: Whenever possible, discontinue at least 4-6 weeks prior to elective surgery associated with an increased risk of thromboembolism or during periods of prolonged immobilization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Risks vs benefits:",
"     <b>",
"      [U.S. Boxed Warning]: Ospemifene should be used for the shortest duration possible consistent with treatment goals and risks for the individual woman.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F17917986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (minor), CYP2C9 (major), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2B6 (weak), CYP2C19 (weak), CYP2C8 (weak), CYP2C9 (weak), CYP2D6 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F17917984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May increase the serum concentration of Ospemifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Ospemifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estrogen Derivatives: May enhance the adverse/toxic effect of Ospemifene. Estrogen Derivatives may diminish the therapeutic effect of Ospemifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Ospemifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Estrogen Receptor Modulators: May enhance the adverse/toxic effect of Ospemifene. Ospemifene may also enhance adverse/toxic effects of other Selective Estrogen Receptor Modulators. Selective Estrogen Receptor Modulators may diminish the therapeutic effect of Ospemifene. Ospemifene may also diminish the therapeutic effects of other Selective Estrogen Receptor Modulators.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F16337720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F16337721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies. Use is contraindicated in women who are or may become pregnant. Ospemifene is currently approved only for the treatment of moderate-to-severe dyspareunia due to vulvar and vaginal atrophy (VVA) of menopause.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F16337722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16337723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if ospemifene is excreted into breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F16338130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for signs of endometrial cancer in female patients with uterus. Adequate diagnostic measures, including endometrial sampling, if indicated, should be performed to rule out malignancy in all cases of undiagnosed abnormal vaginal bleeding. Assess need for therapy at regular intervals. Monitor for signs/symptoms of stroke and VTE.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F16337747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ospemifene is a selective estrogen receptor modulator (SERM); it activates estrogen pathways in some tissues and blocks estrogen pathways in others, and specifically has agonistic effects on the endometrium. In women with VVA, ospemifene was shown to improve vaginal changes associated with the decrease in natural estrogen production associated with menopause (improves vaginal maturation index, decreases vaginal pH) and significantly decreased the most bothersome moderate-to-severe subjective findings reported by women (vaginal dryness and dyspareunia) after 12 weeks of therapy (Bachmann, 2010).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F16337759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: A significant decrease in vaginal dryness and dyspareunia were observed after 12 weeks of therapy (Bachmann, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 448 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: &gt;99% bound to serum proteins",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic via CYP3A4, 2C9, and 2C19; forms a metabolite (4-hydroxyospemifene)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: Increased approximately two- to threefold by food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~26 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: ~2 hours (range: 1-8 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Feces (75%); urine (7%; &lt;0.2% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bachmann GA and Komi JO (Ospemifene Study Group), \"Ospemifene Effectively Treats Vulvovaginal Atrophy in Postmenopausal Women: Results From A Pivotal Phase 3 Study,\"",
"      <i>",
"       Menopause",
"      </i>",
"      ,  2010,  17(3):480-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/33/4629/abstract-text/20032798/pubmed\" id=\"20032798\" target=\"_blank\">",
"        20032798",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Portman DJ, Bachmann GA, Simon JA, et al, \"Ospemifene, a Novel Selective Estrogen Receptor Modulator for Treating Dyspareunia Associated With Postmenopausal Vulvar and Vaginal Atrophy,\"",
"      <i>",
"       Menopause",
"      </i>",
"      , 2013 [epub ahead of print].",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/33/4629/abstract-text/23361170/pubmed\" id=\"23361170\" target=\"_blank\">",
"        23361170",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Simon JA, Lin VH, Radovich C, et al, \"One-Year Long-Term Safety Extension Study of Ospemifene for the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women With a Uterus,\"",
"      <i>",
"       Menopause",
"      </i>",
"      , 2012  [epub ahead of print].",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/33/4629/abstract-text/23096251/pubmed\" id=\"23096251\" target=\"_blank\">",
"        23096251",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tan O, Bradshaw K, and Carr BR, \"Management of Vulvovaginal Atrophy-Related Sexual Dysfunction in Postmenopausal Women: An Up-to-Date Review,\"",
"      <i>",
"       Menopause",
"      </i>",
"      , 2012, 19(1):109-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/33/4629/abstract-text/22011753/pubmed\" id=\"22011753\" target=\"_blank\">",
"        22011753",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 88428 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-422ACB6E1F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_33_4629=[""].join("\n");
var outline_f4_33_4629=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16255099\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16255541\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16338124\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16338125\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16338126\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16338127\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16255098\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16338128\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16255083\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16337718\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16337735\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16337724\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16337725\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F17917986\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F17917984\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16337720\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16337721\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16337722\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16337723\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16338130\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16337747\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16337759\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/88428\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/88428|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/58/25508?source=related_link\">",
"      Ospemifene: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_33_4630="Adrenal myelolipoma";
var content_f4_33_4630=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F72437&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F72437&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Adrenal myelolipoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 577px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAJBAYwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3n4ofEDSvhxoFvq+uW99PbTXS2irZojOHZHYEhmUYwh7+leYf8NV+B/8AoFeJP/AeD/49R+2t/wAks0r/ALDUX/oievn/AOBfwj/4Wp/bf/E7/sr+zfI/5dPP8zzPM/21xjy/fOfagD6A/wCGq/A//QK8Sf8AgPB/8eo/4ar8D/8AQK8Sf+A8H/x6vMfDP7PvhzxRqmq6boPxKjvL3S5PKu410Z12NuZeC0oDDKkZUkdOeRXh3izSP+Ef8Vazo3n/AGj+zr2az87Zs8zy3KbtuTjOM4ycetAH1/8A8NV+B/8AoFeJP/AeD/49R/w1X4H/AOgV4k/8B4P/AI9XxVRQB9q/8NV+B/8AoFeJP/AeD/49R/w1X4H/AOgV4k/8B4P/AI9XxVRQB9q/8NV+B/8AoFeJP/AeD/49R/w1X4H/AOgV4k/8B4P/AI9XxVRQB9q/8NV+B/8AoFeJP/AeD/49R/w1X4H/AOgV4k/8B4P/AI9XxVRQB9q/8NV+B/8AoFeJP/AeD/49R/w1X4H/AOgV4k/8B4P/AI9XxVRQB9q/8NV+B/8AoFeJP/AeD/49R/w1X4H/AOgV4k/8B4P/AI9XxVRQB9q/8NV+B/8AoFeJP/AeD/49R/w1X4H/AOgV4k/8B4P/AI9XxVRQB9q/8NV+B/8AoFeJP/AeD/49R/w1X4H/AOgV4k/8B4P/AI9XxVSgEkADJPagD7U/4ar8D/8AQK8Sf+A8H/x6j/hqvwP/ANArxJ/4Dwf/AB6vjmHSNRmIEdlcHPqhA/Wp18P6kfvQLGM4/eSKv8zQB9f/APDVfgf/AKBXiT/wHg/+PUf8NV+B/wDoFeJP/AeD/wCPV8iDw7dAnzZ7OID+9OD/AOg5py6CoLCTU7IY/u72/wDZaAPrn/hqvwP/ANArxJ/4Dwf/AB6j/hqvwP8A9ArxJ/4Dwf8Ax6vkhtDtQwH9qxdM/wCqali8OGcv5Go2eEGSZN68f980AfW3/DVfgf8A6BXiT/wHg/8Aj1H/AA1X4H/6BXiT/wAB4P8A49XyKdAb+HULBj6B3/8AiadF4bllkCR3+nlicAeYw5/75oA+uP8AhqvwP/0CvEn/AIDwf/HqP+Gq/A//AECvEn/gPB/8er5El8O3Mbsi3NlIynBCzY/nihvDOqAZS3SX2jlVj+hoA+u/+Gq/A/8A0CvEn/gPB/8AHqP+Gq/A/wD0CvEn/gPB/wDHq+ObjSNRtyfOsblcDJPlnAH1qhQB9q/8NV+B/wDoFeJP/AeD/wCPUf8ADVfgf/oFeJP/AAHg/wDj1fFVFAH2r/w1X4H/AOgV4k/8B4P/AI9R/wANV+B/+gV4k/8AAeD/AOPV8VUUAfav/DVfgf8A6BXiT/wHg/8Aj1H/AA1X4H/6BXiT/wAB4P8A49XxVRQB9q/8NV+B/wDoFeJP/AeD/wCPUf8ADVfgf/oFeJP/AAHg/wDj1fFVFAH2r/w1X4H/AOgV4k/8B4P/AI9R/wANV+B/+gV4k/8AAeD/AOPV8VUUAfav/DVfgf8A6BXiT/wHg/8Aj1H/AA1X4H/6BXiT/wAB4P8A49XxVRQB9q/8NV+B/wDoFeJP/AeD/wCPUf8ADVfgf/oFeJP/AAHg/wDj1fFVFAH2r/w1X4H/AOgV4k/8B4P/AI9R/wANV+B/+gV4k/8AAeD/AOPV8VUUAfcvh79pXwdr2v6ZpFnpviBLnULqK0iaWCEIHkcKCxEpOMkZwDXt9fmt8J/+Sp+Df+w1Zf8Ao9K/SmgDwD9tb/klmlf9hqL/ANET157+yPLqkHhf4lSeHrX7XrAt7QWkO9U3SkXAXJYgAAnPJ7V6F+2t/wAks0r/ALDUX/oievkDQvEeueH/AD/7B1nUtM8/b5v2K6eHzNudu7aRnGTjPTJoA+uPhl8L/FXgDxb4S1SGK0vILixks9bSACJ4Sx80O7NK3nMJG27lA+VAMV8ufFj/AJKn4y/7DV7/AOj3o/4WP44/6HLxJ/4NJ/8A4quau7me8u5rq8mlnuZnaSWWVyzyOTksxPJJJJJNAENFFFABRRRQAUUUUAFFFFABRRRQAUVraRoV7qatLEoitk+9PJwo+nqfpWvb2en2JQwxfapBw00w+VT7J/jmgDn7LTLy9GbeB2Tu5+VR/wACPFaUGgwo2L6/RWB/1cC7yfx4H86vzT3F18k8jHb0TsPoPSmGI8bQRjv6GgBI4NMt1UwWTTsoJJuHzn/gIwKtR6ndQBltvJt1dekMYTP5ColTDEcFwOMd6csacbeeODQBExnmK+ZLIztzksSM5qKSLfGWAYhTjp3PWrm0fZnZRgg5pqkAEE7QRkAenrQBWMB3Zx8xGOaXy9qjbgt3qfnePmyPr196aygMwJ9x7CgCDYSpDY5HT1xTmiOIww7Yx/OpM5jII5I+Y+gp77WRctgDjmgCv5YABBBcjnjGaHTByDhieOOlWRhW56E54PYU1v4iwy3cUAQGPcxwv404SyBgySOu3uKfkMoGCMHB/wAacVCqPujn5hnrQA5b+9TKrczA9fvdaHv55yPtSW91xz50at+GetRuEGMtknsKXBAPAX6D+VAEMtvpcx/fWbwHPL28hxn/AHWzVSTQVkJ+w3sUh7RzDyn/AKj9avqhLZPIHQHtTCOAcE5HAxQBgXun3diwW7t5Is9CRwfoehqrXY2F7Pabo1bzo34aNxuX8jxUV1baPeqzNDJYT9AYvmQ+5B6fhQBydFad9otzaxmaPbc2v/PaE5A+o6j8azKACiiigAooooAKKKKACiiigAooooA6v4T/APJU/Bv/AGGrL/0elfpTX5rfCf8A5Kn4N/7DVl/6PSv0poA8A/bW/wCSWaV/2Gov/RE9fFVfav7a3/JLNK/7DUX/AKInr4qoAKKKKACiiigAooooAKKKKACiipbaCW5nSG3RpJXOFVepNADY43lkWONWd2OFVRkk10dlpVvp+yTUQtxdEZW3BysZ/wBv1Pt+dXLGG10SB/JYTagV2yS44i9Qv+NQlFYDkFXPJxyp+tAE1xd3ExJMxKkZCDhcegHQVGuNo4yM54HIPtT1QkRliAQeTg1I5QYePnPHTg/4UARxQZUNKxXb8wPf6VKzK2SOmMEZqExs75jJYdQpHNbmleGNU1Bg0du0UJ6PJxgd6AMZBwuMgqe/8qkS3MnzKVUkkFScDNegWPgKFFQ31wZCeqxjgexP4VuWXh/SrUqq2iHA3bnG7+dAHlsdldMFVYi5ODiM5/l2q4vhnVZyBHaOEyeXwOv416tDZ28JxbwIrf7OAKdIqIHE7BFxkEDpjtQB5ZF4M1Vss6wxgcYaTnFTx+CbxgWe5hQnA6E16LdoTAqho04G+SXjisHVfEulW5P+khpVPAgG48+hoA5WXwhcKZAs8ZKEEcEZJ7Vn3vh+6tZmSWa22qRyz4A/OtTUvF1zcoUtIFgT7oeQ5b6+gNcvcl55vMurh5HPcnOfegC2dKnwNkttKR3WZeuKZc6bdoGb7O/C5LL8wA+oqW205rhFeKHCDjPTJpJUu9PIMLyRgdw3NAGfv2YzkMOQpHvTcYz1Gf1ro9O18IcalbRXCH+PbzV6M6PeyMbe3hZj0L/IR9KAOOcnGVH4460OR8meSOeO1dTd6JZfLujnh38cHIz71Qk0FzmS0lSRQduxhtINAGOSVzg/MecDn8KELLliQB3PXIq3Ppl1bFmeCQ989eaqsNq4kcj29PagBqqrgucqgPHFRvGS7bR8q/oPepJOqAEkngAdqYULAjnrzjv60APiLWr74mZG6g56/hTbq1stR5mQWdwx4ljX5XPqyjp9RUilGK71AIPc5pNgHOMkHqT0/CgDntR02509wtwnytysinKt9D/k1SrsIZmjDQmNZbZyN8T4Kn39j7isrVdHVY5LrTC0tqnMiHl4fr6j3/OgDEooooAKKKKACiiigAooooA6v4T/APJU/Bv/AGGrL/0elfpTX5rfCf8A5Kn4N/7DVl/6PSv0poA8A/bW/wCSWaV/2Gov/RE9fFVfav7a3/JLNK/7DUX/AKInr4qoAKKKKACiiigAooooAKKKKAHIrO6oilmY4AHJJrsLW0Oh2zxpuOoyqRNIn/LEf3B7+v5VW0KzXTrVb644u51P2ZSPuL/f+vp+dTsdqZzvkbkOvf1oAYCjEkbg4HBA4PHpUqoUUNhQ/XaO4pYUBYvtKk/db0NWraznuZVCwu0/cKuRg/0oAikcyqP4VAxjbjFT6VpkuoSrFaqxGcksuB7/AFrSOiJaIXvzm4JwkKDdn64rpPC1nrCTtMY4YUIwFdOPqPSgDR8P+GbKyi33ZU3eQVz2x2/Ot97kuW8hgrDgq3C57gVSaxYkSXt3nGCFQbQD6jvWhbxoykx7w2OHYdcd/egCFblT83nIAw+524qGfV7CNRulV2xwMZJ9QavS2ME8g82NCpHzBflU1LFa28SgRW6Rn1VckUAY8d9czktY6dO7npvPloMfXk0jWuu3vM9xa2UJJ4hXe35njNdBwBvIIBPU84pGUyHdjD/3Se9AHPN4Xspwf7Rubu8BOcPKRz64FUrvwPpciEQCSCQnG4c4P0rrMKc8k47Ec03hwSSTn070AeJa/os2mX/2eVQQeje3Wo7LTGZo5ZOInOFzwWGa6b4kXol1eKywFZUBcjis6S9UXcUSkeTCgA560AbkcsNvbqo2lQRhcdK5jXp/NkIGDk5pb/UuHWM7lODkDjPrWSw823knZgCDtxjn1/KgCqrMXOCfVR2/E0oZRh+jYxleeaVwFVBuJYnsKQow4UYZucY6CgDattVvLHclyfOidQxy2Tjtgium0LVLG4mVYh5TOcEuRx6iuA+fZyW24+9n9KeWaM9CVAUjnnPoKAPbIYbWUIiSRYA524Py/wA6z73wzpl5I2xl+bqvVs9jXm1lql5buA4Yq2O/IHsa7vQfEWn3Cqsp8m4X5fm4DfjQBzeu+EZbVmkgBljHXb1rmnsponxsI/2XyCK9W1efFo8cSNE2Q3mFdwYfUViWRSedGmChQcsvDZoA8/CspO4AY/D9aaHI25Hy56eteopoGj6rE6SxiO4HO5ejelclr/hG701WuETzYCeqnH6UAc5IivzG7MfTH8jSW7y2siyKxRgenXOfX+VHJbb5gTHXA5J+vpVgMsoAZgsh4B3D/IoAytb0qNomvtOXEYGZoB1jP94D+7/L6Vz1dnFI9pcK6HawznPQj0x6VjeINOSEi9skIs5Tjb/zyfup9u49qAMWiiigAooooAKKKKAOr+E//JU/Bv8A2GrL/wBHpX6U1+a3wn/5Kn4N/wCw1Zf+j0r9KaAPAP21v+SWaV/2Gov/AERPXxVX2r+2t/ySzSv+w1F/6Inr4qoAKKKKACiiigAooooAK2PD9hFM73l8pNlAfmUdZG7IP6+1U9LsZNRvEgiIUHl3PRF7sa6i6njKwWllB5cNsu1Aerk9WPuaAGyzSXU7TO6SFsHOPuj0x6YpRC7SKsce92xj+Ic0Q28ksqwW3Ejcnjha9E8OaJDp8ALKr3AG5pv4AfT2oApaT4fFrbJNfoJZ3/5ZDoB71sIbieUW+kRRx25GGkCcr6inW1vNe3OwCR493zknnH8j7CuktbeG1WOGIhm+905P+970AUbDSbLTog0kbSSZzvPLMcf54qx5d/crsLC1gI+XpvYf0NaKxc7iB5p7nof8KchIXDYK9Dnn9fagCtZ2NvbHcAXYjG8nLA1aTAfa3BA79qRQFyQ24YJ+729/WkHP3c4PX69vwoAGQElcfIeeB69/pQ23ywQQGHHPf680KFRtgYf73pn+tKBICFwHUH5vU+9ADckHdtYoeMKKcQoOS/zHvjoKRG2/KpOB93cetAxnrx3Hp7UADDcAwPybeMetJJP5aPI2AU+9uHb2p6kJkoVBA59DXI+NtbFraNaWj5aUYJxwg9aAPONYvH1DWry8VchnODnt0AqqHweDls9z0PtRKAkmIUDLjnB49zWhplok5a4YjcSFXuKAKUVtNcuwROF5ZhnH41HOqIHRTmQHGc5GPatjVr1fKW1tGC2yD5mGPmbHc1TsrJZY5pbgosSL95zjNAGWgOGYgtHjBx1z6H8aHO4khCP9rpmustdCFzaJdRBFif7rMeCPWsfUrGJSwguFlZOCqHp7cUAZUQAIIA2jng9KYSvJDEvnnsAKcy7XYZUE8ZJ/pSYLKMBgvcgc/SgAZyVJJYkHHoTVS81S2UBI4n3r1KPgGnag8lrA7xEKcbc9+f8A61c7QB23h7xrdWEgRG2p02TMXQ/X0r0TQtW0PWmR3RLO+6EdN349xXiGm6fdandpb2ULSysegHA9yewr0A+ELjT9Jw8pmuY13MgGAO4AJoA9UtoHtSrW8cciA9uOtWJpY3DC4RgMEYPIwa8U0Dxle2hEcNy55/1M3IP413GleNra6VRqkJhcjlwfl/KgDF8UaXaC4L2T5BHpnb7H2rlpo5IGxIBu65PAr1rUNEstZtRcW7ooYZV4jw3+9XI3WhC1ka2vFYeZny5AMgf/AFqAOWG6dTnlsc5PNFq0QMlvd/PbTjbKOm30YD1Bq7qGmXFi4baxQnKlPun8aozpuQsgC7jjA9frQBy+qWUmnX0ttKQSh4YdGHZh7EVUrr9YtTqGkeYObqxXgY5eLPP/AHz1+hNchQAUUUUAFFFFAHV/Cf8A5Kn4N/7DVl/6PSv0pr81vhP/AMlT8G/9hqy/9HpX6U0AeAftrf8AJLNK/wCw1F/6Inr4qr7V/bW/5JZpX/Yai/8ARE9fFVABRRRQAUUUUAFORWd1VASzHAA7mm10egWf2a2+3yj98+VgH90d3I/QUAXIrUabZ/Y49v2lzmeQfMCeyfQd/eprSKZm8qNMyN0XOMD2NQQASSCMxqxY9iM/Wu28LWUa7pFGShwOMmgC1o+h/ZFRNyiWQ5djyyr3FX7mV7xpEgAS3QhN+ceafTHpWhBpk2s3Tx8fZUXM0vIOOu0GrUFmiSecQFtV4jXGCoHcmgC9YW62dlFFFgytwQOhPfr0q5FGkce4MwcYBJ/xqO0LTr9ocHaR8p64Hv8A41aKkZaJd5XkjGfyoARvmXc20KRwcfy/wpcqf9ZkgDG5f50jlBllLK2c4x0PrW69hbR+Bf7RMam7OpeQZdxP7vyt2MZx156UAYKr15GT+Rp6hB90KD2DcfhTAST8vzA/eGePbFBXjD9PTuKAFVA7EMB5Z4xnp9P8KUcBcksT1pFUsArkOAMYB5Hoar3UrpIuDh1+8MZBFAFvIQkgjbj05BpgO0bmUEdmxj86ZFdCTOSRtwS3U+xxRK6AgtKBkZxg0AY/ivUm0/S3mhwzkfLngZ9a8mubx5ZGeY75W+8Tzx/hXa+NNShud0SFRGMjH415+d9wzCHcXA5THX16UAMCvt2KxALYwDg1aLS2cO1Qu5umB0rRe2EnnR8kwRqQAuDyM/0rNtWMhdJlJQ5we6mgBLAK7lGRvLVssw6A/WtDxjpVzPp9lHbZW2yWfaOp9TVnRIES/jRhmMeo4z7ivQpbVJrfaVGwcMuMZGKAPKb29ubu/wBC0rSZyXtots2GwvXncPoP1q/b2caPfNFtSENjO05Ld66bTfCWn6Zqsl8BKJnzy7ZAzVHXpoLKBooF2hyWbHGDQBxMsKs5yFYZ7N60u4DIVSDwGYjGKHlaVzIHIAznAxmmIDIY0jyO3zc5oAju4/tVtLD8ucHaR0JHPX8K5eGJ5p0iiUtI7BVHqTXcy2SWK757uN267YxyvtXMRsLPxFBLbAFRMroD6Z6UAevaPaQeHdJjsrVsyBv3jMn32I5P+Fb0NuLjRyCfMQqc5J7f571UndASCF7Mw4/Sqd9rUNnaQlLiNYDkbMbt2elAHh+ox/ZtTuY0DJ5crBQeoweK6KFi8UbSxnftBAIzg/StDWrq2vrmSRLFGllPzzMuWOKzcOp2gsXxkknmgDZ0jWbnRroNZSlhn5oXJ2/l2r0zTNSsPElhgBRKo+eI9VPt3xXjq4TzM/MGGBgdP/r1c0XUJ9NvYp7bcGUgHB6j0NAHpBRbOdrK9hWS3k7kZwPUDtXL+K/DraS5uLYGS1k6AYwp9a7ucRa1oyywZVj869yD6H+VU9GmW8sZbK6O7A6HnaO4J74NAHlNvMYLlJI8q6cupOQV7jHuK5/xDYLYagRBk2swEsLEdVPb8DkfhXY+JNPk0vVZEVdqHkcZJrMurf8AtPTJbcDM8GZoOpJ/vLn6c49RQBx1FFFABRRRQB1fwn/5Kn4N/wCw1Zf+j0r9Ka/Nb4T/APJU/Bv/AGGrL/0elfpTQB4B+2t/ySzSv+w1F/6Inr4qr7V/bW/5JZpX/Yai/wDRE9fFVABRRRQAUUUUAX9Hsvtt4FYHyIxvlI7KP8en41v3DvPLuUER4CqqnGxR0AFM06A2WjQ7SBNdHzWzgYUcKOevc/jT4w78ycr6AcH/AAoA1PDlk096qOAM/wARHAHqfT616NY2/liOC1O+TO1FI/rXM+EbXZBJcMzBHGFXH6V6F4WtkuLxpxwkQ2lSMgetAG5cJFpOkxWg2LJMMucdfc1xl/PLeammnW7FkUB5GAxgV0GoX8UktzcJIPLQEBT0AFY/hS3ZorjUJhH5ly5KkcbVzwMUAdAgEK/u1cIFxgN1H0oUDAZeD3w2KGwhEeVxkEBTinSEsRu2A9AVHBoACGZ/uNlfvduPUV0w2D4ZAgEj+2OmOSfJrmMbVY4O3PBByK6Zsr8MMA8/2xxt7/ufX+tAHMv80WV6E5wDnH19DTN2WOEyR+vvUgZpCSuE7HA+9+NCBQcBSwzySen0oAZFtkBLjOOh6A1V1It5IADZHbviru1du2MfJ1AJ4/8A11DeRGWEgFt3Xd3P5UAZCXCMqujEe5HBqDVJrgWbiGRQoGTz1NWGLJKwwScDqOaayKxOQST94HAB+npQB5LqErzzSbsn+Ft3Ge/51BaEyTIYmbzWOGHT8a0/GNq9pq823hX+baAMD/Gs2ztZbu8hhgi/eSN/yzA6+poA37e5TLF4ys6L5bAjAYVQg0S9vLkG2tGEJP3mBGD7e9ehaTolrp4UPAv2kcu7HduP5cVr7nZVYKgUDDHOOKAMXQNAFhaL9qRGn6sM/pWyyII/3ZZCCMKDkGkGTneXBA3Kwbt6UzzH3fdwwPTjn8aAK986JG5UfOB19fcV5z4hmNzchXb5QOd3evQ9Q2C0YtsGBk/L1/xry97km/d3IXDHLE9cdKANjSNEWbaZVDjGAOma1ZfCkLpypDDn93kHFR6DqUJbbNKSD03H9K7WMxuqnIAxwoHI+poA8w1TwzPbsXgU4B43HOP8a5DUrRvPzcxbGz2yMfT3r3m6ijmGCAdoxxkD+Vcfr2hxTKZIowSCeAMgfWgDmodelkiEblnAXblyPT1rPvbtrpkPy7VXaAp6f41FcQtaymJyO5GF/lUB5QDcfXnr+VAE2AVKMjAk546kUyTCnABZyMYUk4piOuQisy+u1untUpXcyhQVABO5vr60ANjyVYnLY5GcZoVkII3I4XjAG7NWC0SMyqjMpGTkY3fj3pkSPKxVcRgD5c8AfpQB3Hw+1EhGt3yV9NuP/wBVbWoRyWV410mfkbJHbBrg9Bnkgvcry+emSK9OjiF7blptxLpjjmgDK8WWaaxo4uItpkTnKrk4x3NeYRN9nuBIN3mocqxbpivUtDmPk3FpIRmF9u3+8DXn/ivTWsdVkOY9rfMCozxQByPiS0SC+E1uu22uV82MY+6f4l/A/wBKya627i+3aVcQE5miH2iIAcnA+Yflz+FclQAUUUUAdX8J/wDkqfg3/sNWX/o9K/SmvzW+E/8AyVPwb/2GrL/0elfpTQB4B+2t/wAks0r/ALDUX/oieviqvtX9tb/klmlf9hqL/wBET18VUAFFFFABU1nA11dwwIMtK4QficVDW54Pg83Wlk+XFvG8xz7KcfjkigDoNQlgN3IpdGUYSMMuMKBgVHCVQr8mfMO3huM/SqkbyZKKXBB+YMlaekWsk93Ch3cyDocE/hQB6FpMaJbwxuHAjTedwyB+VdfoSR2uiNOjENICRjIIz7d65ia3mSaVYQHVtgALcjsa7PXYVtvDcaSQuhCgbg3SgDzvUbm4uNTh0m2ztmcGRsDKqOoruo1SONIwu1FGBgjHFcV4EsN99e6ncCRm3mONnXqR1PWu4GVyGCqMdCD/ADoABjgDC4HyselMYkHCDJxzj/OKeSPukDcO3TIpCQxG1DnB4JwM0AIT5ZxIXXAyfYetdSNn/CseCrj+2OCD38jtWFo8MV3qlva3ZNtHK4jEu0HYTwDjPIzjPPSvTD4Dv/8AhF/7JFzbbzqP2oy84CeVtzjH3s9v1oA8oIyOCBx1IzmhI8/MFJOCcZyPy71c1i1trPUriC2n82KJygmIA8wjgkDPTPvVPDqu49+6+vuOaAHcHbtUZbvkgE+x/Sm4DADdtkft2pymbAHEiEHKjI3e/NNLEjc4AU9M9R/jQBlXK7Lhg446j5scfh2qFgvUq+09MMTWjqEIMauFVgp6EEH+fFZt0DHvkUyRsOSuMg+woA4Txer32u2tjbRiWRlAHIzTdO1nQPC+pvY3M8lxdA+XNKqnZER2B9umRXR6JboUu9VuAWmuDtiyPuKOOD1GaoN4U0O6v3uru13TMd2A5AY56kdKAOmjhg1B47yOUrIAADvzkdjUjMqyMlzCEc4Ax/jVFUSIL5X7vbwDjJX247VeW+jS0keZS5VS/wBQKAFAjC7fLwwOck9vanhhHuBGxh0bPH44rnl8R3l5n+xtLyAP9ZK+4D+tOvbLXr23HnSmJjxIsWAADQAniTXoLW3e3SRTKylflySc/wBK84kJEhyNhb+FgcZ7816LpvhhLWBHaZrh84cuTgis/XPCKCCeaKRlKggqAKAOe0m0SZWm88LJEpdpDzt9qs2fii4tZDG00jA9+Tx+NYAmMB8qU7FxjDDbmoGZgCGwCOd+7igD07S/EVtcRKGm57Lk5J981cvb6GSNh5irgdAOa8phm+z/ADJIzMTzjp+NXjqd01sRuLRE4G3Jz70AO1sBp2ZPlIPUkY+prJkRsgAoAf4sg5qxJJHKAH3cLxkCo42VXG0HjoNp/nigBjRYQ42kEccDn6Y/nT4kCquV2qDk4Gf1qxZr9plWOJRIW4JZT1+vpVm/0+5RWlDL8noegx9KAKLAI7MhwehC1AUdHTcI/vYG8nPXrjvU1tdRzZW1lJfq2W+Y49hV60treBDczv8AOPuIQNzH1xQBWVfJu22b25HC8A17D4bZX0+3IGB6E4A/CvF5AHO/azhmySxBNew+DXV9EtdpDNu24A6fjQBU1GJ7DxTHIIx5FypVivIyKx/iDpjSQC4ILbP7tdt4qgLWNrJghlkz14/Guf111uNOkhYow27uB+dAHlNlM9tcRyqrKVbc5zkkdxXPaxaiz1O4hUERhspn+6eR+hFdDcbRKyBWC54FZ/iVN8Njc7gzFDC2P9k8fof0oAwaKKKAOr+E/wDyVPwb/wBhqy/9HpX6U1+a3wn/AOSp+Df+w1Zf+j0r9KaAPAP21v8Aklmlf9hqL/0RPXxVX2r+2t/ySzSv+w1F/wCiJ6+KqACiiigArovCcZNvqkqht6xKikf7TD/CudrqfDYZPD9844D3EaZxnOFY4/UUAWGZiP3xfI/hKnIrZ8MrJ9vgMOS2/cOgP51l4ZGBYKD23Eg10ng+Az30r52sIyQ3GAfcdP0oA7/T4hea3bLLw7TICVOcAHuK674jEReGryWEkeWhwp+Xt78Vk/DnTF1LxNY2iuglEbEuR/EB+ldN8SdHlg8G3Yus75rlIYVXndlucd8AUAcP4Vs1s/D9pEg6qHcDjBPPNbG1dp37D1HYYpqI0cKxbH+TCgsuCPxoG4sTvYnupXNACKu04ddq+xwp/H1pwywYxu4X0Jyp/EVGyEKzZPHPGD/OmTPbxLm4dVA+6WYAH8OxoAk3lAEfkf7R4H+FeznxaP8AhXP9pCT/AEzZ9lznnzcYz9cfNXz1c+LdJgyoufNfoU3bqij8bWBh+yiaWOFn37N2cN0zj9KAOmBUM20Bh3wvBP1pDtLYj+Vj0DA4qjbalZ3iho5d3ThccCrJcN9xwyD+EsMflmgBzJIGDEbgeTjOB+ZpcLDkybEJHPy5FACsTtUbR1IPI+lKFIVmUx7RyM4z9MGgCG7jJt32He2CQRzyO1eb674lDW/2aKGSO4ztbcT8pHHAFemD+8rbMDO0Lz+BzXl3jCzkTxKBGvEwDjkYzn0/pQB2empFNpMUUZVyqDH/ANenJaeWCZgi4z96qthI1taRieLa2OcIOD9e1VZbS71VpI7W4TyywZmIxxjJHFAGkWiij3bVcD+6dxYemPSnxWTXkJadfs8R+YQJyx78n+lXLa18mMk7ZSAMrjgfTNTGMIfmjBJHTPH4UAJCqkbBEE2DPyjAYfhSRPuAHlvnsCuMD1PPNIxjI+VzkDqBzj09abLJHKwTzIg3AIbkr+lAEvLoWKEx5wM4/MUx4RIjiX7noeM/p1qVV+VSCgJ688/h7UydAu0hVKEYxnH6d6APOviNpK29zDdxxoocbG53Y965NUnldAsQcN0OePb8K9T8V6Uuo6cbeJ5IWyB8oGM56+tecX0Fzo0z2c6wzFP41PY+59fSgCWFLaxAlutk9x/cTpST6vNc/wDLKBYc42beSPWssmadhmRiMcAkA0rRpHxyWA3DHUfWgAkBJBHAPT/Jp8VvNJgKsjjuGBwB9ahmZEIAYhR2NXtE0e98QeZb2cwtkKn52HUd+hoAw18RGyusWkSvEvBYsQX/AMK1PEfiR9V0dINN064gRhmeTGQfYEdq66y8OaPoMccwjzOgINxL8+T7L0HtU1x/ac8lv9jCtYZzcK6jcyn0A6YzQB4vG7xSK8bFHU5BHBFdJHO86KVYMp5LOf8A61dP8SvDcbWKarp6JuiGLiNF5A7Ma51IjDbQK5xIsSkggnHAoAcuB8wB3Ade2AK9V+Hjm40RInLkrJ/CvavJg5HG5WXOSP8AOa9J+F10ZHkgbIycjA4NAHoWtJjS1jKgkc8cDrXN3EAe1kZldyVxndgfyroNdfdbRquMH+Hb/wDXrBmcu8p3rsjjOd3c0AeRaljz3CysoBIJxWfqYWbRJ9uSYZUfLAg4OVP64rSupMzzHzNxLHIAA/KqsoWTT79CSQYS2PcEHr36UAcjRRRQB1fwn/5Kn4N/7DVl/wCj0r9Ka/Nb4T/8lT8G/wDYasv/AEelfpTQB4B+2t/ySzSv+w1F/wCiJ6+Kq+1f21v+SWaV/wBhqL/0RPXxVQAUUUUAFdp4d+XwllX2s18w/KNf8a4uuz0LA8HZIbAvn5Ujj92nagAMZBLS+ZgnkYGD+Fdz4CW2eW48x1zt4BPIFcLbxiacKWfJPcdq9K8KQRtpU11szhSgJXjAoA7jwbqP9j+JbK9LAiPcGyMZBHtWt421uTxHq1qvmlYbdy4UdCce9ctbF3tZJcJyQUAPUetWNPUPKC2wNjtISvWgC8TwNyvsPBUEEfWmlgw+QltvYjIA9TUnSMFeMdh/nmuT8a6+dKtzbWfz3k2MErnYPr60ATeIPENno4KsElnPKrH2Pqa811fV77VJGkuXdkPCoOF+pqMpNM5klBd+d56n368GqxjZH4G0AAgbcYoAYrmNCG3Dn5Qe1KXkz+7O3oSScH8aSQMvLFXB6sDu496jXCkhd8aD/a4H4/0oAvabez2qv5UwUNwTkHipBfXRkWRbpwfr8v8A9aqlmpaGeThkQcMGBOO1EsXy7lyvTI5GaANW28Ranbl8zSK+4n5m3D+fStm08Y34RWnMKkf3zgGuRjGMBX4PLfNyR6VLIsJfMa7Vxg/NuOP5UAeiweLGKeZLZsshGMo+Afz4rA1DVkl8R211dwGKNBhlb5t3pXP6dfy2TAYV42GGikPDD29DXW6T9muDb3EFuFVG/ewMTmP3+lAG8l7Be2+8RTG3IwcI3T8qq6aILW7nktLoeWTym3lSPY1vrtZF8uTapHBUYzntioL2yW4VjsCXCniRAMj69/woAtq5kUlgWY87wuOPekJYjaQWJPQfw+9cst7cRvMjyqs0LbShPDe+2s3U/EOo7nhRY0mA+ZlH3h7UAdlPcfu2aN1dF+ViFxjPrUSCLYZYlVnH+139vavNzqF4kTIsokVyGbPXI610XhrXY7hkgvMLKTtKjgEeuR/KgDYs7+9bUI0vUWCCRwruByPxrorpDA5SMmaPbuVmIUj29yKzL2CB7dnJMkaEHDse3PHfNWYpBJCswH7tl+VWHT2NADJ2UBjlQgG4hnBrzvxJpL3N1Nf79qk/LuXIx613V5bzvZt5TOC5DDPQKP5VzniWWcQQxJM02/5WXaOPcUAcnDbbIx5jBuOApyR7880y6SNY/nBVPu5I+YV0mo6Y0Js4rQOHlGASc4Hc9KzNZ0PULOAyBxNlgvyYHWgDnIU84vsTleSA3HTvXT+Bre2nvZorxmLbEMS7yDkHPbt9ayLvSL3STHPcIMPw3Zee3B5pthO+n6hHeW7KArc/KQSPSgD1+WJHRo3t4njbqrYP5D/61Z8ukQSeaU8uEN8wYNznHTAqPR757+3N1DmJTwCXXJ9sdvzqxbXd0sw8y02clQR8xDepwcAUAZMumC2eO8e5CW5Ty50mYBCueCQTiuF8WyWs2t3DW0wkgcKyGMjaRjqAO1aHxWu9dxs2p/ZSkFiqg7m/2h0xXIWtzLc20c8xjSQrsU7NqnbwOAMce1ADosBgEfLf7SFQP6V1fgGd08QQIzj94MfKC2f6VyySsWyZAx77TgV1XgRA3iO0z5r7VJyemKAPXNQUzR4RN6kcZPP51zd2nlrPyDJsKgEEYHeukuXXDDjceemMe3vXM6jATbzqpHKEszcfgBQB5VKFxN8pCbiemc1ACxtb3Dk/6NJnIOcY+lSMFWSQ5VDnPAz/AFphJFlqDtIXX7OwHBOM4FAHH0UUUAdX8J/+Sp+Df+w1Zf8Ao9K/SmvzW+E//JU/Bv8A2GrL/wBHpX6U0AeAftrf8ks0r/sNRf8AoieviqvtX9tb/klmlf8AYai/9ET18VUAFFFFABXYeHCz+Er5VwDDdo2Tz95SP/Za4+uv8Ch5rDXLePBPkpMAf9lsZ/8AHqAJ4DIEXeBkngjNd74YukbT3sTcAbSTjGc57f8A664fy2M6je+4Y5K5A+ld74GS382dJY2kmJG3PIIA9aAOos4VGk/Z/wCLaML/ABc1dtYxGfkBUpwwPFOjHXaqFWGCFFMtZXLSKGcgEZUjNAFiXIiZm2RlRnDHGB35HevIdXum1S+u7h5XILfIjcYA9/evS/Ee9NIulVnEjJtGBgfhXl+nW0sd0rTLlFIALHBxQBPpipdW48rO9OGUjg/Q1m3mxXYEpuDYAz39hW/cxw2HmeTKI2B3HaO9ZE8ss8pkO1lzwNpxn396AMxlZsEKAF6h4wf5VFIuSGHyvnkbO/1Naw3x/KkRdR1O3HNQFEbLx7Sc4K54H9aAKtmC0bgOuWyAFIX9anhzICMsmeOU4NWbRVMm8lcKvzBeeO1LJPFvXaxLHIJzkY9BigBscC7lDKBg9+v0xUz228bfMcd1yQAM+3eoN6mM4LMxP8I5BpqEOr4k+bqSRnH5UAWI7RYQA7Rue56E1s6c62MgnVnZFP7wHjcp65/pWKCsYQMHJ7dOPwq1dNvttyzgHqMLnPtjFAHoen3cLLsVvMjzyM4Kk9K0cghVYNsP3SeCPrXm+m6jLHpAmjfEiEw9MMe4/L1rSTVZJ9LaOGZyWGCxPOT1GaAIfEV3FD4hdmjkKFAu4NyXHHUVk6XaX2q38azTh2PG0joO36VPaWWp6jIsUNu7GMYDNIcD8a6/w3oR00ma6fzJ2OFCtjH0NAEGo6FZQabIJGXCqTnqenQ/pXnPlMkw2MqFSSrKMBSa9N8VzJHDBbq8m2eQAyY+6O/JrH1bRIbgrHZosIGCzt1PuKAOfm8QalJafY3dZXb5CSDnn09q7Pw357WMaS3JnlUYy3GxfQ+tcrcaE66lJGuRAU38E/MPrWnaXk+lQGOQksADGxAwfxoA6i/W4ZIjaZ8zrkDtVSwjQyfaZXW5lI5fIx+pp1hqsc1v5ksjBgOSwxz7DNZd5cyQ3lpJtQ2spKyEttIOeCRQBu26K10xePBI4A5wPSs6/ulvb5YAQ6QtkpG2SPqK05ZlO3yA5U8Z67eKoW1pbW95NMqB5DhmB6mgCrqunpfNEZ0AtEOWJyOa4/xRpa2l6DaASq38OThfevRb4C4tsxyo4IzhiQrAdq4TxNK0u3ywtuV4+V88/SgDpPCkMFz4MMBKSM+5HTdtBb3xzirdolvaNDbRbQeuwyZBx6ewrjvA+tLp0z210zfZpzy7/wALfXNd2beHes8cYeNUwroOADQAxLCLVIJ4p1jlgkUoY27fnXlniqO2t7mGxsIEWOAFcHtzXouvXI0TRdUv7VVabydyqDuHPGT+deOeE7S91jX4mzLIGf8AeP1oAtxKflDhRg/5x1rpfBDtH4hgJVEyp+8oBNRavotxZLIWysYJPzjOaueAY867Hhd2Iydw54zQB6uuVVsBsEfwnJ/M1gawAltetg4MZJPVjW65BBK7wc4Hy5x+lcz4mkQaZfspzhQMngkn2oA8kzlJSWkXJ4BXNMvwYtBvmcOC5jjUueTzuPA9lqR1PzKQGAGfk+UD8etU/EJWHSLSFdwMsjSkEdgMDnr3NAHN0UUUAdX8J/8Akqfg3/sNWX/o9K/SmvzW+E//ACVPwb/2GrL/ANHpX6U0AeAftrf8ks0r/sNRf+iJ6+Kq+1f21v8Aklmlf9hqL/0RPXxVQAUUUUAFdP8ADxwfEf2Y4xdwSwZJ6HaWH6qK5ir+hXh0/WrG7GP3MyOcnAwCM0Adclu32lVBYHPIHQ1raUbj+2IDbSMrq4yQMZ9RUerQJY61dlVQlHLKFHHPT61FYTiK6gnmcjbKGPODQB7JatHLDvwGyeM8ZNKEKSgYCHHcZ49cGmW7iWFJkZFRhuDZ7fTpUssrIoYv97uV7f0oAx/FrvDpZ8tyHcgAgcVxMkBI33LM7Dn5T0HbI/xrofEeoW0upR28ZyY1wQCSD3PSs0Tr5WYOMclQp5oAqSFJraVFQbQOAQR+hrFEjqGR1wEOAZMYH0q5NeNl1EeQzZ3K3P5f0pn2gGEs8Q2fwkKQfSgCu037wDzcgjJOcVG5BG1ERCTyw5B/xqwoyDlM7ujLkfyq5YRB8orOGGQTjJFAGTOzwqYkJ8w8Zxgf/WqkJcyHGd3TBUf061fuoDHM/mOXIyQSOQPaswKoLH7oPKsGxmgCzuTsdufQY+vGenvUsJwNpc9Mgp0I9jVQZ5ZNxC88g/y61LCS7AZGw+h5INAFqNTx5bGSM9M8Y56E4qUy7mKBWIwRnHNQBghx8wJ4244/P+tRSExn5yUDHg7f1J70AXrOV2hlWNjtYqQDgEHpjFbthE9vpflSRKtxM4Ealev/ANasLw3Cs928cjAh+rY4H4VuajBLczCCzuYklCffLHKLQB31lE0FuI4jGshALBOppzqrOd0nzqc/Mh2n6+1c34M1JLm3azuJ0kuoSfnHVxXUxupT5gwJ4PfNAGdqluLzT5oDsL/eUA9Pp3FYYkl0+yie5mVgPlIden1rqk3yAMjSLjueo/AVyPixEtZbsz5dBtYRNzuJ6n2oA1Gkt4pIp42XzGTaM5wQexB4rOuZ7Wfcvyq3XGR+YFcfdX90ChiZkixhVPzNj05/pQXKNFI7s0m0EHONv40Aaerf6FGJIBuyDtwMn3OKyZtfn+zmN1OW75zn1GM0moXcs0aZJdsYOxcNj+tZccZyQHxn0Pb0IPFAG3P4quBaqkcamRcZcnj2NR22oX9xcCQSF0J+YgjIH+FVY7NwRt4PQB84q1bWl0HCCISg8iRh0/AUAbsl1JcRqIZZPNUcIgPX+lUH0gX1wolaTz3HzcE59ia6bSbLyLVN0J/2tv8An9KkupoULwxR7pMZCqPvGgDmb3w1JAqjcrIOMjqPx71mwHULS8+zW8kwPAUL0x7iusGm6rqpiS9lSzEeNhizuP1rodK0WCyjG0MZTyzsDuJHcHvQBmabpBfT3j1KNW81CGVhyc+1afh/SrXTYPKs7aNE6YCgHPetTY20kmVgOCyjG2mxkrjcDnHccEfyzQBDqlkLi0kLE5C5Gf19q4P4eWcaa5qMuMCIBRtPue9d3rM0VtptxNMZY9sbNxkf/Wrnvh7Zm20ZrrBzdSGQFgQcZ70AdHeAmMKrMQOeRXD/ABBnMFstu6gCQ5+9z/Ku5nYFgrOOei54NeZ/Ee+FxqaQpGzpCuGI4AoA4sRLuOyRt3vxms3xawXU1tVOVtYli/4FjLfqT+VbmlQxy6hBGSqRq298dMDk8/QVyF/cteXs9y+d0rs5z7nNAFeiiigDq/hP/wAlT8G/9hqy/wDR6V+lNfmt8J/+Sp+Df+w1Zf8Ao9K/SmgDwD9tb/klmlf9hqL/ANET18VV9q/trf8AJLNK/wCw1F/6Inr4qoAKKKKACiiigD028ulvtE0m+ck+fbiKRieA8fyk49TgH8azYVR45IsnPUYI/GjwXI994Z1GxRlE1nILuMMB91vlbH4haekZ81HcDIHzNjOaAOt8DazFYI9nezCOBslHOOPY13emXBv9PkmBLoo3blPVfrXiUvlbsgqD3bb/ACr3P9lqe1v9T17Rb3bKk1uHRW64zg4/MUAeTeIQ1p4infe3Lhk3DI20y/uLiFUj3oRIA6kLxg+xrv8A4z+FpNMvpAyNutG7A4eI/db3ryyaWXCu0kbIEAAxwAO3FAFmHkk713ZyzZ7/AE5q6rhoyp3cn1xj8qyYpHL4YZ4OAuP5VPBJMCG2nbn72eM0AXBIdu1hnHLfN/nNaenTbZQgZHBHQj5h9MVmxvmNBlwCDyCNtT6fsW4GYgWA4JNADvEVsEt1dJQm5x8rLg1zyEchf3rHqwHH/wBaup8Rsz2cCvuMat1759q5tojGz7QShPXAGDQA2Mb2wAVIGN2f8/lU0KPwGKsvBBHBzVfazYVmQbfmCocc/WpYvlB+YAjp14P16UATIhZigd9vX5l/rTZ0wx3sqDGPlBwtTggjFyxdSeDg/rU9vYfbtQgto4tzFgC+7kj8ORQBY0CJxEZVRmd1AjjTqxJwAO/Ne1+HPgzYrbW1542vbmS7l/fNYw8EA9FZv6U34WeFba58apcXMC/ZdLiE/wA4z846c16Ne6hPd3UjTEvuPROnbAH50AR6R4D8DFHjh0GKBQPvlmEg/r+Vcb8QPhzqBeW88EXy3Uca/vLN+ZB7qT1/nXoiO20opiVQRv38kHGRjBqDT7iWCfzhNtYN8wxknn+VAHiGjXg/s5Y7wrDdw/K6McNnuK4TxreedfvJCWHGAWI6D1New/HXwYja7aa9ZyMkGouqSCLjD45J+uK8m8dacmm29mkRWSSRyzMV46etAHIhHn4xuOeqtzkd/rXVaZp0s1uY7yMy5xyvBX8e9WfCGnRiASSD5xyN3IAP4c11qxIjjHOQOUXn9KAOQm0OFCqjJwuBg7eM1Yh0eIDLRKQTypHBrqDCuSWRc5+93B/HtTUjxK3lsoO3IDMCfwoAyrPTF5ARUQH5Rnge1acOmrGAxQZXnOD839anj8oN+6k87j8QPSphyFJXjvvBII+lAETxFiQpiCgcyAY/MGnW1nbpIGiJSQ85+9mpoxjJMuR1wEyfocVKYycNhgx5BB6fj/jQA2IqrOqRsoHXB7/TqKlDDZjKuw7kZNIwJIHzCUdmwKCOD55IGMAY6flQAMCQC2/A/iTg/wCNKAeQRvIGc5H+fzoyyKNseSDgjJJolnijR52V0Eali2NuAPc0AYHi6a5ljt9JtDHGbyQeZwBtjHUnt+lbUtsun2dum5Fj2hIwo4I/TFRfDbw7ceKvEL6jMjMZzhC//LOIe49a2/G8kQ8Q3cMSRLa2YEIcnIYjrkdjQBg6rP8AY7KaecKsUUeem76V4hez/aJ3l84by5ILfLx+Fdl401m3mt5bKyCvGWy+0EDj61xG4hE2LkHsQW4/CgCR2FtoeqXWXDMgtk53KS5wf/HQa4muq8VSCDR9OtMFZJS11ICMcfdX+TVytABRRRQB1fwn/wCSp+Df+w1Zf+j0r9Ka/Nb4T/8AJU/Bv/Yasv8A0elfpTQB4B+2t/ySzSv+w1F/6Inr4qr7V/bW/wCSWaV/2Gov/RE9fFVABRRRQAUUUUAdB4Fv1sPE1qZv+PefNvKD3Vxj9Dg/hXRXFnLY6pPBISPLcq2AVGK8+BIORwa9Q1qf+09F0rWVyzXEWyfB6Spwfzxn8aAKFwmxyVOR23Ct3wH4muvCHiyx1oKZFgbE0cYzvQ/eX8v5VixnfaI+XyuFJJBq1Bp5uEZYZmMg5k3/AC/5FAH2H4n03TPiR4Oj1HRpY55Hi3Qt0JBHKMP6Hoa+OvE2mSaTqM9pOR+5Y4Vh5f6dzmul8Ja3q3grVYksr2aO1nYcxkmPPuDXW+N7aPxgxu5SY74nqF+Vm78ehoA8aGWzmRumS24fkB1qa2QgKw3gjhO2OO/pV670qXTr3ybhVQ9FUKcnn1q5Dpu8FmeQk84zQBSYbUVUBD/3iBlv61raXBKp3t5YDc+hNOt7ZYoGE8IYqcgnoKlEgRwS0eTjhRyT+HagC1qK/abBzjzMHKkAE4x29q5J4E8wSnarBuNjYJ/A/wCFdXFcIyqdvzP9FB56c9az9TtPNmL8xN6gAZ/SgDC2glUOcdcngZ+nU1OscbEBC4PfYpOPY9zUMkIjdhOr7lI7Dn0wO1NjuFjPJ2467VP5HHWgC0kKA7m8xGBxt24x+GeK7nwLppijfUJgSR8sRxyB6k1z/h/T5dSmR3T/AEcAFsjk/THNd9bzwQ3sVp5qKAowjHg/SgD1L4V20sfh7xDcNtkkdtoA442//XqXSop3Z2mKzgZC4YcDsfzxTPhLeJDq11px+ZbiPf13cj1/Cu01Y6H4YsXub9lSNvuqRksfRRQBzW2I3qWbFJLpxln6HP4d8UuoRS2SMbiJ97HGT8q4/wA4rNbxt4Xur+OZob2AKCvmheMnjJFdstjZ+INJhksbtbi3YL+8Y7s4HQ+lAHF/EW3mm+HNrNgLLFcLJx83t3rwL4lwu8NhNgYUkEjO0k/5NfRfxVurey0ez0aMEscSNjoFHr9T/KvEPG9ubrQblfm+Vd6FBwcdhigDA8DXyT2eyRQZU4zwcfhXTCNgPk5Q8bhxmvMvCt9Hp2p5MriN/lYBckV6XEwkRWihMhDZB3YOaAHYzgSZPOOTkH3zS5TbhwpYHO3bgn3FIxCpmdW8rPGQSVP4U/K7VEbOU6hzj+tACIS3zI564BXOM/UUocjhyzOecb8D8+9KSN77gn+0Bxg/ypjnaMplM9cgEf1oAtQOqp8rBVBwVBzUqshbiQDsH9PrWDeX62ytIFRiB/DlTTNF1aO7kzCVGT2x1/A9aAOkPK/vYw69RtI+X/gVIQVHzkbexcZojZGGU3bgORj9cU9WYLlI3KgjHBAFADQOVxyo6OnH5ZrK1o/bZ4tODFt5DTsDjanp14JPFXNU1CGxtWcwx+cx2RxOeXY+h/rXW/CDwXLdXjarrIQoreZMWUEMw6KG7gUAeheFtPi8HeA576SLZMtu0zAjBHHyr/Kvljxjr12BJAdjSTEtLIhwxJOcEDrXsvxl+IUF9K2iaTMkltG2JSpP71h2BH8IryVraygtJtQuY/MmXJKuC2T2wcfzoA85ddqquArk8hyB+WaYima7hgVgJHIQLu4JzUtxMJpGkaPknPzJx+XNT6fMLCxv9TkVUNum2EJwDK3A4I7dfwoA5rxhdLc6/ciL/UwYt4+c8IMcfiCfxrFpTzSUAFFFFAHV/Cf/AJKn4N/7DVl/6PSv0pr81vhP/wAlT8G/9hqy/wDR6V+lNAHgH7a3/JLNK/7DUX/oieviqvtX9tb/AJJZpX/Yai/9ET18VUAFFFFABRRRQAV3nw5vI72zvvD1zsPn/wCkWpbr5ijlR9QP0rg6nsrqayu4bq1cxzwuHRx2IoA722u3sbv7kTAHY67CcGus0HUYZz5DRR/aSx2N5ZAcY6A81z+oeR4h0+PWdNJViMXkQbHkv3P0Pasazmkt2WRJR97ILNkj3yOlAHpup2IvrGJAyQ9SFIHBHY96baXNxbxrazOrsOI2U43KO3fmsXRfEEUqpDeyeZKp/wBcE4Ps2etbV4toTtNv5MjkPFKgyAfqOlAGxIlvexfZ9SMW7oJNpB+lZN3ostjlbRN6jGGDYq5DC92g+3ENPwMgZDj39K3o2KxKsYCEdBu2/SgDjUtJNpZg2MZxs4FV7mLyjuO0AD/dwfUmuh1HTXuUDW4kikJx5kT5DH1Pasl7PX1BjSMXCryCYx2oAyGnSMFkKEjkHrikjUXKMMHrkv1/HFaMOi6lPIVmt4VPBJft+FX4vDUUbFry7QHGWSHgfnQBzt1aM4KovmZAUbz83Pf2q7ovhW4LLLfYC5+RM5GPpW0j6VpsoSGJ5Jj3VC5J+vPNXAZrmPCK1upHLNywH07UAVdQv7fSbcW9tHm6k+VFAOSah0bQbrUlkE4cXgcPHtG459DVyztLe21BfssUfnA7zLcZbJ9eK0Y7W+mZLi6vpfPLfK8bbEx7LQB7n8LfCD6DYfa9S2SalMuNwH3F9M+9S/E/wxNrtlDc2kg861DfumGRIDjj68Vt+DJpn8N6ct6V+0+VzjjKg8HH0xXJ/FzXY7KC0htL9UvYn84wBuHXsGA7ZoA8WSOZ9VGnwQzPdM+wxLEQyt6Y/wAa99+Fvhm88N6PMupOn2m4cSNFGcqnGPzPeuA0ebSLEL4uu7mR7vWCsYjEuHDgEMPbGK9L0PxTpn2a0tLrU4nvW+TlhljQByvxQ8NXmoawl9ZsHBjCFF++pGeQO45ryPxLp89qBDqEMmQeDICDjuMV774+8VW+h21ugtHv7i4BaOJGC8DuSenWuO07xRoXiyYadrdsLZwv/HvfjK4x1STuaAPlfWdKk0q7yEZIWO5HPyjH17Vq6L4h+ySLHPIxgfqHbJB9jXpOsafp0V9eafYyC6so3IQP1x3A9frXHat4JtyGfTJPJcdEcYGfQGgDc03WLW7XfZXIkfHOQeOe/HerivC2fk69Rk/yryyW0v8AS5z58E0TA7hIgJBP4VoQ+Kr9cBLpy2Adsygr+BHNAHooUk5ZEcADBbIIHucVFNMkNuWfHpgk5X2zXAt4s1KRA5EbYznYCCfzqjc6vdXan7RJnIxyc/TJ7UAX/EmsCZzHbjzFzg7+uPwrNsNeaFtjeXGO4UYwfrjmqUroxAlUnB+Uhgc+/BquctKEVBLv+VRtoA9R0HXYpVCGVw3QqRkj3FdBc6pbQReY8isxwFQfeJ+mK850LwnqjlZpJ/skJ/hf7wrs9PtraxUmzBllxgzO2SMe/pQBZsbVrnUxcakQXH+rXBKwL3we5NXdZ8fX2u3Z8OeH3ew0aBNsrIuC/rz3zXP399eaqz2VjtWE8TXIA247ge/vVrR7JNG/0aNmkV+TI/c/WgCeLTIrSVvKs1Y4wr7eGH49DXI+Nb5VgW22yRyMcvzgj2NdHruqx6PEn73zZsZRO5z/AEry3V7+a+vpJZm3M/OdgG76ZoApHdNcLFHBIWc4Tnr/AENVfGt2sP2fRYGHl2mWm2nIaY9fyHH51szz/wDCMaat5IB/aVyp+yxHnywesp9PYetefuxdizEsxOST1JoAbRRRQAUUUUAdX8J/+Sp+Df8AsNWX/o9K/SmvzW+E/wDyVPwb/wBhqy/9HpX6U0AeAftrf8ks0r/sNRf+iJ6+Kq+1f21v+SWaV/2Gov8A0RPXxVQAUUUUAFFFFABRRRQBq+HtdvdBvTcWDgbhtkjcZSRfRhXb2L6T4lYPYTpZakTk2k/Rj/sHHP0rzOlBIIIOCKAO3v7W5srspdLslDEjcuPy5/WtjRPEs9siwXMMcsJ6bv4ffINc5pHjS6hhS01mFNUsAMBZf9Yo9m/xzW2ul2Ws2j3fh24SREBL2kikzJ+Hce9AHoWg6xDfWjRxnMi9I8cnj361KlzcWYcalAXsz8oliI6H+9ivJrO5urKbfGxQocBnGCv4etd/4f8AFcN4BFft+9Iwp2/K/wBR2oA620jtDGhtVjCADbtlJBrrPAOrw6BqEl1cwm5hYY2kjKnuVH+NedW+l3drc/abCdYI3OfIC7kbPv2roYLk4C3sYicjGSAQfoRQB7hF4v8AB+qAm8W3RsZP2iAHH4jNZHi3xD8OtMsJWu4bG4YJkRQR/MfxFeVyIQqt5qoO7lBnH1qB4oGRo3j3KwxlhuJ9/agCNLqwukk1SytZLW1PMVu+G2r656k1T0n7Y1xNdFitpIMxxn72MdT/AIVqIgiQDavAwCTjj6elTQwYjAchFPZGxn60AUpkkHl3Ai2y7dpXd1FXo8lA0Skc9yT+FNCIScqo7Zzz+tOTKEDazxNyGYg7cdRQBox+NdfspRZu4WLZtSVF+cr3HpWVczJ9qjmZSHf5M/3vrROYd4kBLOOVPTj1xVW8ilmiCrBvAkDo27nHpigCnb6e0F3G7yhreNpZERmJOWxWvpEVvbXkWotCftIOTltuB6UHStQsLW0murd43d2VS0ZGAOn/AOum3ObuZ4JE8tSvDjnAPbNAGtq2vzeIbo3txboiqvkwDjcEHofQ9ayLoCW5hkcuFiGQjYJU/h1qYRLEieUTjZsBY8VGxWUsJcMp/iz/AIDrQBHcRI6FlkCsed3IqGW4dYiskHmhRhipwD+VWo0KoAuxmXozdcf1rNuBaxTtLNK8DEZB3bQ2PTtQBDBPa6grR/60EYClev1zWdqnhC21LD6fZzrJnjyoywz9B2q7FeRWNwzxpLNFMucmPIBz24rvPDHjDUdMtUitWt2KjnzEzt9PTigDxwfDLxaxBs9D1B1Y/e8ggEfj2rasfgv45uFHmaPHErf89JE4/Ddmvd7H4o3IAivLK3ecd0kKhvcA1DefEzU51eO1sobZuQHJLn6gdKAPE9W+D+taPaCfW5bOCMjAVWyxPtUvhzRrDSVHlxiW5fjzWHX6HpW34mk1bxFfCTVtUlubdDnAAXafYdMVRluBZR/ZbEeexHfhV9yRQBeuLuK3gaW6CCMjG7dwfasGRzfhESJ7exPBB4d+e3tUd1ZQlPtWr3LOUGQN4wv0HesHVPF8iW5g00SlB/y0lXO0/SgDrL29sdNt1VmijjTlVIO059q53UvGsEQ2Wcao+MCRgSufb1rhL28nuZS1xIZJW9+PwBq7Y2Ba2a91SVbPT14Mkg+8fRR60AV7q6utSumLebJIxxhHyD9B2qzPLZ+GYxPqY+0akRuhs92dvoz+g9uprN1DxpHao8Hhu1FsDwbqUAyn6dlrjJZXmlaSZ2kkY5ZmOST7mgCxql/canfS3d4++aQ5J6AewHYCqlFFABRRRQAUUUUAdX8J/wDkqfg3/sNWX/o9K/SmvzW+E/8AyVPwb/2GrL/0elfpTQB4B+2t/wAks0r/ALDUX/oieviqvtX9tb/klmlf9hqL/wBET18VUAFFFFABWt4Z0G98SaqunaWIWu3UsiSSqm/HYE9T7Vk1NaXE1ndQ3NtI0c8LiSN1OCrA5BFAFvXNF1HQr5rPVrSW1uF/hcdfoehrOr1BvinHqryw+LdCtNVsJ1BdVJjlhfu0b9s9ce/WuN1iw0y71KZvC8spszho4LxlSZSeq+jYPTByfSgDBoqW4gmt5ClxE8Tj+F1INRUAFT2V1cWN1Hc2krwzxncrocEGoKKAPQLPXtJ19Amr7NP1H/n4AzFIfcD7p/SpNS0W+sMSXA3Wh5SWMgKw7YxXndbWheJdS0YhbaUSW38VvMN8Z/Dt+GKAO00nXrrS2Cpct5R/gbnPtiussfG1vKirfQGIEZyG3Zrh4NW8Oa0ytcA6ReNwcjdCfx6j8atXHh3UYYBNZGO9gA3CW3IYGgDvU8UWcs0f2S8+72dCQfzrWt9ZgZNqSwMT3VwN34GvGpJ5YgEnRweyEbSfxpUdUh8zYUQnBIPX2oA9jXVbVUT7TdRRsG+6zDBPbmrUN3bShWSeFiOPkP3vxzXiglUnqpxyO+PoKMshBDTIjdAGwT+FAHt73cG5laSNSvOTjg1Ql1HT7QTSSXsYJ6Zbn8q8gPmjAEpUdT83P480xhukVWmHlt13HmgD0m48ZaVb8QlpnXqxIOawU8Y3y60L3TmaN0YbFBGzj1HeuU8y2D/e5H3VyFFTxzWrtlGc5IIBGRx1NAHo3iD4va/rtktjqkkMY+6JYY8EH1rd0y4hvbUPCyO6ABmLZOa8fCpKcCRTu6cf0NXdD1m70STcFLREfMvAz7ZoA9hlQsn3iT1B3daSNVVR5eBIckjGAciue0zxvpk0TGeRoG4Gxh/XvWlb63ps6/ubiIFTyXYDP09qANTA2Lt254+tV5YQZW34ZG+7nkCqsurWEQZ5b23DYHVx/KqkPiDTHlMcN2rsfvYXue/sKANKONrYbIiBA/Kgj7p9qiSJlJIysnYbcDFRSapbw5JkjQHnmQEVXTxFpqKQ9yCe4QZ6dxQBoOiBd1wyKgPBIwQaZHdSMDHZ27zFOSx+Ufma5nUPGNijP5MEt0euZBgH86xL3xvfMB9mWCzX0HJP+BoA7ie4ljVpNSnFrCvJVTwPxrltW8ZRKrRadAXJ+X7QxO0e/wD9auM1PU7m6kMkzTXB6kSnp68dqqwQzXr+XbrM5J4GM/nxQBZ1TUpb2bfdTeeT0GSFHrioLZZbyRbaNNzE4VVPzf8A162x4ai023F14kvYrCHrt4LufYDrWPqvjiGzjktfCtqLWNuGu5ADI/0HRaANWewsPC8Kz+I5xLOeY7CPBdvQt/dHvXCeI9fvNeuhLdFUiTiKBOEjHoB/WsyeaW4maWeR5JWOWdzkk/Wo6ACiiigAoopyKzuFRSzHgADJNADaK6K28KXSxpPrU9vo9q3Ia8bEjD/ZiGXP5Y96y9Va0E/k6f8APbw5VZiu15ufvMO3sOw/E0AUaKKKAOr+E/8AyVPwb/2GrL/0elfpTX5rfCf/AJKn4N/7DVl/6PSv0poA8A/bW/5JZpX/AGGov/RE9fFVfav7a3/JLNK/7DUX/oieviqgAooooAKKKKACpXglSFJWQ+U/3X7E+mfX2qKtDS9UlsBLHsjntZsCWCUZVvf2I7Ec0ANttUuoEEe8Swj/AJZTKJE/I9PwqYzaXcj97bS2cn96Bt6Z/wB1uf8Ax6qt/wDZWmL2IkjiY8RSNuZfxAAI/wA+5q0Aa40SS4ydMuba9HXaj7JP++GwT+Gazrm2ntZPLuYZIX/uyKVP61EOK0rXXNQt4hD9oM1v/wA8Z1Eqf98tkD8KAMyitezvNKeZjqWnSFH72k3llfoGDD8KuS6f4dunP9na3Pa9MJqVqR/4/EXz+KigDnKt2Go3unSCSxuprdwc5jcrz/WorqEQSlFmimHZ4icH8wDUNAHYW/j7U9gTUoLTUExgmaIBvzGP5VaXxR4fnx9q0aeJjyTDKGH5HFcLRQB366r4RlDBhqUQIwAVXr68Gjz/AAm7H/iZXcY/64t/hXAUUAeiC58JRgsdVvZCDkKIW5/MVXfxD4XtgFt9MvLrB6yuFz+prg6KAO2bxdpe8bfD8QQYx+9yf5VZg8WaBJkXOkTRBhgmJg3+FcBRQB6PHJ4Wvztg1N7NjyBMhUD8en61bTw7qf2cy6bcW9/bdhE4Jry2rFpeXNlKJbS4lgkH8UblT+lAHbT21xCxF3p8yMeDgHB+lVS0Soqyeep4xwOtQ2vxC8QwoFe5iuMdDNErH8+Kur8SLtgoudK02YAc/IQf50AQGSMjLFyB8hHv/SgSwoTh3aNuqngqfY1a/wCE50yRR53hqDd/eScj/wBlp6+L/DpU+b4fkyRziUdfXpQBTF0sZ3IpJI5ycg077TcE7reB2DjGApyB9asS+PrOEN/Znh61ibPDyvvwPoAP51UPxH1kAiKKwjHbbByPxzQBoWumaxe/KLeZ1PcritVfBd4iia/uLe1tSMku+MfXNcXeeOPEV2HDalJErjBEIEePoQM/rWDdXVxdyGS6nlnkPVpHLE/iaAPSbi58I6Nlbi7m1adOFWHBX/vrgYrHv/iFeCLydDtINMixjco3yfmen5Vw9FAE11dT3c7TXU0k0rdXkYsT+JqGinIu51XIGTjJOAKAG0VbNtFHMFmuotm3duiBf8O3NW1k0a3A2w3l6+OsrCFc/wC6u4/+PCgDLVWZgqAsxOAAMkmt638I6w8IuLu3XT7U4/fX7iBfqA3J/AGmQeJ76yZzo6waZuUqWtY8SY/66HLD8CKyLq5nu5mmup5Z5W5LyOWY/iaANj7NoNjn7TeXGpyj+C0Xyos/77jJ/wC+RSt4muLdTHotvb6VH03W4JlP1lbLfkQPasCigB8ssk0jSTO0kjHLMxySfc0yiigAooooA6v4T/8AJU/Bv/Yasv8A0elfpTX5rfCf/kqfg3/sNWX/AKPSv0poA8w/aF+H+q/EfwXZaRodxYwXMOoJds147ohRY5FIBVWOcuO3rXz1/wAMqeOP+gr4b/8AAif/AOM17r+1B4x17wR4B0/UvDF99hvZdTjt3k8mOXMZilYjDqR1VecZ4r5f/wCGg/if/wBDN/5IWv8A8boA6v8A4ZU8cf8AQV8N/wDgRP8A/GaP+GVPHH/QV8N/+BE//wAZrlP+Gg/if/0M3/kha/8Axuj/AIaD+J//AEM3/kha/wDxugDq/wDhlTxx/wBBXw3/AOBE/wD8Zo/4ZU8cf9BXw3/4ET//ABmuU/4aD+J//Qzf+SFr/wDG6P8AhoP4n/8AQzf+SFr/APG6AOr/AOGVPHH/AEFfDf8A4ET/APxmj/hlTxx/0FfDf/gRP/8AGa5T/hoP4n/9DN/5IWv/AMbo/wCGg/if/wBDN/5IWv8A8boA6v8A4ZU8cf8AQV8N/wDgRP8A/GaP+GVPHH/QV8N/+BE//wAZrlP+Gg/if/0M3/kha/8Axuj/AIaD+J//AEM3/kha/wDxugDq/wDhlTxx/wBBXw3/AOBE/wD8Zo/4ZU8cf9BXw3/4ET//ABmuU/4aD+J//Qzf+SFr/wDG6P8AhoP4n/8AQzf+SFr/APG6AOr/AOGVPHH/AEFfDf8A4ET/APxmj/hlTxx/0FfDf/gRP/8AGa5T/hoP4n/9DN/5IWv/AMbo/wCGg/if/wBDN/5IWv8A8boA6v8A4ZU8cf8AQV8N/wDgRP8A/GaP+GVPHH/QV8N/+BE//wAZrlP+Gg/if/0M3/kha/8Axuj/AIaD+J//AEM3/kha/wDxugDq/wDhlTxx/wBBXw3/AOBE/wD8Zo/4ZU8cf9BXw3/4ET//ABmuU/4aD+J//Qzf+SFr/wDG6P8AhoP4n/8AQzf+SFr/APG6AOr/AOGVPHH/AEFfDf8A4ET/APxmj/hlTxx/0FfDf/gRP/8AGa5T/hoP4n/9DN/5IWv/AMbo/wCGg/if/wBDN/5IWv8A8boA6v8A4ZU8cf8AQV8N/wDgRP8A/GaP+GVPHH/QV8N/+BE//wAZrlP+Gg/if/0M3/kha/8Axuj/AIaD+J//AEM3/kha/wDxugDq/wDhlTxx/wBBXw3/AOBE/wD8Zo/4ZU8cf9BXw3/4ET//ABmuU/4aD+J//Qzf+SFr/wDG6P8AhoP4n/8AQzf+SFr/APG6AOr/AOGVPHH/AEFfDf8A4ET/APxmj/hlTxx/0FfDf/gRP/8AGa5T/hoP4n/9DN/5IWv/AMbo/wCGg/if/wBDN/5IWv8A8boA6v8A4ZU8cf8AQV8N/wDgRP8A/GaP+GVPHH/QV8N/+BE//wAZrlP+Gg/if/0M3/kha/8Axuj/AIaD+J//AEM3/kha/wDxugDq/wDhlTxx/wBBXw3/AOBE/wD8Zo/4ZU8cf9BXw3/4ET//ABmuU/4aD+J//Qzf+SFr/wDG6P8AhoP4n/8AQzf+SFr/APG6AOr/AOGVPHH/AEFfDf8A4ET/APxmj/hlTxx/0FfDf/gRP/8AGa5T/hoP4n/9DN/5IWv/AMbo/wCGg/if/wBDN/5IWv8A8boA6v8A4ZU8cf8AQV8N/wDgRP8A/GaP+GVPHH/QV8N/+BE//wAZrlP+Gg/if/0M3/kha/8Axuj/AIaD+J//AEM3/kha/wDxugDq/wDhlTxx/wBBXw3/AOBE/wD8Zo/4ZU8cf9BXw3/4ET//ABmuU/4aD+J//Qzf+SFr/wDG6P8AhoP4n/8AQzf+SFr/APG6AOr/AOGVPHH/AEFfDf8A4ET/APxmj/hlTxx/0FfDf/gRP/8AGa5T/hoP4n/9DN/5IWv/AMbo/wCGg/if/wBDN/5IWv8A8boA6v8A4ZU8cf8AQV8N/wDgRP8A/GaP+GVPHH/QV8N/+BE//wAZrlP+Gg/if/0M3/kha/8Axuj/AIaD+J//AEM3/kha/wDxugDq/wDhlTxx/wBBXw3/AOBE/wD8Zo/4ZU8cf9BXw3/4ET//ABmuU/4aD+J//Qzf+SFr/wDG6P8AhoP4n/8AQzf+SFr/APG6AOr/AOGVPHH/AEFfDf8A4ET/APxmj/hlTxx/0FfDf/gRP/8AGa5T/hoP4n/9DN/5IWv/AMbo/wCGg/if/wBDN/5IWv8A8boA6v8A4ZU8cf8AQV8N/wDgRP8A/GaP+GVPHH/QV8N/+BE//wAZrlP+Gg/if/0M3/kha/8Axuj/AIaD+J//AEM3/kha/wDxugDq/wDhlTxx/wBBXw3/AOBE/wD8Zo/4ZU8cf9BXw3/4ET//ABmuU/4aD+J//Qzf+SFr/wDG6P8AhoP4n/8AQzf+SFr/APG6APRfBH7NXjHQfGmgaveal4fe20/ULe7lWKeYuUjkViFBiAzgHGSK+uq+IPh78cviLq/j7w1puoeIfOsrzU7a3nj+xWy743lVWGRGCMgnkEGvt+gDwD9tb/klmlf9hqL/ANET15V+zDpuk3HhX4kanquiaTq0+l2UNxbLqNok6owS4bGGGQCVXOCM4r1X9tb/AJJZpX/Yai/9ET147+zZ4w8JeHNG8b6Z401WTToNZt4beNo4JJGZds6uQURgCBIvUd+/NAHpfwuvNF8SeJdA0/WPBHgoW2raY16GTw59iZJV6xxmUsLgY5LJwK+Z/ibbQWfxJ8WWtnDFBbQatdxxRRIFSNFmcBVA4AAAAAr6a8MeMPg5oWpaFeP451bU20K3e20yO9s5NlqrjaxAjtkLEjjLFq+X/iFqFrq/j7xLqWny+dZXmp3NxBJtK743lZlOCARkEcEA0Ac/RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAWrWzluY3eMqAmOpxn6VFNC8LhZBgkZrU0KKCWNvN8/erggKflIx3961f7Kgky1sSCeA7c7KxlVUJWZ3UsHKrTUonI0V1194VMekPeRs7EfMGOMN7YrlpYJYgDJGyg9CRVU6sanwsxrYapQdpoiooorQ5wooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOr+E/8AyVPwb/2GrL/0elfpTX5rfCf/AJKn4N/7DVl/6PSv0poA8A/bW/5JZpX/AGGov/RE9fFVfav7a3/JLNK/7DUX/oieviqgAooooAK0LPTzNCZZCVT+EAcmqtnGJbqKNvuswzXWlAGTbtKgcKO1ZVZ8uiO3CYdVW29jHttIjMZaZnyeRjjFZd3EsM7Ij7wO+K79fD93LZrcsm+FlZsJIu4AcnK5z056c1iy+HUeOSaNG8tSATnoT0rKNdX95nXWy6TivZo5Oit6axgUYkiKsPSsSQAOwGMZ7V0RkpbHm1aMqXxDKKKKoxCinxxvK21ASasnT5wM4X6ZpNpblKEpapFOippLaaP70Zx7c1GVYdVP5U73E01uJSV0FldaaNHkgu7aT7QSPLk6Add31zx9MVTWxtpLvbBdCSLPUjaSKjn3ujX2N7crvcoQQSTuFiUk/wAq1F0WVrYFcGbOdpPBHpWtDGLWRbdo2jbOCuw7h+HWrEcF5MT5MIwOu5wK5512vI9ClgoW97V+RPZWMEVsoQoj4yyehxzUhiWAhVuI+csQDkcVDNp+uXDOdjMxAyq46ds1VutD1/hpbWRh67ga57wb96a18z0faunFKNN6eRclufMBg3qI2bJB6j2qWS0AjUiMvH0JK5FHh+7utGulnn0FbwqhU7/m+bn5sH2PSo4/FN9ZpcQLbpGJY3hXzkJaJWOcr7jsfc03BuygwWKjZuon9wy70HSZ4xiQW87cnBwAfpWHe+FryJd9qVuo/wDY6/lWlBfQJBLFLDDI7EESsfnXHUD6/wBKvW9+LaVGtipXaNyhiQT6+1NSq0/hd/UzlSwuIeseX0/yOCdGRirqVYdQRimV6BqtxY39q3nWZ8w/LvGBg+1cfJpc6nB2gk8KTzXVSrc695WZ5WKwXsZWhLmRn0VfutMmtbeOSXG5yQEXkiqrQyou943CdMlcCtlJPY45QlF2aIqKKKZIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHV/Cf/AJKn4N/7DVl/6PSv0pr81vhP/wAlT8G/9hqy/wDR6V+lNAHgH7a3/JLNK/7DUX/oievjC1ge5nSKMZZjivs/9tb/AJJZpX/Yai/9ET18ZWF09leRXEQBaM5AbofY0ne2g42uubY6K20CJY97gvggEnpWjb6Vp5V/PAUAcEJurnbnXriVXEaJEW7rWtYTzro0EARWZnMrSc7mB6KfYdfxrjlCpa8pHtUKlBy5acLjrnw4oRryxR3t4yN0keSq+m7+7n3qe3DNDGropbkfL1PPpTbTUjazPFK8yWs5VJ1jbG5Qc9Ohx2zW/oGnJI+oapE7fZLBwEcHDMxbCAf7Xeom2o+8dVGEPaWgrEVxrV/v3y3c4IjWFip2nYoKhTj0BI/GqjasLoRNv3xwgIgI4UZzgD0rf1u1sYtPmLKft5lywVt6BCoPLd2zmuK2pBCoOD1wVPWsoRU7nXWqOk1a1i1qcZui0iAlnO48YH4VzF5p7q7Mu0DupOMV2mkypN+7aGSY8cRnDAZ5xUWqaZuQzPCxiDlGbqOPfvWtOo4OzOTFYWFePOtzgkiZzhSuc4wT1pZoJIT+8UjPQ9q2LrSUacPbHEfde9WIoCyeRMPMQjgkciuv2q3R46wcruMv+AZFrHb+Vl5P3h7A4xVmKKRZOJW2dQDzVbVLE2cgKnMbdD6e1MtbmRTsA3g9AabXMrohP2cuSatY1HYRIWc4UdagFy8uBFbsc9CTinW1s74luOW7Kegq+ECpwMD2rN2R0qMp67IwLxZwy+eevQA1GsZTZJIp8st2roPsyNKHYZcDArb0nSY5iktxGCRyqkdD60qmIjTjdkLBSm73LlvILtfNVJXmkA3TTMSzcY5J5PFW0s40GW647cVafyoEySABWPfanGrEI+T6CvHTlVfunsXUIrmC9k+zzB0c5HHJ7VYj8VxRRO08EQwp24QkE9h1/WsSUyXLc8A96SK12Lygcdwa6VShZc+rMniZrSBup4tuLwg2unWijoMrgA/TvWdqBvrjLXBiQf7MdQiUwpiJNrdjirwhu7hR+9XJHdaJSUXdaIzdWc1Zsw7vSJJYRKZhvPQYAq/o+hRjmZ2c/WpxY3EEg8xxJk+mMVtWcLIuT39qmtiZctosKeHV+Zowrnw5I0rNZttYc/MciseTTNSSRw+z3IOa75mZAfl/EVTuSvklsZNZ08XUWj1LqYWL1RyixzpGkZCse1F1p93PbsjvgNWr9jmkcOcjPT2q/Fps7kF3zj2raWI5ddDJYVy0ZxK+Gb2T/VFSPVuBUs3hDUo7NrlfKkReoVua7poG3AP2q4LZjEUR22t1A6GolmFRW2JeXQPILmxuLcbpYiF9RyKq16nqGnL5LBl68VkHw3BtH7pa7KePg1eRyTy+SfunB0V2F14ajI+RSp/2TWVc+HrhMmJg49Dwa6I4mnLqc88LUj0MSirFxZ3Fv/rYmUeuOKr1smnsYNNaMKKKKYgooooAKKKKACiiigAooooA6v4T/wDJU/Bv/Yasv/R6V+lNfmt8J/8Akqfg3/sNWX/o9K/SmgDwD9tb/klmlf8AYai/9ET18VV9q/trf8ks0r/sNRf+iJ6+KqAHINzgc8nHFd5pkA+yxyomYIyFZgOntXCROY5EdeqnIrvY2k/si2e2jiMEreYs6x4YsBgoW74Pb8a5sSro9TK2lN9xusWtvchpIVMbZ4XrxW94cU6ZYxKsiuS3mi3I3IZBwpkXI7HIPPSq+gg3M5hntY5RLwDLL5YU9c59a0jb21q2yKUzRIOZhkGQ464PQDpXnVKjjHlPpaNCMqntLGNr8m59kaGMfxDduy3c/wD1q5dI3V2Q/MoORmu1ms3eyk1CEfJG+0tj5V44GTwSc9K5PUdXe306SxE37lpRP5IUcuBgMT16HpW+Gbtyo4Mysnztk1t5lrLvtZ5IiylSVOMgjkfStHSri2lu4o9Xllt7ZcndBGGOcccd8nHJ6c1i+HZHvIdrSJuDYJb+Eev0rbNsF2CVGjYqCDkEEetXN8rtIyw6VWClDQJhbTrGLa3MTpndLv3GX6jgAfQfnTGsxa3MEs5DxjDlo8NgdcHt9RVuOFgoGEIP4Uphxwsmcjox4Nc/tXc71h4yjYyvFVq1zIwlt/ImH3lCbVyeQQOgGPSsWwsRGVUDfITjIH6V2E0B+zThC0zpEJmOTiPnBHuOgz9Kw9Ocw3aPk7Afn29cHrj3xXXCb5bHlVqEfaXa1EWFnKxQjfITt2Y5zU1harcu6ySxwRIpdnkOOB2HqfQCtDULax/teUaezQ2bSDyxI+5ljOO46nk1c0m08i9FzbrlEcmISDdjngj39zUTqRgryNI05SehXW1tbuS3ntrGSCJQFdTJuWTA+8M8gnqR0HStdI/JiLY561pRWhfLy8sfQYA78UTQAqRtryK2J9rLyOunR5UcTq1xK7HJwPSsTBaYAZLfzrf19USUqp3N39q5mQvHNuDFHHQqcGvXw1nBWOPGe7I27SdiVVVOR2xWvBHK3ULj6VzWlXUiTE9c9Se9bD6oYvlUZNY16cm7RRFO0lc1VtUcjIFWI4QhwKraZdfaY9wU0+9uTDg4Jrgalzcpuopal5Y1YDOKnhT5R6CsW01SN5QjNhq3LchiOcg1lUjKGjN42sOeIFc1QngGeBxnJrbMYIzVKaPH0rKnM1UbjPJtjbwH96k5kYOzY8vbjjHfOc5rQs7LMAfOQQT+A71k38MjKjIx+TnFaumSNtVGL+XnIUdz05q6rvG5rGNkQz243cjpVi2hUJgDqOKtyxDknpVdJ1jmWMg5IJHFc3M5KyK9nfYgu7TMYyOlRGzyvQVsld6A9jzS+V7VCrNKxm6aOfkseOlVJrNADuAH1rp3hz2qjeWPnqB0AINbQr66sn2Ke5zcunowIKg1i33hu2mckx7W9V4rupLbngVWkts8EV008VKOzOaphYz3R5peeFZUybeTPsw/rWFd2FzanE8TKPXqK9gmgAQnFZc9osufk+vvXoUcwl9rU8+rlsX8Oh5TRXf3nhy3nXIi2Me68Gub1Hw9dWpLRjzUHp1r0KeLp1NL2POqYSpT6XMSilYFSQwII7GkrpOYKKKKACiiigDq/hP/AMlT8G/9hqy/9HpX6U1+a3wn/wCSp+Df+w1Zf+j0r9KaAPAP21v+SWaV/wBhqL/0RPXxVX2r+2t/ySzSv+w1F/6Inr4qoAK29D8Q3Ol20lqVWezdt/lt1VsY3Kex/nWJRSaUlZlQnKElKLsz0S21SG52vG4PAyEH860I5lnjdmXcMgAFsY/CvMba5ltpN8DlG6HHer02uX8sJjMu1T12DBP41wzwevunvUM6tC1VanVat4ghs4hbI7SKWy0SNjHbPpmuDd2dizklj1JpDz1pK6qVKNJWR5WLxk8VK8tF2LFndS2kwkhOD3HY12mj6jDeIjPsZl+9GSRXB05WZGDIxVh0IOKKtJVF5hhcZLDvTVdj1BY3ZT5bKeOm6mzFGbaYWi4GAT1rhLTXLy3IBcSKOzVvWviK2nX97mOTGPmOR+Brglhpx8z3qOaUammz8zaX7L5EiMskl2Y3BVpNqAdQwxySMHIPB4qroth9tuPLi2bm6M7bVX3J7VBbwfbJAyElT0YHIrp9KsUt4girgHkn1rKtVVKNuppCHtJc3QnstHtYw9uZopoyyv55tyDkDoCedufpnritW3tkSXavzqvQkYyO3FS2qKAAeCfarcUQD56+9eNXxEpv3jpjBQHpEMdKr3MJCmtKNRjA6imzxFx04rjVSzKRweraJ55eSEkMexrk9R06S2fE6HJ716tLbGIlsfKTjHpVLUtLivIGWRfyr1sPj3CylsY1qCqHlYPlABBzQm4SrvXg9jXXw+GD5x3vz2wO1TS+GFl+4xA7V6Tx1K+5zLBy7kOlzRxwqoUAVJqMLyIWjUkY7Vp6d4dSBRklj71qGxCjBFeXPEQU+aOp0eystTzVleKfc6bWHOK6PQdREriJ+GHT3rT1HRo5lYhfmxwax7bRrm3ukdegPNdMq9KvDXRkxpNM7SJA8eRVa9hIGQMEVd09WEQDDBxUtzGGXpXjKfLI6Iox7dJJ3G7AXpWilsoAAFR2UIWVgWCjk5NbFrEjjnA75qq1S2xu0kVPKyuDUEdkpufNI5HHFWdSujbOkcSb3YnA9vWrNsdyhsDnnI6VlzSjHm7luL5eYI4gFIIpAnHAqy6nHFIB6VhzGaiVTEOPWo2h4461dK0xlGOgyKakKxmvFgVUuI+MgciteRAaqvCGJ45reEyeUy2t96/WolswgC4Jx61teSO1RvFgnitFVexLjcx3tB6VUnsgQcgVvmMEVFJbjHStI1mjGVJM4HWfD8F2CSm1+zL1rhdT02fT5dsoyh+646Gva57bIJxWHqemR3MbpIgZT1Br1cLj3DSWqPMxOAU9Y6M8iora8QaHLpjmRAWtyeD/AHfY1i17kJxnHmieHUpypy5ZbhRRRVkHV/Cf/kqfg3/sNWX/AKPSv0pr81vhP/yVPwb/ANhqy/8AR6V+lNAHgH7a3/JLNK/7DUX/AKInr4qr7V/bW/5JZpX/AGGov/RE9fFrxsqqxxhunNADKKKKACiiigApyIzsFRSzHoAM06CJp5ljj+8xwM1daY6cXitn/esMO+OnsKTfQuMbrmexSlikhbbKhRjzg1HTmYscsST6k02mS7dArS0bTJdQnHynyAfmb+gqTw/pR1K4O/KwJ94jufSvRNOso4I1WKMBVHArjxWKVJcq3PQwWCdb35bfmO0uyWGJFVQFUYAHatqBcYqO3TvjiralQelfPVajk7s+ihGxbt0yM1ai+Q8moIT8vHephlsVwy1NS/CQQOmasMo29OazIty8jOCcdavxuwX1Fc042HYqzxNKhUEgE8iohCQuGHNa0KiQkgZ9hTniUjNHtbaAY32cdcc0+CAA8irzx46CmoOMkYNV7RtGiV0MMQx0pjQDjI6irI65496kjjSTYISS+CWVuOncGpUmRJIypIBzxxUf2cZ6VsNb4t/OYDbu2rkHk4qIwfLn8uOtUqhKSbKkEeOO1LOh21YK7PvcYqe8tWt3CSDkorj6MMijm6ltJGJEMTj1zWogwCxOW6mq/lfvgR3rRjiwoJHB9qdSexrbZlO3VLiYy7TuA24I5FX0g2JjH0qS3jUyDdhR61oyWrfKipv34ZW9Qfauec29tgnPWxkuuAKaAG6dKs3CbWwQQaQLnqeaSloPoQbSPeonQ84GKveXxTWShTJM4xk00xgHpzV7ZTGT2rTnBlIx4z71G6Z7VeKevNRlKpTJKJj46VFIM8VoMlVpIj2rSMhcpQdMjkVVmtw3OK1vKJ7dOtIYeDWyqWIlFHM3+npcQvHIgZGGCD3rzjXvClxYiWe2/eQKCxU/eUf1r2V7celVL20DREEDkYruw2PlRemx5uKwsKq13Pn6itjxRpZ0vVHjC4hf54/p6fhWPX1UJqcVKOzPmpwcJOL6HV/Cf/kqfg3/ALDVl/6PSv0pr81vhP8A8lT8G/8AYasv/R6V+lNUSeAftrf8ks0r/sNRf+iJ6+Kq+1f21v8Aklmlf9hqL/0RPXxVQAU8LuICZJPbHNMpaAAgqSCMEdjU1nbSXdwkMQyzU5Z1kBFyrPxw4PzD/GrGiXcdlqKySFhHgqSByAamTdnY0pxi5pSehfmittFQAus14R0H8Pt7VhSO0kjO5yzHJNTajKk99PLGSUZiRnriq1KCsrvcuvUUnyxVorYK6vwl4X/tWL7VdMy2+7CqvBfHX8K5VQWIAGSeBXtnhjT2stLtbeXG9EG7b69TXHmGIdCn7r1Z0Zfh1WqPmWiFsNGtbSIR28KonoKufYgoAQECtWKDdwKtLbZHIAFfMTrzbuz6WKUVZGSlpgDipltwPvDIrRZAo6c0zZu6Vj7VsuJDDEQAMdqtRw+tTRQ4xVlI6wnUKsRpGABlQR6GnxpzU3lnAHehRisXK5SRLpt2+m6hBewJGzxNko4yrDuDUt5Pb3N5JNap5UUhysROSh9PpVdl4qDmORXThgcjjNUpOUeVk8i5ubqT3ELxSskqlXU4IPaq7LjkVrWdvNrEziIM1yfmOf4s9T+eABVO8t3t3eKRSHU45GKLNK/QqE18L3M9s5PPNOgm8iVHaPeARxnBxT9hP8NDALkZ601IbV9GPuZUmuGaNGVS+/ax+77AelWElgSMK+WJXB/2DnqPXjtWe8gGARyM/N6ih5dzbmJLcDPsBxTtfUn2ZDPKC0g3AjPy8Y4p+n6zC8traXcKstu+52yd8inGRz24pGijkYORkisnU7IpcxXUAO9GAbHde9dFJxfus1ajLQ6G+linu5ZYEVI2clVVdoC544+lWEZXgQdHHcdxWfaIXh3HtxWpYmIQyoY/MmlwkWG+62euO/Fc89W0FrRt2LmnwfOrOFKEkDd90kdjW5Fc6dDBtjU7dg3Nsy+ccgE9OeAayLFZZm+zIgLElUB/vE9qsa5DFYNHbQSPIwQNKxPBY9h7Coi5Ri5RRz1EpzUG9THn+eZiA2M8ZPIHalAx2pEyxye9SgGsWzpemg1iecDAPFRkgCnvUL88URQJXEYhm9B2zSHnjpTdvrUmMDNXsNpEJwOKjPNPl4BIqt5nz4PfvWkVcSjclKkpnHtRNE9vM0cseHA5Vuo4pgY5JzSEn+LkVSE0ySa08sIN8TyN1CSbj9MCq4Uc5FPBVSCOg9DginKMke9Nsiz6kRiHOao3gG04rWmASPJ61jXbFjxVUtWYTjc4Tx/poutLeRFzLD84x6dxXlde8X6B4mVhkEYNeIajB9mv7iE/8s3K/rX1mU1XKDg+h89mdLlkprqdF8J/+Sp+Df8AsNWX/o9K/SmvzW+E/wDyVPwb/wBhqy/9HpX6U16x5Z4B+2t/ySzSv+w1F/6Inr4qr7V/bW/5JZpX/Yai/wDRE9fFVABRRRQAUUUUAFFFFAF7RIftGr2kX96QfzzXu1mMqCRgmvHvAUHneII2PSNS39P617DbcH3FeDm87zjHse/lELQlLuzf0uIXMwiTOyNDLMx7KOSaYsw3sI12gg4B9P8A9VZySv5ZbaoJ698VHFcyNKElyzkk5UcYrx6sXJadD1lC7ZeuJQi5PSnWDCZhjoaiuIzJC2ByRxVjwnH+6YzhlZRjPofWuVpcjZaRqwW7PnYrEL1wM1MYQHyucAZ5rotMjSNxa2i3Ewlx5soUgjAOQoH8/eqOpwpa/uxHsaQeYR/dBJwPy5/GuapBxjzXJhU5pctjLWMu2F69eabJEF5yDg4Iz0qwoeN2AOCy7fYg0x4y7ERKWC8cDms0b31K2R7U1gDTSCCaUZ545qrFuI+3kkglWS3kaOVDlXU4IqxPeefbmOWMmXcD5hbJP51FEhPaluLZvLyUPA3cjHFNTfwmbir6i6ZKhvJI5LYTLIu1Qp5U+oqrqltLZztFKOhxkDg/Skt5prS7iubZtskZzg9D9ak1q/Go3JuDEYyRll3ZGfauhcjh5i5Wp6bGRMw24K4bPBz29KdGhZcnODwKmitZLmOSWNCUjIDEds9KIk2tkjPaqd0ja62Q+CIjG7jtV2RVntBEIgDE24t7HjH5j1pI1GatXFp5KQSxktISOo459D3rn523oS7XVzMtysErBkDqQRjJH41dtG8qZXXGV55HX2qu6stxIky4lDEMD1BqVQQ34USZpa6Og0+5jF9PJ5ghhK7m46nrtH1Pesq6kM0rvjG4k49KYnzH2pzdgKycnaxkqahLmEUUppKaSR0qNw3GyHNRE7s4HAqVdpYbyQueSKmmLYSRIlEe0kcA5Gep9OT3rSK7D5uXQpkYGcg57UmeOtTTiLcywF2QHhmGC34dqiVcjjA+pqh30K08oCkZ4+lU2dSQcip77CxFjg8HgmuEvbudboKhJjzyQeld2Goe12NqcVa7O7jbI4xTiCVz2rA0fUGJEcxyOxNb6kMuB1rKrTdOVmKpBwepGwP8PFSx+uOlCKC3qKdP8iccVk3fQwkyrezZ4zWXMxPTvVmfJyTVJzzxXTTikjCTKd1yPwryHxnCYfEFzxw+HH4ivZJUBBPavL/iRB5eo20oHDxlfyP/ANevbyqdqvL3R4+ZxvSv2IvhP/yVPwb/ANhqy/8AR6V+lNfmt8J/+Sp+Df8AsNWX/o9K/SmvojwDwD9tb/klmlf9hqL/ANET18VV9q/trf8AJLNK/wCw1F/6Inr4qoAKKKKACiiigAooooA7j4Wxu99ekCJYgilnfrnJwB7mvT0VFYMxwvfNeVfDRd+o3Q5yEBx2616nGoK4fp6Gvm81/j/I+lypfuAl2yFyGyoHRTV/Trd5diBFLsOFDdKqQW+JCQOvX6VsQrlw6rtZemOMCvLqVIpWPT8kTpG3lluigbTitLTLZ4WW4MD7Zd2zYvB7HFUZS8km4tkyH5gBjJ9cV1cF+tlZweauRbqEKdCSeeK4lZ7uwScorRbjV+0WTrcWsLx7CQ28YwSOfbHHSsttRa61Qy3BErBg7r/eH9324rXOorb2s32FV23CfMCSdw7gH2PXvx1rNhshbSSKzqSmGmdT0J7D1NTVtHRa/lf/AIYVLZua1/E1GksdQRxHbxwSMdqg8sABxg989MYqlpsRTVXzFucA55I/P/69V7df9IUBS2DgYOM/5FSNqAa/eaRDtORsVtvHp9KlVbtSe4cjV0tjLlKiZip4B4pEwW6Yq15CTHbFhpGBIj6ZYnAAP41Rtn5McnBU4IPUVNny3OrmTJw+z1PtmpJLgSKqtEDg5Dbjke3Pb/GomXcQq/eJwPeo3Z1JjIwM9CKIoTSZNciGWQtbxtHHgZUnOD3x7VXYxpJG7Rhwp+ZegYelK2VXIUZHVhUtzbFFidW3KwyCOx7j+VWt+YVraGNcX8MN++wSwQt91ScjPoT3H1rVjLSwbwoeR+QEOMYOelQz2a7FMqsGkG5BjqPU1ahlSO0jhjhCyKGBkycsDgj8sfrXQ6kWuxTcbLlRFH8r4Jz+lb0FtdajpssUMatGuHOEyw+noKwSCD711HhfWHsra4ig2iZwfmbpjFY0VGU7SdkY12+W8FdmKglltPKunIihm2ljyVyOPc9MVDdRNDOqsm0lQcH3FPnjZpbiZFLrEVVmPqT1q54yuvNurWWUxoxgSRihznIwAffiny86b7FQlaaj0ZWiUHazAhDkZA64qMn5jVS1nMncgD3qbzR2rmcGmayi0PZu/QVBK5Oeaa7lgTnArm/EGuDTiqRLvlbsT0rajQlUlyx3JSOh3bQCcH2zUl1emVQoRIo1GAiDAxnOT6npz7VzmkauL4Y2kOo59BV+SX5uvNbSoyg+WRbjrdlxZgR9409H8wDA61TU89qlDcD0rNxJkxt0u9D6Gubu7ZmaXlI42ChtoAyF6Z/nXUnDHA5FRPAAGA6Mu1vcelb0K7paGlKoo7nO2tmhCSQPuA4P1rZgyi8mpjGuRwAAMYHFaOm22niGW41OdvlyqW0X+sc44bPQAHGaudT2jsRXxGhUgPPtT5huNQI23HrUwkGR3rka1uc7kULpcZrOZfmOK2L6USSFljSPP8K9Kz5Bk10U5WRi2VHUgexrgfidb5sLebHKSkfgR/8AWr0IjJPpXIfEaHdoExH8LK3616OAny14+pxY2PNRkjkPhP8A8lT8G/8AYasv/R6V+lNfmt8J/wDkqfg3/sNWX/o9K/Smvrj5g8A/bW/5JZpX/Yai/wDRE9fFVfav7a3/ACSzSv8AsNRf+iJ6+KqACiiigAooooAKKKKAO2+FhA1a7Gfm8kEf99CvVYY8jnpXkPwvuYIfF1vBdNsju0a2D54V2HyE+24KPxr2G3LKWSQbXVirA9iOor5vOYONRT6NH0OUzTpOPZlu2iIOBya07ZA0ExKgsqjn8az4A+/ORtx0xVxT8ueh7V8/NnsJFm3iad4ljcbtxIGORx1ra1TTrhXtnOXWQEblbdhs4JJqlo5VfszAAv5pyducDArqNSv1+zXM0cai4LNGYQuF24AHHrjvThCMou71RFScoySRgWrWiGNHYxohYM69N2OPwzS+W8iAh2WHIYj1Y5A49/WuJXVJrzUZbe0t5DsOGIXAXtzXbaLBd28avfRR/Z0BYpKcCXjpkc5547Up4aUUuZGlVez1vqQv5tvICvyyxt0I6EVBrYdHF4NjRSfeMYOM8Z469TV2ZSpkyhCseAxyR6c96qT8QlSSFBycnj61ywkk7FQ1aZmWV+huQJCVDfJyO3+NaBeNYrhBIpd9oBK43Lx+RBH41zt7C1xNtgcHPYevb8ahim1CLeJ7dysfAYMCa7vZXV4nTUpJ2aOjhbybmN8LMAQwHYHsDU97cyX0jytGuY8KXVcfnjisnT9btbnTvIe3RmVyzMDh84wB+fJ9ansbpoYXjAG1yNwz1xUyi4RcWYKLvdrVGlJviAjU/LIFV/r2/nSRJN9n8lcSRb8rgZII9Paopr5TYurDndu396taPqdra6RJPcXMZnc7URhjA9c5/DFZxhzbOyJm5Rjewy7gcSwEuikDGAcY4pl5p09oiSujBDxmsqfVYLm6wlyoO7gg5rpmuQ2lJCm4MMEktkAY5GPrT5Uovm+RDlKNjMR964Y54A59B0FT2UcqShowAc4GaqMuBlelWbK6t8yx3sJaJ142/eDDpg9vesqestxydloWVubOKG4W6DGWRcxvGcgEc5Pt9M1xOtme/aMKD88uTjoMV0uuanBcRCCKKKONMHcg5ZuhyTziqlmUKptC7QCWr0cNyqd3skY8zir9WZbme3jSC2Qs55LnoB/jVu1M+1RNt6c47mpVRmdmdtxJz9KklAijRiOG6HHX6Vyymnokegql1YDgqa57VtHS8nEhOD3rZknGOvFUI71ZtxQHaDgE96qjzwfNEI3WqIbW2Syj2IP0qUMSecZp8jhh1/CoOVBPrxWt3LV7ilIsxyDPJ7dKlhVppQkeN3XkgDH1NUg27C4yeg5ruPh74dsNTgudQ1iOWW3gkWGK2hPzTynnb64xj/Ip06LqyUYnNXrRpQc5HMAESEBlyO6nIqVz61pa3pL6TfslwkcMsmZfsqNvNupPyox9cVlvjNc1SLjNxfQITUoqSImPzCjofpVrTbv7Bfw3Q5MZz90N2xwG4/OoCrP85I+YkjJHrR0JcncgdtuSaiS4weeRSTtwSaqDqOa1jG61JbJpZS7kj8qAN3vUJOTxU0OcdKpqyJIp12c9K5Px6f8AiQXef7o/mK6655xmuG+JUuzQmXOC8ir9e/8ASuzArmrQ9TkxbtSlfscp8J/+Sp+Df+w1Zf8Ao9K/SmvzW+E//JU/Bv8A2GrL/wBHpX6U19ifLHgH7a3/ACSzSv8AsNRf+iJ6+Kq+1f21v+SWaV/2Gov/AERPXxVQAUUUUAFFFFABRRRQA5GKOrISGU5BHUGvoO6nUvZTl5c3ttFcuXxnc6gk575OTXz1Xsnh/WpL7wzpLXO7zraLyInJzlVY8fkRXnZlTU6Xoz08qm41mu6O8050Vw8mWT0x7VoCMGFpV5TO3nrk1zenXalFBJ9K2oJQWOAGB6Z7V8dVg0z6eKvqdN4bZUEsXDfvUkb5Q2AoJJFWdT1aC4tkjnEhbEk8mGC7pW7njpjHA61FolxZ2Nn/AKQDI8hIfHXBHAH60zQLE6hqTAGFIVPIldePpn0pU5ydoQd7mE4xu5y6Hnujx3Gl6vqTXHlSqxEnluCrOp/uMD78jvivStFSa+08vbWwlkiZY3Qk7nGM7uD1ycAY/rWBrcfm6pcNOgEolbOMH6cjitLwdeyWWsxxo5ijndUdgoOBnI/I4rsli1XcaUlZbFVoN0+eO+5JdYSSZIndoy2cSDBz/wDW6VXlb90duRu4cZznmr2tMItTvYiASJcBh39x9apMWSGTLYQtsIHO4j+grxpRam12Kg7xTKEsUZXGwNKGzuU9vTFVY4lVCxz8zNkY/r3rUeAKkjBgUH8RG3jP6ZrPkIxleW9DwK3TdrHRGdzkPFMElhcpfWw+RlxIq+o706y1YNApkO18D5e9dBdwR3cEkUuOfQV5tr2h3lhK0gkcpn5JMk5HYGvXwyhXgoTdmV7Vx2VzobrUrq/ZrLTUPmDLuxPyhRWvNocs+jxQXMoMmdyvGe+P5c1wnhuwv9Q1aIJIQFID4HL/AP169bks7yKxuXTGIwFlIA9fT6itMTCNFKMHt2M/bOe+lzA8NaNHaPmZFbaeCa6xHQQtNvVCuAEzyx+npWZJGqQ2rfaY5Xlj3sqf8szn7p96SKQh+GOfWvLrNyk3PVkNX2LTEgelQShiNoJHrV2GLzIeFcsD8zHoB2pYrCaW8S2RczMeAD14zXNFO+iHdI5TxBBKbUhCVz3HU+1VfDIeNZpGkJLYyN2etbWrwNcRmBozsP8Ae7+hrE0+0uI7GaUEKsLDdk4J+bHTv1r0qTcqLh1M5R1uzpkkQY3HAAz1xms/Ur97m5Z2K7j2AwPyFQfaN6Drmqc8uCcnmsadOz1OiLUNWWVZyCSeDSbfyqkt0On9asxTb1wa1cWgdW5OseV44NCxswOOlCzZHSpoGBPArNtonmuOsClveRyTW63EQPzRMSAw9Mjp9a6/w74kttEt7u406zK6tclgrH/U2qdhGOST7muXdNqb5MBfWqslznhTgU6dacXeG5jVpQqaSL01xJJNLLPK0sjsWZ2OSSepNRM+TxVe1SW6mjihVnkc4AUZrutD+HmsagrlFggiDbTcSsSD67VxyPelDD1KrtBNsVSvTpL3nY5bR5ba31WCa9i86BGy6Aj5h+PH51JrjWEl00umxywxyfO0MgH7s56AjqPwr23w14RsNO0u3ia3tXvWizNLtDndnqpPYVwmpRre3uqRWltKbqwiZpQ21jI4YfMWxzz0X2rtq5fUo01zNXfTr9/6Hnwx0KlRuKenmecSR/LnGD71Sfhj69q9pgnt9Ia5imNm9tqEQljacjaWCgnDYwAcEY9a5Hxx4ittTZVTRY7IJzkyAlj6nHUemKh4dU4c0pa9v68tTSGKlOVlHTvc4RASc1chUDqKjQndvOPXpwaezY5zXJJ3OsivQAMivL/ilcfurOEHlmZyPoMf1Nei302EOT2rx34g3gudeMa7gkEapye/Un8zXr5PSbq8z6HlZlU5aVu5L8J/+Sp+Df8AsNWX/o9K/SmvzW+E/wDyVPwb/wBhqy/9HpX6U19QfPngH7a3/JLNK/7DUX/oieviqvtX9tb/AJJZpX/Yai/9ET18VUAFFFFABRRRQAUUUUAFd54CvFl0u6s3ZzJbv50a4yu1uH+n8Jrg6taddzWN0k0ErRN0JXup6g+o9qyrU/aQcTbD1fY1FPse1WFxyoxmus0SIXM8cO8KXOAScV5jYXso3MuGVCAzL0weh/Guki1ZovL25LZ7dq+VxWFlex9hTqKUbpnbS7oZZY5gd8ZKn2IpEYk5PJI71UsL6G5t5XuY5pZyMqyt3z1bv+VS+awXGNinsK8mVNxOiMi3HLjdkbs8UIxjkBK4J5GRUEcu09cCopbiRpPnZn2jGSegFQoXKsaxnLtlwA35Yp8V2scisMEr0B6VQgmnuEbG+RV6knOOPU/Sq4Q+duJ6HgVPs9dRRgndM2J7kC2lVt7PKQzNn0rHmmCgtIrKvZiOtX0Zid/HtwMVRu3dgEyCoOcHpmqhq7MSVtEUzdxGbG7r6Vblitb20kimw2V+UnjDCo1G5QNox9OlP2KEAAIbPPpXQqnLsNLW5j+EQbO5a58lCY5CMAblJ6YJHfmuntb+W3kf94SZQUkDc5U9QayIrGKORnj/AHZJydpxuPvVzYzDCONwII5/WqrVueScWTKCk22PnT5gke5wgIiJGPlotrSR8FWw2cHitWK4SNnjhUuzsP3jY3H2+maa4wX27Sy9vX1rnnKy0I5iSztX8syMXZYx86KcHHrVqbTZre1mvoriAzQlVMJb5xuHBHqfbtVS0u2jZjvCKAcKVzuyOhqjrN1Z2UYljlEpKkshTbt9ge+TToJN7akNSbsS6JZQX2tw212z7JsgswKkNgn8MEVT121aCW+WM/6M0gTheG5yOe/TP4Vq6XGp1greymOUbcSAc54x+hrG8Ta7aprs1jEqTRpJ5vzscuRwQfbAHSvShRapy9TCU26q9DGlTb92s27cpx1Fat3dLdAFFWJV4Cr2FZNz8z4rOmtdTqk7xIIPm74q5EGLAbsD2qusLbhxWjZR4+91/lVVJJK5CLdvDwg3qzNxjuPrVmOIoRgY75qOOMA4AwKsbwq4rilJt6FIo6lNI67c8L2rOhLlsVozLuJNQxRhTzzW0GoxsJnTeDLXWzcfaNHtzI2Np3YAYd15xn6V7Loet69rGgXcaWkFpq8BCqJVIjZSP0NeRaNdH7PZ2sEESiK5Est0JCrvH3Qjpt96900K4ZrSS4G1I52/cDbjf2BLHk54/CvXytKTajNruv6XT5niZk7Wcory/rzOXh8E+ICPPl8UypfsCGCA7Qp7A5/pTvDmn6D4Qmu49Y1yCfUpVBlEhxsUHPTnvg5PtW0bvSRdwahdSSi6g3CSRWPl7wvzIe2R2FeOeJNYbWrm/WUw2+yWWaJnXLsGOfLz2/8Ar1pXlQwtpxV5dLtv5+TMqMamJvGTsutkkeoeKdZ8G6d4fSCZLO/gRjJDZwEPuY5OTjoMnqa8V12y1FbxGvdPezW5YvBEy7QFY8Bfas+JntpRJBKquOhI4YdxVzxF4jv/ABBPDLqMvmvEmxMDbtHpgVw4jErEq7VrbWX5v8j0qGFeHdou6e9/8ilMjQyOj43IxViDkZBwcVWlkpC27kniqt5KEQ81xxjdnVLRamTrl+ltbSSSHCIMmvGb64a7vJrh/vSMWNdT481czz/YoWyiHMhHc9hXH19Xl2H9lT5nuz5rH1/aVOVbI6v4T/8AJU/Bv/Yasv8A0elfpTX5rfCf/kqfg3/sNWX/AKPSv0pr0DgPAP21v+SWaV/2Gov/AERPXxVX2r+2t/ySzSv+w1F/6Inr4qoAKKKKACiiigAooooAKKKKAOn0HUwtm0LEKwAXaMjcM5De+OldPYalDI6hmOa81hkaKVXjOGU5FdJp0i3kfmwEJOv3k/r9K4sTQjLVnr4LFtLkZ6PBfyRXEZhYqRyrKeQRXTW95LcRhpmZnKgD0GOBXnehXzsdk6YI45rs7K4XauMV87i6XL7tj6ClVU4mmLk+d5e05x1HSkZt7Zbrmn2EsccpkdcrtPHvTvPhUP8AdIYYz6GvP2eiN1PyJLbCsxJ4PQDpUzSoOhrn7y8mifMSBoVXc5zgjkD8eoqSC7EqI4Y4boMVcsPJrmZok2dAJgRtGB/WoS53cdPWo4GwpwOeh4qF5WXJJ4rBQ10CxYMgHejzqovMx6KaiMjHHDVoqQWNLzsDrTojucHPFZLFv72KvQTKF5pSp2WgPRF2W7EdwqK2GI6A9RVxHBSudhmW5vHkQHZGdm49z7VrK+0AZH51lUpctkZyVi3v+U8isLW7eSdoy+DErglSSAw9CRyK1RJGCCDliOSR0NWLa6to3KX0fm2z48xQPmx/snsadBunNNC5uXVK5o2ssQ0i8ivbZxI+yRbhW5TAwBk9jXj2q6pAuuPOmZFJ8tin3lYdeOw6fXmu9n1e6Gm3Vs23yQ+E3EE7VztyfYHmvGb3UFa4kl2LGykxHHPmHJyxz+H5V9JhqXOrM8bEVHSk5J6ndWt35lsky52N/P0qzZSfauc8L/n+lcXZa88TwhHDCLA2A5B967rSAJYFMeAzcg4+8PWuXFUPYq51YXEqqrF0RgCrtpENucU0wFTzxmn+YVXCmvJlK+x13sEzbT8v6VA8nbP1pGYkmo9uTk5pqNhDzIfwpUf5vm7dKFT5cikCHPpRoI2tK1SXT5kmgSMyKcjeoYH2I7itePxVeNaNa3bPJaswJVGKFMHopHTjj6VysXygk09n3DAzSjOcNIvQylShN+8jptQ8XltEl0iysIbaykk8wgOzkHuck5ya5KWQv6bu57058heRyaj2k1cpyqNOT2HTpRp/CRSc9qiKnPpU+0DvUUjjBpxZo3YikcItcZ4y1wWFs2w/vn4jX+v4VseIdXg0y0eWd/oo6sfQV4/quoTalevcTnk/dXso9K9jLsH7SXPLZHlZhi1TjyR3ZUdmd2dyWZjkk9zTaKK+kPnTq/hP/wAlT8G/9hqy/wDR6V+lNfmt8J/+Sp+Df+w1Zf8Ao9K/SmgDwD9tb/klmlf9hqL/ANET18VV9q/trf8AJLNK/wCw1F/6Inr4qoAKKKKACiiigAooooAKKKKACrFldSWdwssR5HUdiPQ1XopNJqzGm07o9C0y8ivLZZrdsMOGU9VPpW9p99hQJDtI75rymwvJbKcSQtjsy9iK6+3vBcW4dWBjPI9vY15WIwn3HvYLGe00luj0L+27eOII2WPqozmrOkXd07XNzLGFJG2IGMEnIwcntxXnVr5vmiRG2gevSvRPDXie+WBIpCjiMFVzg4BGDXm1cP7CLcNT2YVedaIWeImFyEAKgHk9Pp71a0K8ns0ZYgikgruKAkD2J6Vp2l1CYfJkQSQt96Juh9ee1JBHnO+NVCkhQDkAZrzXWtGzOpSunFospIHtSpRN5PDZ5A9Me/rUM9ooK4cOSATjOB7fWp41UYIFPJySScsTkk965Oez0BaGbJEQeBUTowHtWnIfpVWWMv1zj06VpGfcLrqZM8oVgBlj6ChFlmOD8qenc1eaAKMqoH0qS1MsJZo9oJUqcgHg9evf3rb2itoLn7DbVDARmONgOzLmpXy7E7VXknAGKkhGcAip9gA6cVzynqT1uVlQ46/lTGBVTnNTXM0UMZJIBqjDN9rmjhRgDI4UH61UIynsjKbsmyXXbL7HplmwIV7mEzCPA+7yMn2Pp1rxjVbSJrp3eRIsZA4JJ9sV6L4x1QFpJI+EcmOBXOdqJ6H8P1rzy4tnnU3kYeSPcAzkcK5/hr6XBwcUmtrHz+KndWluQSWc1qYpUZXVwOUww5HQnsfbrXp3w3Iv7GWAqxuISWTnqO/14rzOWV422CU+WxUsueG/CvRfhRKY7hZ5wHiLspQnAPGOavGrnp2kRhXyybR2OoR+SVjBDsF+faOFPoT3NUT0rpPEXlo6SROjtONzhcYHp07/AJVzMpyeK+XtaTiexSm5RTYqIT160/y/fiqrM2OCRSI7E4LY96rlZumXtoFDMAOlRRrJ1Vt1SRwTSuoHLM20AHnP+TUWC4wvngCr9pCTyVy2Ogr2Pwh4CtF0xY/EejWoukAxKk7MZAfUZ4IrhvHmkaTa6zdLo91FBBBH88DsSTICMqn4EHn0NdlfL6tOkqsrJPp1/E4qeOp1JunH7+n4HGXUikkAZqqWc9FqdiOwFRNIAtckVY7rkT8c1zviPWIdLtHlmbpwAOpPoKteINYg0uzee4faOijuT6CvGNd1efWLwzTHCD7iDoo/xr18vwLrvml8J5mNxiorljuR6xqlxqt209w3H8KZ4UVQoor6iMVFcsdj5yUnJ3e4UUUVQjq/hP8A8lT8G/8AYasv/R6V+lNfmt8J/wDkqfg3/sNWX/o9K/SmgDwD9tb/AJJZpX/Yai/9ET18VV9q/trf8ks0r/sNRf8AoieviqgAooooAKKKKACiiigAooooAKKKKACrum3rWkpyN0T8Mv8AWqVFJpNWZUZOD5o7ne2kqTiEQNmNh1FdDaAW2CMjI615Zp97NYzrJC3Tqp6Gu80vWrbU4lTcFlx80bdfwrysXQlHVao+iwWPjU92WjL4vr22v96ymRCemc4/Cu4068aWNCf4hXnQMdrcvKoJOeeeK6jQtTScEAEEdK8zF0eaKaR7EJPqdtC42jIwDUn7sru8wg5Py7fy5rJjuSVBB/CnC63DJBH1rxXSZW+poMQSMMvI7nFSLAzQiQtHtJxjcM/l1rO80MB2p6MQOtJwaB3Log+XOKiaEg8UeeAvXmmC4G7mpSkInjiI9qJlJXGaiF5z0pWudwPFFpXBFXUrY8RFRuUc9ec/1rKjthAwJkKkHOR1Fas13vJ3MS3vWJe3BWZQOhPNdlLmehNS6Wph+OVZ9NWVcmKAlUBHQE1yNnGUZmUkoRnyweD6ZFdvq4WewureTIC/vVI9RXHyqtsyFGUgnhs9R/8Arr3cFVfJbqeDiqaumUPsjy6osUaHeBn5uirXd+D7qKxhEscm+IHfwPlO3rxXL6Q7XMtxKvAwUz6Vf8KXCwQqlyiM8LsxVuAT0rSv7ys+licNGz9bnrkk9lqFray6YxYSFy5kwp4G7J7DjgCsyZMRq46NmuVtdSnnmmmkfJd97AcAn6Vs21/nbz9c14OIoqM24KyPQoqSVmy2EyORzUiQd8cYqe2aORiT354q63kMqBYyhAwTuzuPr7VySm1odKZSjGztU8AVAJQ+2VWBVcdR65+vapAsHzbvMzkbQMYP1pl+8UlzJJbw+RExyse4tt9s1N7leR7lN8SNCtfD0V9NcrJdGIMbZQd2/GCD6c/pXhWpar/a2o3F/KV33DmQ7egyegrNvdkkZV+RWJd6nbaWryXdxHHGPuqTz+XevUrYirjYxjLp26nLQwtHC3mnv3OgmmUVzfiTxFa6Pblrh8yH7ka/eb/61cnrvxC3KY9KiJbp5so4H0FcBeXU95cPPdStLK3VmPNdmDyiUnzVtF+Jw4rM4pctLVlvXNXudYvGnum46IgPCD0FZtFFfRRioJRirI8OUnJ8z3CiiiqJCiiigDq/hP8A8lT8G/8AYasv/R6V+lNfmt8J/wDkqfg3/sNWX/o9K/SmgDwD9tb/AJJZpX/Yai/9ET18VV9q/trf8ks0r/sNRf8AoieviqgAooooAKKKKACiiigAooooAKKKKACiiigApykqQVJBHQim0UAdBp3iSeJVivVFxD0yfvAfXvXeaJf2k8Aa0CsnfZ1H1HUV5HU1tcTWswltpXikHRkODXHXwUKq93Rno4bMqlHSWqPdob5AOtWVu1boQa8jsvGV5GqpeRR3AH8f3WratvGGnuAJPtEJ+m4fpXjVMsqR6HsQzKhNX5rep6J9rXGCcN7U77cF5JwK4+113T58GO+hz6Odp/WtEXIlUFXV1PdTkVySwrjpJHVDERls7nRfbY/L3MwX3JqI3YYZByPUVzN3PPujWJVZM857Va+3qVxkDHFH1ayujdTVrmudRVG255qxHfgjkiuD1C4lExZQceop0OqPDCXuCF92OK2eBuromVSK6naXF4N2ExkVi3UziQM3TPPtXPv4htYV3yXkbMT91OcCnDxFpToGmu/fAU5q4YOcPsv7jmli6WzkvvL97dh42Cvh8YFY9z9lls9rxOs7MMkcgAeg7VHP4m0dJQUWeVc/3cY/Oq83iywBPk2kp9CcV2UqNSO0WcNWtQf20akUIYfuIdinGR0B98VZgshyzDLH2rnU8WwJg+ROW9MgCnjxvt+7Zk+mXpyoYh7IzjiaEftHY2NsY2Gc1sxIgx2rzb/hPZh0sk/77/8ArVXm8dag5/dwwoPfJrnll+Im9V+Jqsxw8dn+B64kyxH5Wpz6mq9zmvHh441EIR5cBY98Hj9azrrxNq1wxJumQekYC1McmqSfvWJlmtJbJntr63DChaaQIo7scCub1n4g6fbEpAzXD+kfQfjXkU9zPcNmeWSQ/wC2xNQ110slpRd5u5yVc1nLSCsdhq3jzUbsMlqBbIe4OWrlLieW4kMk8jyOe7HJqKivUpUKdFWgrHn1K1Sq7zdwooorUyCiiigAooooAKKKKAOr+E//ACVPwb/2GrL/ANHpX6U1+a3wn/5Kn4N/7DVl/wCj0r9KaAPAP21v+SWaV/2Gov8A0RPXxVX6K/Gv4df8LN8K2ujf2p/ZnkXqXnnfZ/O3bUkTbt3Lj7+c57dK8U/4ZG/6nb/yk/8A26gD5Vor6q/4ZG/6nb/yk/8A26j/AIZG/wCp2/8AKT/9uoA+VaK+qv8Ahkb/AKnb/wApP/26j/hkb/qdv/KT/wDbqAPlWivqr/hkb/qdv/KT/wDbqP8Ahkb/AKnb/wApP/26gD5Vor6q/wCGRv8Aqdv/ACk//bqP+GRv+p2/8pP/ANuoA+VaK+qv+GRv+p2/8pP/ANuo/wCGRv8Aqdv/ACk//bqAPlWivqr/AIZG/wCp2/8AKT/9uo/4ZG/6nb/yk/8A26gD5Vor6q/4ZG/6nb/yk/8A26j/AIZG/wCp2/8AKT/9uoA+VaK+qv8Ahkb/AKnb/wApP/26j/hkb/qdv/KT/wDbqAPlWivqr/hkb/qdv/KT/wDbqP8Ahkb/AKnb/wApP/26gD5Vqe3uri2ObeaSM/7LYr6j/wCGRv8Aqdv/ACk//bqP+GRv+p2/8pP/ANupNJ6MabWqPmhdd1IHP2uQ/XmlbXdRbrcH8hX0t/wyN/1O3/lJ/wDt1H/DI3/U7f8AlJ/+3VHsofyo09tU/mf3nzT/AG7qO3H2g/kKoz3E1w+6eV3P+0a+pP8Ahkb/AKnb/wApP/26j/hkb/qdv/KT/wDbqpQjHZEyqTkrSbZ8q0V9Vf8ADI3/AFO3/lJ/+3Uf8Mjf9Tt/5Sf/ALdVEHyrRX1V/wAMjf8AU7f+Un/7dR/wyN/1O3/lJ/8At1AHyrRX1V/wyN/1O3/lJ/8At1H/AAyN/wBTt/5Sf/t1AHyrRX1V/wAMjf8AU7f+Un/7dR/wyN/1O3/lJ/8At1AHyrRX1V/wyN/1O3/lJ/8At1H/AAyN/wBTt/5Sf/t1AHyrRX1V/wAMjf8AU7f+Un/7dR/wyN/1O3/lJ/8At1AHyrRX1V/wyN/1O3/lJ/8At1H/AAyN/wBTt/5Sf/t1AHyrRX1V/wAMjf8AU7f+Un/7dR/wyN/1O3/lJ/8At1AHyrRX1V/wyN/1O3/lJ/8At1H/AAyN/wBTt/5Sf/t1AHyrRX1V/wAMjf8AU7f+Un/7dR/wyN/1O3/lJ/8At1AHyrRX1V/wyN/1O3/lJ/8At1H/AAyN/wBTt/5Sf/t1AHgHwn/5Kn4N/wCw1Zf+j0r9Ka+a/Cf7Lv8Awj/irRtZ/wCEv+0f2dew3nk/2Zs8zy3D7d3nHGcYzg49K+lKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Axial image from abdominal CT scan shows an 11 x 15 cm mixed signal intensity right adrenal mass (arrow) with large amounts of macroscopic fat consistent with adrenal myelolipoma.",
"    <br>",
"     (B) Gross pathology cut section showing a 19 x 12 x 9.5 1030 gm adrenal myelolipoma.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_33_4630=[""].join("\n");
var outline_f4_33_4630=null;
var title_f4_33_4631="Pulmonary air leak in the newborn";
var content_f4_33_4631=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pulmonary air leak in the newborn",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/33/4631/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/33/4631/contributors\">",
"     Caraciolo J Fernandes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/33/4631/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/33/4631/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/33/4631/contributors\">",
"     Gregory Redding, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/33/4631/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/33/4631/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/33/4631/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary air leak occurs more frequently in the newborn period than at any other time of life. It occurs when air escapes from the lung into extra-alveolar spaces where it is not normally present. The resulting disorders depend upon the location of the air. The most common conditions are pneumothorax, pneumomediastinum, pulmonary interstitial emphysema, and pneumopericardium. Rarer forms are pneumoperitoneum and subcutaneous emphysema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Air leak begins with the rupture of an overdistended alveolus [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4631/abstract/1\">",
"     1",
"    </a>",
"    ]. Overdistention may be due to generalized air trapping or uneven distribution of gas. The air dissects along the perivascular connective tissue sheath toward the hilum, resulting in a pneumomediastinum, or into the pleural space, producing a pneumothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4631/abstract/2\">",
"     2",
"    </a>",
"    ]. Less commonly, air may dissect into the pericardial space, subcutaneous tissue, or peritoneal space, causing pneumopericardium, subcutaneous emphysema, and pneumoperitoneum, respectively.",
"   </p>",
"   <p>",
"    The perivascular connective tissue is more abundant and less dissectible in preterm than older infants. This predisposes to air trapping in the perivascular space, resulting in pulmonary interstitial emphysema (PIE) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4631/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on the incidence of air leak primarily reflect the incidence of pneumothorax, because that disorder is most common. The incidence depends upon factors including birth weight, the presence of lung disease, and the method of detection. In a report from 1930 in which chest radiographs were performed on 702 consecutive newborns, the incidence of spontaneous pneumothorax was 1 to 2 percent of live births, mostly in infants with otherwise normal lungs [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4631/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence is increased in preterm infants, who often have pulmonary disease. In a report from the Vermont Oxford database, pneumothorax was reported in 6.3 percent of 26,007 infants with birth weight 500 to 1500 grams in 1999 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4631/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of spontaneous pneumomediastinum detected by screening symptomatic infants has been reported as 25 of 10,000 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4631/abstract/5\">",
"     5",
"    </a>",
"    ]. However, because pneumomediastinum is usually asymptomatic and may not be undetected, the actual incidence is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of air leak occur in newborns with underlying lung disease, especially if mechanical ventilation is required. Preterm infants are at increased risk because they frequently have respiratory distress syndrome (RDS), although treatment with surfactant replacement reduces the incidence [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4631/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Air leak also complicates pulmonary disorders that affect term infants. Pneumothorax is a common complication of meconium aspiration syndrome, occurring in 10 to 30 percent of affected infants [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4631/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/16/21768?source=see_link\">",
"     \"Clinical features and diagnosis of meconium aspiration syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other conditions that predispose to pneumothorax include pulmonary hypoplasia (in which pneumothorax is often bilateral), pneumonia, and transient tachypnea of the newborn [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4631/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/2/32804?source=see_link\">",
"     \"Transient tachypnea of the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mechanical ventilation increases the risk of air leak. Contributing factors include high inspiratory pressure, large tidal volume, and long inspiratory duration. However, in a case-control study of ventilated newborns, inadvertent overventilation (indicated by low carbon dioxide tension) was not associated with pneumothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4631/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PNEUMOTHORAX",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumothorax consists of air in the space between the parietal and visceral pleura.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with a small pneumothorax may be asymptomatic. However, signs of respiratory distress such as tachypnea, grunting, pallor, and cyanosis usually accompany the disorder. An early sign of pneumothorax may be a sudden decrease of voltage of the QRS complex on the oscilloscopic cardiac tracing [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4631/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Findings on physical examination of the chest include",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chest asymmetry with enlargement of the affected side",
"     </li>",
"     <li>",
"      Decreased breath sounds on the affected side",
"     </li>",
"     <li>",
"      Shift of the point of maximal cardiac impulse away from the affected side",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A large tension pneumothorax increases intrathoracic pressure, which may cause increased central venous pressure and decreased venous return. This, in turn, may result in decreased cardiac output, leading to hypotension, bradycardia, and hypoxemia.",
"   </p>",
"   <p>",
"    Pneumothorax is often preceded by pulmonary interstitial emphysema or, less often, pneumomediastinum (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57634 \" href=\"UTD.htm?9/20/9536\">",
"     image 1",
"    </a>",
"    ). Pneumothorax in RDS has been associated with increased risk of intraventricular hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4631/abstract/15\">",
"     15",
"    </a>",
"    ], chronic lung disease, and death [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4631/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Pneumothoraces may also be seen following open chest surgeries; however, prophylactic chest tube drainage of such air leaks has not been found to decrease postoperative complications [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4631/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumothorax should be suspected in any newborn with the sudden onset of respiratory distress. The level of suspicion should be high in a mechanically ventilated infant with an unexplained deterioration in oxygenation, ventilation, or cardiovascular status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Transillumination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transillumination of the chest with a high-intensity fiberoptic probe in a darkened room may help make the diagnosis of pneumothorax. When the fiberoptic probe is placed against the chest wall, a pneumothorax lights up the affected hemithorax [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4631/abstract/19\">",
"     19",
"    </a>",
"    ]. In a life-threatening situation, the air can be immediately evacuated. If the infant is stable or findings are equivocal, the diagnosis should be confirmed by chest radiograph before an intervention is made.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Chest radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large pneumothorax is usually easily seen on an anteroposterior chest radiograph. Characteristic findings are air in the pleural space outlining the visceral pleura (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65732 \" href=\"UTD.htm?37/48/38671\">",
"     image 2",
"    </a>",
"    ), atelectasis with flattening of the diaphragm on the affected side, and shift of the mediastinum away from the pneumothorax. The affected side may appear hyperlucent because air accumulates anteriorly when the infant lies in the supine position.",
"   </p>",
"   <p>",
"    Smaller pneumothoraces may be more difficult to appreciate. Detection may be improved by a radiograph taken with the infant in a lateral decubitus position, with the affected side up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants without a continuous air leak or respiratory distress and who have no underlying lung disease or have no need for assisted ventilation may be observed closely without specific treatment. The pneumothorax will typically resolve in one to two days. Infants with respiratory distress should be monitored closely. Oxygen supplementation should be provided as needed to maintain adequate saturation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29656?source=see_link\">",
"     \"Oxygen monitoring and therapy in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infants with respiratory distress should be monitored closely. Oxygen supplementation should be provided as needed to maintain adequate saturation. Studies in a rabbit model suggested that increases in inspired oxygen concentration up to 50 percent may improve the resolution of small uncomplicated pneumothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4631/abstract/20\">",
"     20",
"    </a>",
"    ]. However, because of the risks of hyperoxia, especially in preterm infants, we do not routinely administer supplemental oxygen above the concentration needed to maintain adequate saturation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29656?source=see_link\">",
"     \"Oxygen monitoring and therapy in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In mechanically ventilated infants, ventilator settings should be adjusted to minimize mean airway pressure by reducing peak inspiratory pressure, positive end-expiratory pressure, and inspiratory duration. In some cases of infants who do not require high ventilatory settings, spontaneous resolution may occur without chest tube placement.",
"   </p>",
"   <p>",
"    This was illustrated in a retrospective study of 136 ventilated infants who developed pneumothoraces [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4631/abstract/21\">",
"     21",
"    </a>",
"    ]. Of the 35 (26 percent) who were initially managed without the insertion of a chest tube, 14 were treated with needle thoracentesis and 21 were closely observed (expectant management). Resolution of the pneumothorax without further interventions occurred in 27 (77 percent) infants. Subsequent placement of a chest tube occurred in eight patients, two from the expectant management and six from the needle thoracentesis groups. Infants managed without an initial chest tube were on lower ventilator settings and had better arterial blood gas parameters than those who required initial placement of a chest tube.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Thoracentesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thoracentesis is used for the emergent treatment of a symptomatic pneumothorax. It may be the only intervention needed in an infant who is not mechanically ventilated and may be a temporizing measure in an infant who requires ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4631/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. The procedure involves aspiration of air with a syringe attached to a 23 or 25 gauge scalp vein needle or an 18 to 20 gauge angiocatheter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Chest tube placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tension pneumothorax and pneumothorax that develops in a mechanically ventilated infant usually need chest tube placement for definitive drainage. In most cases, the tube is placed in the anterior pleural space and connected to an underwater seal with continuous suction at a pressure of 10 to 15 cm H2O. The position of the tube and resolution of the pneumothorax should be documented by chest radiographs. Resolution usually occurs in two to three days, although the air leak sometimes recurs.",
"   </p>",
"   <p>",
"    Complications of chest tube insertion include bruising of the diaphragm and mediastinal structures and perforation of the lung. Hemorrhage, cardiac tamponade, and phrenic nerve injury may occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36951?source=see_link\">",
"     \"Diaphragmatic paralysis in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PNEUMOMEDIASTINUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumomediastinum consists of air in the mediastinal space.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of pneumomediastinum are asymptomatic. Large collections of air may result in tachypnea and cyanosis. Pneumomediastinum is usually suspected on the routine newborn examination when the heart sounds are distant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis is made on a chest radiograph. If the amount of air is large, the pneumomediastinum can usually be appreciated on an anteroposterior view as a halo of air around the heart or on a lateral view as a retrosternal or superior mediastinal radiolucency [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4631/abstract/5\">",
"     5",
"    </a>",
"    ]. It is most reliably seen on a left anterior oblique view, in which even minimal air in the mediastinum surrounds the thymus and lifts it from the cardiac shadow, resulting in the characteristic \"spinnaker sail\" sign.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumomediastinum usually resolves spontaneously, and requires no specific treatment. The patient should be observed closely for evidence of cardio-respiratory compromise and development of other air leaks, especially pneumothorax. Infants with tension pneumomediastinum should be treated emergently with ultrasound-guided percutaneous drainage of the tension pneumomediastinum [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4631/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PULMONARY INTERSTITIAL EMPHYSEMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary interstitial emphysema (PIE) consists of air trapped in the perivascular tissues of the lung. This results in decreased compliance and overdistention of the lung. The interstitial air also compresses airways, resulting in increased airway resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;PIE typically affects mechanically ventilated extremely low birth weight infants and may involve one or both lungs [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4631/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. It usually presents within 96 hours of birth with gradually worsening hypoxemia and hypercarbia. Ventilator settings are often increased in response to the poor gas exchange, which may exacerbate air trapping and lead to further worsening of oxygenation and ventilation. Overdistention of the lung may cause vascular compression, resulting in decreased venous return and impaired cardiac output [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4631/abstract/28\">",
"     28",
"    </a>",
"    ]. PIE may precede the development of pneumothorax or other air leak.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of PIE is made by chest radiograph. Interstitial air can appear as either cyst-like or linear radiolucencies. The former are approximately 1 to 4 mm in size, and must be distinguished from the bubbly pattern that often follows surfactant administration. The linear radiolucencies are coarse, non-branching, streaks that are seen in both the peripheral and medial lung fields (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81501 \" href=\"UTD.htm?36/34/37423\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73752 \" href=\"UTD.htm?7/52/8000\">",
"     image 4",
"    </a>",
"    ). These must be distinguished from air bronchograms (eg, in RDS), which are smooth, regular, branching structures and can be seen toward the hilum [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4631/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no definitive treatment for PIE. Management is supportive and directed at providing adequate gas exchange and minimizing the risk of further air leak. This can be achieved by decreasing the mean airway pressure as much as possible, by reducing the peak inspiratory pressure, positive end expiratory pressure and inspiratory duration. The inspired oxygen concentration should be increased to compensate for the decreased mean airway pressure. We often use high frequency ventilation in infants with PIE to avoid large cyclic swings in tidal volume, although trials of this intervention are not available [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4631/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Supportive management of unilateral PIE includes positioning the infant with the affected side down, minimal chest physiotherapy and endotracheal suctioning, and if possible, decreasing ventilator pressure and inspiratory times [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4631/abstract/32\">",
"     32",
"    </a>",
"    ]. Placing the infant in the lateral decubitus position with the affected side down promotes aeration of the unaffected lung and reduces aeration of the lung with PIE [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4631/abstract/33\">",
"     33",
"    </a>",
"    ]. In severe cases of unilateral PIE that do not respond to supportive management, collapse of the affected lung by selective bronchial intubation of the contralateral lung or occlusion of the bronchus of the affected lung by use of a Swan-Ganz catheter may promote decompression and healing of the affected lung &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4631/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PNEUMOPERICARDIUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumopericardium is a rare condition caused by air in the pericardial space. However, it can cause cardiac tamponade that is life-threatening [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4631/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumopericardium typically occurs in a mechanically ventilated preterm infant with severe RDS who also has pneumothorax",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PIE. The disorder is rare in an infant who does not require mechanical ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4631/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The typical presentation is the abrupt onset of hemodynamic compromise due to cardiac tamponade. Acute collapse may be preceded by tachycardia and a narrowed pulse pressure. Findings on physical examination include bradycardia, hypotension, increased respiratory distress, and cyanosis. The heart sounds may be muffled or distant. Some infants have a pericardial knock or a characteristic millwheel-like murmur. The electrocardiogram may show low voltages with a small QRS complex.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis is confirmed by chest radiograph. In the anteroposterior view, air is seen surrounding the heart shadow within the pericardium. The gas shadow does not extend beyond the reflection of the aorta and pulmonary artery (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66017 \" href=\"UTD.htm?6/0/6144\">",
"     image 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4631/abstract/38\">",
"     38",
"    </a>",
"    ]. It may be difficult to differentiate pneumopericardium from pneumomediastinum. Air under the inferior surface of the heart is diagnostic of the former.",
"   </p>",
"   <p>",
"    Transillumination with a high-intensity fiberoptic light source may be helpful while awaiting a chest radiograph. The presence of a pneumopericardium is suggested by illumination of the substernal region that may flicker with the heart rate. However, it is often difficult to distinguish pneumopericardium, pneumomediastinum, or a medial pneumothorax with this technique.",
"   </p>",
"   <p>",
"    In life-threatening situations in which the diagnosis is strongly suspected, the diagnosis is made by a therapeutic pericardiocentesis. In these cases, a chest radiograph should be obtained after the procedure. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Pericardial drainage'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants who are asymptomatic may not need intervention. They should be closely observed with frequent monitoring of vital signs, including pulse pressure, and chest radiographs. As with any air leak in an infant receiving mechanical ventilation, ventilator pressures should be minimized [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4631/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Pericardial drainage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic infants require pericardial drainage. Immediate aspiration of the pneumopericardium by pericardiocentesis should be performed in an infant with tamponade. This procedure is both diagnostic and therapeutic. Vital signs should improve as the air is aspirated. However, the air often reaccumulates and tamponade may recur. Thus, continuous decompression with a pericardial tube may be necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4631/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     OTHER AIR LEAKS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumoperitoneum and subcutaneous emphysema are uncommon types of air leak. Pneumoperitoneum may occur when extrapulmonary air decompresses into the peritoneal cavity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4631/abstract/40\">",
"     40",
"    </a>",
"    ]. The diagnosis is made on an abdominal radiograph and usually has little clinical significance. However, it must be differentiated from intraperitoneal air due to a perforated viscus.",
"   </p>",
"   <p>",
"    Subcutaneous emphysema typically occurs in the face, neck, or supraclavicular region. It typically presents as crepitus detected by palpation. It usually has no clinical significance, although large air collections in the neck may cause tracheal compromise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary air leak occurs when air escapes from the lung into extra-alveolar spaces. It occurs most commonly in the newborn period especially in preterm infants with respiratory distress syndrome who require mechanical ventilation. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Incidence'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H4\">",
"     'Risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common pulmonary air leak condition is pneumothorax (air in the space between the parietal and visceral pleura). Patients may present with signs of respiratory distress or be asymptomatic in cases of small pneumothorax. The diagnosis is made by chest radiography. Management is dependent upon the size of the pneumothorax and whether or not the infant has respiratory disease requiring significant mechanical ventilation. Management options include evacuation of air by either thoracentesis or chest tube placement, or close observation with the expectation of spontaneous resolution of the air leak. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pneumothorax'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other pulmonary air leak conditions include pneumomediastinum, pulmonary interstitial emphysema, and pneumopericardium, and rarely pneumoperitoneum and subcutaneous emphysema. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Pneumomediastinum'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Pulmonary interstitial emphysema'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Pneumopericardium'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26\">",
"       'Other air leaks'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4631/abstract/1\">",
"      CHERNICK V, AVERY ME. SPONTANEOUS ALVEOLAR RUPTURE AT BIRTH. Pediatrics 1963; 32:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4631/abstract/2\">",
"      Macklin, CC. Transport of air along sheaths of pulmonic blood vessels from alveoli to mediastinum. Arch Intern Med 1939; 64:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4631/abstract/3\">",
"      Davis, C, Stevens, G. Value of routine radiographic examinations of the newborn, based on a study of 702 consecutive babies. Am J Obstet Gynecol 1930; 20:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4631/abstract/4\">",
"      Horbar JD, Badger GJ, Carpenter JH, et al. Trends in mortality and morbidity for very low birth weight infants, 1991-1999. Pediatrics 2002; 110:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4631/abstract/5\">",
"      Morrow G 3rd, Hope JW, Boggs TR Jr. Pneumomediastinum, a silent lesion in the newborn. J Pediatr 1967; 70:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4631/abstract/6\">",
"      Soll RF, Morley CJ. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2001; :CD000510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4631/abstract/7\">",
"      Soll RF, Blanco F. Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. Cochrane Database Syst Rev 2001; :CD000144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4631/abstract/8\">",
"      Jobe AH. Pulmonary surfactant therapy. N Engl J Med 1993; 328:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4631/abstract/9\">",
"      Wiswell TE, Tuggle JM, Turner BS. Meconium aspiration syndrome: have we made a difference? Pediatrics 1990; 85:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4631/abstract/10\">",
"      Wiswell TE, Henley MA. Intratracheal suctioning, systemic infection, and the meconium aspiration syndrome. Pediatrics 1992; 89:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4631/abstract/11\">",
"      Madansky DL, Lawson EE, Chernick V, Taeusch HW Jr. Pneumothorax and other forms of pulmonary air leak in newborns. Am Rev Respir Dis 1979; 120:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4631/abstract/12\">",
"      Yu VY, Liew SW, Robertson NR. Pneumothorax in the newborn. Changing pattern. Arch Dis Child 1975; 50:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4631/abstract/13\">",
"      Watkinson M, Tiron I. Events before the diagnosis of a pneumothorax in ventilated neonates. Arch Dis Child Fetal Neonatal Ed 2001; 85:F201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4631/abstract/14\">",
"      Merenstein GB, Dougherty K, Lewis A. Early detection of pneumothorax by oscilloscope monitor in the newborn infant. J Pediatr 1972; 80:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4631/abstract/15\">",
"      Hill A, Perlman JM, Volpe JJ. Relationship of pneumothorax to occurrence of intraventricular hemorrhage in the premature newborn. Pediatrics 1982; 69:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4631/abstract/16\">",
"      Yu VY, Wong PY, Bajuk B, Szymonowicz W. Pulmonary air leak in extremely low birthweight infants. Arch Dis Child 1986; 61:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4631/abstract/17\">",
"      Bhatia R, Davis PG, Doyle LW, et al. Identification of pneumothorax in very preterm infants. J Pediatr 2011; 159:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4631/abstract/18\">",
"      Aslanabadi S, Jamshidi M, Tubbs RS, Shoja MM. The role of prophylactic chest drainage in the operative management of esophageal atresia with tracheoesophageal fistula. Pediatr Surg Int 2009; 25:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4631/abstract/19\">",
"      Kuhns LR, Bednarek FJ, Wyman ML, et al. Diagnosis of pneumothorax or pneumomediastinum in the neonate by transillumination. Pediatrics 1975; 56:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4631/abstract/20\">",
"      England GJ, Hill RC, Timberlake GA, et al. Resolution of experimental pneumothorax in rabbits by graded oxygen therapy. J Trauma 1998; 45:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4631/abstract/21\">",
"      Litmanovitz I, Carlo WA. Expectant management of pneumothorax in ventilated neonates. Pediatrics 2008; 122:e975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4631/abstract/22\">",
"      Katar S, Deveciolu C, Kervanciolu M, Ulk&uuml; R. Symptomatic spontaneous pneumothorax in term newborns. Pediatr Surg Int 2006; 22:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4631/abstract/23\">",
"      Mohamed IS, Lee YH, Yamout SZ, et al. Ultrasound guided percutaneous relief of tension pneumomediastinum in a 1-day-old newborn. BMJ Case Rep 2009; 2009:bcr2006114322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4631/abstract/24\">",
"      Lerman-Sagie T, Davidson S, Wielunsky E. Pulmonary interstitial emphysema in low birth weight infants: characteristics of survivors. Acta Paediatr Hung 1990; 30:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4631/abstract/25\">",
"      Heneghan MA, Sosulski R, Alarcon MB. Early pulmonary interstitial emphysema in the newborn: a grave prognostic sign. Clin Pediatr (Phila) 1987; 26:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4631/abstract/26\">",
"      Yu VY, Wong PY, Bajuk B, Szymonowicz W. Pulmonary interstitial emphysema in infants less than 1000 g at birth. Aust Paediatr J 1986; 22:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4631/abstract/27\">",
"      Thibeault DW, Lachman RS, Laul VR, Kwong MS. Pulmonary interstitial emphysema, pneumomediastinum, and pneumothorax. Occurrence in the newborn infant. Am J Dis Child 1973; 126:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4631/abstract/28\">",
"      Plenat F, Vert P, Didier F, Andre M. Pulmonary interstitial emphysema. Clin Perinatol 1978; 5:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4631/abstract/29\">",
"      Campbell RE. Intrapulmonary interstitial emphysema: a complication of hyaline membrane disease. Am J Roentgenol Radium Ther Nucl Med 1970; 110:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4631/abstract/30\">",
"      Gaylord MS, Quissell BJ, Lair ME. High-frequency ventilation in the treatment of infants weighing less than 1,500 grams with pulmonary interstitial emphysema: a pilot study. Pediatrics 1987; 79:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4631/abstract/31\">",
"      Frantz ID 3rd, Werthammer J, Stark AR. High-frequency ventilation in premature infants with lung disease: adequate gas exchange at low tracheal pressure. Pediatrics 1983; 71:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4631/abstract/32\">",
"      Swingle HM, Eggert LD, Bucciarelli RL. New approach to management of unilateral tension pulmonary interstitial emphysema in premature infants. Pediatrics 1984; 74:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4631/abstract/33\">",
"      Cohen RS, Smith DW, Stevenson DK, et al. Lateral decubitus position as therapy for persistent focal pulmonary interstitial emphysema in neonates: a preliminary report. J Pediatr 1984; 104:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4631/abstract/34\">",
"      Brooks JG, Bustamante SA, Koops BL, et al. Selective bronchial intubation for the treatment of severe localized pulmonary interstitial emphysema in newborn infants. J Pediatr 1977; 91:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4631/abstract/35\">",
"      Rastogi S, Gupta A, Wung JT, Berdon WE. Treatment of giant pulmonary interstitial emphysema by ipsilateral bronchial occlusion with a Swan-Ganz catheter. Pediatr Radiol 2007; 37:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4631/abstract/36\">",
"      Cools B, Plaskie K, Van de Vijver K, Suys B. Unsuccessful resuscitation of a preterm infant due to a pneumothorax and a masked tension pneumopericardium. Resuscitation 2008; 78:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4631/abstract/37\">",
"      Heckmann M, Lindner W, Pohlandt F. Tension pneumopericardium in a preterm infant without mechanical ventilation: a rare cause of cardiac arrest. Acta Paediatr 1998; 87:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4631/abstract/38\">",
"      Varano LA, Maisels MJ. Pneumopericardium in the newborn: diagnosis and pathogenesis. Pediatrics 1974; 53:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4631/abstract/39\">",
"      Reppert SM, Ment LR. The treatment of pneumopericardium in the newborn infant. J Pediatr 1977; 90:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4631/abstract/40\">",
"      Zerella JT, McCullough JY. Pneumoperitoneum in infants without gastrointestinal perforation. Surgery 1981; 89:163.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4995 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-A1F0AAE071-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_33_4631=[""].join("\n");
var outline_f4_33_4631=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PNEUMOTHORAX",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Transillumination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Thoracentesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Chest tube placement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PNEUMOMEDIASTINUM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PULMONARY INTERSTITIAL EMPHYSEMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PNEUMOPERICARDIUM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Pericardial drainage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      OTHER AIR LEAKS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/4995\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/4995|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?9/20/9536\" title=\"diagnostic image 1\">",
"      PIE with extension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?37/48/38671\" title=\"diagnostic image 2\">",
"      Bilateral pneumothoraces",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?36/34/37423\" title=\"diagnostic image 3\">",
"      PIE in RDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/52/8000\" title=\"diagnostic image 4\">",
"      Severe right PIE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/0/6144\" title=\"diagnostic image 5\">",
"      Pneumopericardium in a neonate",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/16/21768?source=related_link\">",
"      Clinical features and diagnosis of meconium aspiration syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36951?source=related_link\">",
"      Diaphragmatic paralysis in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29656?source=related_link\">",
"      Oxygen monitoring and therapy in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/2/32804?source=related_link\">",
"      Transient tachypnea of the newborn",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_33_4632="Fluoride: Drug information";
var content_f4_33_4632=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fluoride: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?6/37/6741?source=see_link\">",
"    see \"Fluoride: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/59/34742?source=see_link\">",
"    see \"Fluoride: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F172452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Act&reg; Kids [OTC];",
"     </li>",
"     <li>",
"      Act&reg; Restoring&trade; [OTC];",
"     </li>",
"     <li>",
"      Act&reg; Total Care&trade; [OTC];",
"     </li>",
"     <li>",
"      Act&reg; [OTC];",
"     </li>",
"     <li>",
"      CaviRinse&trade;;",
"     </li>",
"     <li>",
"      Clinpro&trade; 5000;",
"     </li>",
"     <li>",
"      ControlRx&trade;;",
"     </li>",
"     <li>",
"      ControlRx&trade; Multi;",
"     </li>",
"     <li>",
"      Denta 5000 Plus&trade;;",
"     </li>",
"     <li>",
"      DentaGel&trade;;",
"     </li>",
"     <li>",
"      Epiflur&trade;;",
"     </li>",
"     <li>",
"      Fluor-A-Day&reg;;",
"     </li>",
"     <li>",
"      Fluorabon&trade;;",
"     </li>",
"     <li>",
"      Fluorinse&reg;;",
"     </li>",
"     <li>",
"      Fluoritab;",
"     </li>",
"     <li>",
"      Flura-Drops&reg;;",
"     </li>",
"     <li>",
"      Gel-Kam&reg; Rinse;",
"     </li>",
"     <li>",
"      Gel-Kam&reg; [OTC];",
"     </li>",
"     <li>",
"      Just For Kids&trade; [OTC];",
"     </li>",
"     <li>",
"      Lozi-Flur&trade;;",
"     </li>",
"     <li>",
"      NeutraCare&reg;;",
"     </li>",
"     <li>",
"      NeutraGard&reg; Advanced;",
"     </li>",
"     <li>",
"      Omni Gel&trade; [OTC];",
"     </li>",
"     <li>",
"      OrthoWash&trade;;",
"     </li>",
"     <li>",
"      PerioMed&trade;;",
"     </li>",
"     <li>",
"      Phos-Flur&reg;;",
"     </li>",
"     <li>",
"      Phos-Flur&reg; Rinse [OTC];",
"     </li>",
"     <li>",
"      PreviDent&reg;;",
"     </li>",
"     <li>",
"      PreviDent&reg; 5000 Booster;",
"     </li>",
"     <li>",
"      PreviDent&reg; 5000 Dry Mouth;",
"     </li>",
"     <li>",
"      PreviDent&reg; 5000 Plus&reg;;",
"     </li>",
"     <li>",
"      PreviDent&reg; 5000 Sensitive;",
"     </li>",
"     <li>",
"      StanGard&reg; Perio;",
"     </li>",
"     <li>",
"      Stop&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F172453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Fluor-A-Day",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F172485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Nutritional Supplement",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F172456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of dental caries: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     The recommended daily dose of oral fluoride supplement (mg), based on fluoride ion content (ppm) in drinking water (2.2 mg of sodium fluoride is equivalent to 1 mg of fluoride ion): See table.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Fluoride Ion",
"     </caption>",
"     <col align=\"left\" width=\"150\">",
"     </col>",
"     <col align=\"center\" width=\"150\">",
"     </col>",
"     <thead valign=\"bottom\">",
"      <tr>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Fluoride Content of Drinking Water",
"        </p>",
"       </th>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Daily Dose, Oral (mg)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"top\">",
"      <tr>",
"       <td align=\"left\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Table from: Recommended dosage schedule of The American Dental Association, The American Academy of Pediatric Dentistry, and The American Academy of Pediatrics",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"left\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          &lt;0.3 ppm",
"         </b>",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Birth - 6 mo",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         None",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         6 mo - 3 y",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         0.25",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         3-6 y",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         0.5",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         6-16 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          0.3-0.6 ppm",
"         </b>",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Birth - 6 mo",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         None",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         6 mo - 3 y",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         None",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         3-6 y",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         0.25",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         6-16 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.5",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream:",
"     </b>",
"     Brush teeth with cream once daily regardless of fluoride content of drinking water.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dental rinse or gel:",
"     </b>",
"     10 mL rinse or apply to teeth daily and spit after brushing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Product-specific dosing:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      PreviDent&reg; rinse:",
"     </i>",
"     Once weekly, rinse 10 mL vigorously around and between teeth for 1 minute, then spit; this should be done preferably at bedtime, after thoroughly brushing teeth; for maximum benefit, do not eat, drink, or rinse mouth for at least 30 minutes after treatment; do not swallow",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Fluorinse&reg;:",
"     </i>",
"     Once weekly, vigorously swish 5-10 mL in mouth for 1 minute, then spit",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lozenge (Lozi-Flur&trade;):",
"     </b>",
"     One lozenge daily regardless of fluoride content of drinking water",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F172467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/59/34742?source=see_link\">",
"      see \"Fluoride: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of dental caries: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream:",
"     </b>",
"     Children &ge;6 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dental rinse or gel:",
"     </b>",
"     Children 6-12 years: 5-10 mL rinse or apply to teeth and spit daily after brushing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Fluorinse&reg;, PreviDent&reg; rinse:",
"     </i>",
"     Children &gt;6 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F172457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F172440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, oral, as sodium [toothpaste]: 1.1% (51 g) [equivalent to fluoride 2.5 mg/dose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Denta 5000 Plus&trade;: 1.1% (51 g) [spearmint flavor; equivalent to fluoride 2.5 mg/dose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PreviDent&reg; 5000 Plus&reg;: 1.1% (51 g) [contains sodium benzoate; fruitastic&trade; flavor; equivalent to fluoride 2.5 mg/dose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PreviDent&reg; 5000 Plus&reg;: 1.1% (51 g) [contains sodium benzoate; spearmint flavor; equivalent to fluoride 2.5 mg/dose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical, as acidulated phosphate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phos-Flur&reg;: 1.1% (51 g) [contains propylene glycol, sodium benzoate; mint flavor; equivalent to fluoride 0.5%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, oral, as sodium [toothpaste]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PreviDent&reg; 5000 Booster: 1.1% (100 mL, 106 mL) [contains sodium benzoate; fruitastic&trade; flavor; equivalent to fluoride 2.5 mg/dose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PreviDent&reg; 5000 Booster: 1.1% (100 mL, 106 mL) [contains sodium benzoate; spearmint flavor; equivalent to fluoride 2.5 mg/dose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PreviDent&reg; 5000 Dry Mouth: 1.1% (100 mL) [mint flavor; equivalent to fluoride 2.5 mg/dose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PreviDent&reg; 5000 Sensitive: 1.1% (100 mL) [mild mint flavor; equivalent to fluoride 2.5 mg/dose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical, as sodium: 1.1% (56 g) [equivalent to fluoride 2 mg/dose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DentaGel&trade;: 1.1% (56 g) [fresh mint flavor; neutral pH; equivalent to fluoride 2 mg/dose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NeutraCare&reg;: 1.1% (60 g) [grape flavor; neutral pH]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NeutraCare&reg;: 1.1% (60 g) [mint flavor; neutral pH]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NeutraGard&reg; Advanced: 1.1% (60 g) [mint flavor; neutral pH]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NeutraGard&reg; Advanced: 1.1% (60 g) [mixed berry flavor; neutral pH]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PreviDent&reg;: 1.1% (56 g) [mint flavor; equivalent to fluoride 2 mg/dose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PreviDent&reg;: 1.1% (56 g) [very berry flavor; equivalent to fluoride 2 mg/dose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical, as stannous fluoride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gel-Kam&reg;: 0.4% (129 g) [cinnamon flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gel-Kam&reg;: 0.4% (129 g) [fruit &amp; berry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gel-Kam&reg;: 0.4% (129 g) [mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Just For Kids&trade;: 0.4% (122 g) [bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Just For Kids&trade;: 0.4% (122 g) [fruit-punch flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Just For Kids&trade;: 0.4% (122 g) [grapey grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Omni Gel&trade;: 0.4% (122 g) [cinnamon flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Omni Gel&trade;: 0.4% (122 g) [grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Omni Gel&trade;: 0.4% (122 g) [mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Omni Gel&trade;: 0.4% (122 g) [natural flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Omni Gel&trade;: 0.4% (122 g) [raspberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Stop&reg;: 0.4% (120 g) [bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Stop&reg;: 0.4% (120 g) [mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral, as base:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fluoritab: 0.125 mg/drop [dye free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lozenge, oral, as sodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lozi-Flur&trade;: 2.21 mg (90s) [sugar free; cherry flavor; equivalent to fluoride 1 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Paste, oral, as sodium [toothpaste]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clinpro&trade; 5000: 1.1% (113 g) [vanilla-mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ControlRx&trade;: 1.1% (57 g) [berry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ControlRx&trade;: 1.1% (57 g) [vanilla-mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ControlRx&trade; Multi: 1.1% (57 g) [vanilla-mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as fluoride [rinse]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Act&reg; Total Care&trade;: 0.02% (1000 mL) [ethanol free; contains menthol, propylene glycol, sodium benzoate, tartrazine; fresh mint flavor; equivalent to fluoride 0.009%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as sodium [drops]: 1.1 mg/mL (50 mL) [equivalent to fluoride 0.5 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fluor-A-Day&reg;: 0.278 mg/drop (30 mL) [equivalent to fluoride 0.125 mg/drop]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fluorabon&trade;: 0.55 mg/0.6 mL (60 mL) [dye free, sugar free; equivalent to fluoride 0.25 mg/0.6 mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Flura-Drops&reg;: 0.55 mg/drop (24 mL) [dye free, sugar free; equivalent to fluoride 0.25 mg/drop]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as sodium [rinse]: 0.2% (473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Act&reg;: 0.05% (532 mL) [contains benzyl alcohol, propylene glycol, sodium benzoate, tartrazine; cinnamon flavor; equivalent to fluoride 0.02%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Act&reg;: 0.05% (532 mL) [contains propylene glycol, sodium benzoate, tartrazine; mint flavor; equivalent to fluoride 0.02%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Act&reg; Kids: 0.05% (532 mL) [ethanol free; contains benzyl alcohol, propylene glycol, sodium benzoate; bubblegum flavor; equivalent to fluoride 0.02%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Act&reg; Kids: 0.05% (500 mL) [ethanol free; contains benzyl alcohol, propylene glycol, sodium benzoate; ocean berry flavor; equivalent to fluoride 0.02%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Act&reg; Restoring&trade;: 0.02% (1000 mL) [contains ethanol 11%, propylene glycol, sodium benzoate; Cool Splash&trade; mint flavor; equivalent to fluoride 0.009%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Act&reg; Restoring&trade;: 0.02% (1000 mL) [contains ethanol 11%, propylene glycol, sodium benzoate; Cool Splash&trade; spearmint flavor; equivalent to fluoride 0.009%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Act&reg; Restoring&trade;: 0.05% (532 mL) [contains ethanol 11%, propylene glycol, sodium benzoate; Cool Splash&trade; mint flavor; equivalent to fluoride 0.02%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Act&reg; Restoring&trade;: 0.05% (532 mL) [contains ethanol 11%, propylene glycol, sodium benzoate; Cool Splash&trade; spearmint flavor; equivalent to fluoride 0.02%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Act&reg; Restoring&trade;: 0.05% (532 mL) [contains ethanol 11%, propylene glycol, sodium benzoate; Cool Splash&trade; vanilla-mint flavor; equivalent to fluoride 0.02%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Act&reg; Total Care&trade;: 0.02% (1000 mL) [contains ethanol 11%, propylene glycol, sodium benzoate; icy clean mint flavor; equivalent to fluoride 0.009%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Act&reg; Total Care&trade;: 0.05% (88 mL, 532 mL) [contains ethanol 11%, propylene glycol, sodium benzoate; icy clean mint flavor; equivalent to fluoride 0.02%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Act&reg; Total Care&trade;: 0.05% (88 mL, 532 mL) [ethanol free; contains menthol, propylene glycol, sodium benzoate, tartrazine; fresh mint flavor; equivalent to fluoride 0.02%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CaviRinse&trade;: 0.2% (240 mL) [mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fluorinse&reg;: 0.2% (480 mL) [ethanol free; cinnamon flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fluorinse&reg;: 0.2% (480 mL) [ethanol free; mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     OrthoWash&trade;: 0.044% (480 mL) [contains sodium benzoate; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     OrthoWash&trade;: 0.044% (480 mL) [contains sodium benzoate; strawberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phos-Flur&reg; Rinse: 0.044% (473 mL) [ethanol free, sugar free; bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phos-Flur&reg; Rinse: 0.044% (473 mL) [ethanol free, sugar free; gushing grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phos-Flur&reg; Rinse: 0.044% (500 mL) [sugar free; cool mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PreviDent&reg;: 0.2% (473 mL) [contains benzoic acid, ethanol 6%, sodium benzoate; cool mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as stannous fluoride [concentrated rinse]: 0.63% (300 mL) [equivalent to fluoride 7 mg/30 mL dose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gel-Kam&reg; Rinse: 0.63% (300 mL) [mint flavor; equivalent to fluoride 7 mg/30 mL dose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PerioMed&trade;: 0.63% (284 mL) [ethanol free; cinnamon flavor; equivalent to fluoride 7 mg/30 mL dose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PerioMed&trade;: 0.63% (284 mL) [ethanol free; mint flavor; equivalent to fluoride 7 mg/30 mL dose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PerioMed&trade;: 0.63% (284 mL) [ethanol free; tropical fruit flavor; equivalent to fluoride 7 mg/30 mL dose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     StanGard&reg; Perio: 0.63% (284 mL) [mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral, as sodium: 0.55 mg [equivalent to fluoride 0.25 mg], 1.1 mg [equivalent to fluoride 0.5 mg], 2.2 mg [equivalent to fluoride 1 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Epiflur&trade;: 0.55 mg [sugar free; vanilla flavor; equivalent to fluoride 0.25 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Epiflur&trade;: 1.1 mg [sugar free; vanilla flavor; equivalent to fluoride 0.5 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Epiflur&trade;: 2.2 mg [sugar free; vanilla flavor; equivalent to fluoride 1 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fluor-A-Day&reg;: 0.55 mg [raspberry flavor; equivalent to fluoride 0.25 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fluor-A-Day&reg;: 1.1 mg [raspberry flavor; equivalent to fluoride 0.5 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fluor-A-Day&reg;: 2.2 mg [raspberry flavor; equivalent to fluoride 1 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fluoritab: 2.2 mg [cherry flavor; equivalent to fluoride 1 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fluoritab: 1.1 mg [dye free; cherry flavor; equivalent to fluoride 0.5 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F172426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes lozenge, gel drops",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F172441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of dental caries",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F172493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Phos-Flur&reg; may be confused with PhosLo&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Fluorex [France] may be confused with Flarex brand name for fluorometholone [U.S.,  Canada, and multiple international markets] and Fluarix brand name for influenza virus vaccine (inactivated) [U.S., and multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F172484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     &lt;1% (Limited to important or life-threatening): Discoloration of teeth, rash, nausea, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F172444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fluoride, tartrazine, or any component of the formulation; when fluoride content of drinking water exceeds 0.7 ppm; low sodium or sodium-free diets; do not use 1 mg tablets in children &lt;3 years of age or when drinking water fluoride content is &ge;0.3 ppm; do not use 1 mg/5 mL rinse (as supplement) in children &lt;6 years of age",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F172430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dental fluorosis/osseous: Prolonged ingestion with excessive doses may result in dental fluorosis and osseous changes; do",
"     <b>",
"      not",
"     </b>",
"     exceed recommended dosage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tartrazine: Some products contain tartrazine.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F172435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F172437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13882220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies; epidemiological studies in areas with high levels of fluorinated water have not shown an increase in adverse effects. Heavy exposure",
"     <i>",
"      in utero",
"     </i>",
"     may be linked to skeletal fluorosis seen later in childhood.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13882221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Low concentrations of fluoride can be found in breast milk and the amount is not significantly affected by supplementation or concentrations in drinking water (IOM, 1997).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F172447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not administer with milk; do",
"     <b>",
"      not",
"     </b>",
"     allow eating or drinking for 30 minutes after use.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F172446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Epiflur Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.55 (0.25 F) mg (120): $8.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.1 (0.5 F) mg (120): $9.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.2 (1 F) mg (120): $9.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Fluor-a-day Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25 (F)-236.79 mg (120): $62.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 (F)-236.79 mg (120): $62.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 (F)-236.79 mg (120): $62.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Ludent Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.55 (0.25 F) mg (120): $13.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.1 (0.5 F) mg (1000): $111.58",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.2 (1 F) mg (120): $13.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Luride Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.55 (0.25 F) mg (120): $7.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.1 (0.5 F) mg (120): $7.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.2 (1 F) mg (120): $7.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (NaFrinse Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.2 (1 F) mg (120): $43.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Sodium Fluoride Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.55 (0.25 F) mg (120): $17.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.1 (0.5 F) mg (100): $7.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.2 (1 F) mg (100): $7.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Concentrate",
"     </b>",
"     (Gel-Kam Oral Care Rinse Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.63% (283 g): $16.67",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Concentrate",
"     </b>",
"     (Perio Med Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.63% (283.5 g): $11.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Concentrate",
"     </b>",
"     (Stannous Fluoride Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.63% (283 g): $14.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (ControlRx Dental)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.1% (57 g): $10.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Denta 5000 Plus Dental)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.1% (51 g): $7.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (PreviDent 5000 Plus Dental)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.1% (51 g): $12.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (DentaGel Dental)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.1% (56 g): $8.23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Easygel Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.4% (129 g): $3.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Fluoridex Daily Defense Dental)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.1% (112 g): $11.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Fluoridex Enhanced Whitening Dental)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.1% (112 g): $14.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Fluoridex Sensitivity Relief Dental)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.1-5% (112 g): $16.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Gel-Kam Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.4% (122 g): $11.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Just for Kids Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.4% (121.9 g): $5.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Karigel Dental)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.1% (30 mL): $2.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Karigel-N Dental)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.1% (24 mL): $2.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (NeutraGard Advanced Dental)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.1% (60 g): $9.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Omni Gel Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.4% (121.9 g): $8.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Phos-Flur Dental)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.1% (51 g): $12.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (PreviDent Dental)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.1% (56 g): $12.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Thera-Flur-N Dental)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.1% (24 mL): $5.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lozenge",
"     </b>",
"     (Lozi-Flur Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.2 (1 F) mg (90): $21.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Paste",
"     </b>",
"     (Clinpro 5000 Dental)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.1% (113 g): $18.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Paste",
"     </b>",
"     (ControlRx Dental)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.1% (57 g): $6.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Paste",
"     </b>",
"     (PreviDent 5000 Booster Dental)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.1% (100 mL): $12.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Paste",
"     </b>",
"     (PreviDent 5000 Dry Mouth Dental)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.1% (100 mL): $12.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Paste",
"     </b>",
"     (PreviDent 5000 Sensitive Dental)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.1-5% (100 mL): $12.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (ACT Anticavity Fluoride Rinse Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (532 mL): $3.67",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (ACT Restoring Fluoride Rinse Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (532 mL): $4.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (ACT Total Care Dry Mouth Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.02% (532 mL): $5.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (ACT Total Care Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (90 mL): $0.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (CaviRinse Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.2% (236.59 mL): $9.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Fluor-a-day Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.275 (0.125 F) mg/drop (30 mL): $50.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Fluorabon Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.55 (0.25 F) mg/0.6 mL (60 mL): $7.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Fluorigard Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (473 mL): $3.71",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Flura-Drops Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.275 (0.125 F) mg/drop (30 mL): $2.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.55 (0.25 F) mg/drop (24 mL): $6.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Karidium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.275 (0.125 F) mg/drop (30 mL): $4.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Listerine Smart Rinse Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.02% (95 mL): $1.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Luride Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.1 (0.5 F) mg/mL (50 mL): $8.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Phos Flur Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.044% (473 mL): $9.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (PreviDent Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.2% (473 mL): $13.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Sodium Fluoride Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.1 (0.5 F) mg/mL (50 mL): $19.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (NaFrinse Daily Acidulated Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/5 mL (500 mL): $2.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (NaFrinse Daily/Neutral Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (500 mL): $2.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (NaFrinse Weekly Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.2% (250 mL): $2.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Sodium Fluoride Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.1 (0.5 F) mg (1000): $4.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.2 (1 F) mg (100): $5.10",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      AFI-Fluor (NO);",
"     </li>",
"     <li>",
"      Arthrofluor (HU);",
"     </li>",
"     <li>",
"      Biogam F (BE);",
"     </li>",
"     <li>",
"      Bobrusie (PL);",
"     </li>",
"     <li>",
"      Carident (NO);",
"     </li>",
"     <li>",
"      Dentalfluoro (IT);",
"     </li>",
"     <li>",
"      Dentan (SE);",
"     </li>",
"     <li>",
"      Dentocar (HU);",
"     </li>",
"     <li>",
"      Duraphat (AT, DE, DK, FI, NO, PL, SE);",
"     </li>",
"     <li>",
"      Floam (PL);",
"     </li>",
"     <li>",
"      Floran (AU);",
"     </li>",
"     <li>",
"      Fludent (FI, NO, SE);",
"     </li>",
"     <li>",
"      Fluodel (BR);",
"     </li>",
"     <li>",
"      Fluodont (AT);",
"     </li>",
"     <li>",
"      Fluodontyl (BE, ES, FR, LU);",
"     </li>",
"     <li>",
"      Fluoen (IL);",
"     </li>",
"     <li>",
"      Fluogum (FR, PL);",
"     </li>",
"     <li>",
"      Fluonatril (HR);",
"     </li>",
"     <li>",
"      Fluoplexe (FR);",
"     </li>",
"     <li>",
"      Fluor (BE);",
"     </li>",
"     <li>",
"      Fluor Crinex (FR);",
"     </li>",
"     <li>",
"      Fluor Kin (ES);",
"     </li>",
"     <li>",
"      Fluor Lacer (ES);",
"     </li>",
"     <li>",
"      Fluor Microsol (FR);",
"     </li>",
"     <li>",
"      Fluor Oligosol (FR);",
"     </li>",
"     <li>",
"      Fluor Unicophar (BE);",
"     </li>",
"     <li>",
"      Fluor-A-Day (GB, IE);",
"     </li>",
"     <li>",
"      Fluor-Retard (NO);",
"     </li>",
"     <li>",
"      Fluor-S.M.B. (BE);",
"     </li>",
"     <li>",
"      Fluoretas (UY);",
"     </li>",
"     <li>",
"      Fluorette (DK, FI, NO, SE);",
"     </li>",
"     <li>",
"      Fluoretten (DE);",
"     </li>",
"     <li>",
"      Fluorex (FR);",
"     </li>",
"     <li>",
"      Fluorid Gel DENTSPLY DeTrey (DE);",
"     </li>",
"     <li>",
"      Fluorilette (FI);",
"     </li>",
"     <li>",
"      Fluoros (DE);",
"     </li>",
"     <li>",
"      Fluortabletjes (NL);",
"     </li>",
"     <li>",
"      Fluorvitin (IT);",
"     </li>",
"     <li>",
"      Fluossen (CZ, PL);",
"     </li>",
"     <li>",
"      Fluotrat (BR);",
"     </li>",
"     <li>",
"      Flura (AU);",
"     </li>",
"     <li>",
"      Flux (NO);",
"     </li>",
"     <li>",
"      Gammadyn F (BE);",
"     </li>",
"     <li>",
"      Koreberon (CZ, DE, HU);",
"     </li>",
"     <li>",
"      Medusit (PT);",
"     </li>",
"     <li>",
"      NAF (HR);",
"     </li>",
"     <li>",
"      Nafluor (AR);",
"     </li>",
"     <li>",
"      NaFril (DE);",
"     </li>",
"     <li>",
"      Natrium Fluoratum (PL);",
"     </li>",
"     <li>",
"      Natriumfluorid Baer (AT, DE, LU);",
"     </li>",
"     <li>",
"      Odontocromil (ES);",
"     </li>",
"     <li>",
"      Oligogranul Fluor (FR);",
"     </li>",
"     <li>",
"      Oligosol F (BE);",
"     </li>",
"     <li>",
"      Oligostim Fluor (FR);",
"     </li>",
"     <li>",
"      Oratol F (PT);",
"     </li>",
"     <li>",
"      Ospur F (DE);",
"     </li>",
"     <li>",
"      Ossin (CZ, DE);",
"     </li>",
"     <li>",
"      Osteofluor (AT, FR);",
"     </li>",
"     <li>",
"      Otofluor (IN);",
"     </li>",
"     <li>",
"      Pharma-Fluor (NL);",
"     </li>",
"     <li>",
"      Procal (BE, LU, NL);",
"     </li>",
"     <li>",
"      Prodent Fluor (PY);",
"     </li>",
"     <li>",
"      Protectfluor (NL);",
"     </li>",
"     <li>",
"      Rumafluor (FR);",
"     </li>",
"     <li>",
"      Sanogyl (FR);",
"     </li>",
"     <li>",
"      Sensifluor (IT);",
"     </li>",
"     <li>",
"      Sodio Fluoruro (IT);",
"     </li>",
"     <li>",
"      Solfluor (CN);",
"     </li>",
"     <li>",
"      Teeth Tough (IL);",
"     </li>",
"     <li>",
"      Vinafluor (ID);",
"     </li>",
"     <li>",
"      Vitamon Fluor (BE);",
"     </li>",
"     <li>",
"      Zymafluor (AE, AT, BE, BG, BH, CH, CY, DE, EG, ES, FR, HU, IL, IQ, IR, IT, JO, KW, LB, LU, LY, NL, OM, PL, QA, SA, SY, TH, TW, YE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F172429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Promotes remineralization of decalcified enamel; inhibits the cariogenic microbial process in dental plaque; increases tooth resistance to acid dissolution",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F172443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapid and complete; sodium fluoride; other soluble fluoride salts; calcium, iron, or magnesium may delay absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 50% of fluoride is deposited in teeth and bone after ingestion; topical application works superficially on enamel and plaque",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine and feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Berman L, Taves D, Mitra S, et al, &ldquo;Inorganic Fluoride Poisoning: Treatment by Hemodialysis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1973, 289(17):922.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cummings CC and McIvor ME, &ldquo;Fluoride-Induced Hyperkalemia: The Role of Ca(2+)-Dependent K",
"      <sup>",
"       +",
"      </sup>",
"      Channels,&rdquo;",
"      <i>",
"       Am J Emerg Med",
"      </i>",
"      , 1988, 6(1):1-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/33/4632/abstract-text/2446637/pubmed\" id=\"2446637\" target=\"_blank\">",
"        2446637",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fisher K, Picciotti M, Henretig F, et al, &ldquo;Fluoride (F1) Toxicity From a Topical Dental Care Product (TDCP),&rdquo;",
"      <i>",
"       Vet Hum Toxicol",
"      </i>",
"      , 1991, 33:365.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of Medicine),",
"      <i>",
"       Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride",
"      </i>",
"      , National Academy of Sciences, Washington, DC, 1997.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McIvor ME, &ldquo;Acute Fluoride Toxicity. Pathophysiology and Management,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1990, 5(2):79-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/33/4632/abstract-text/2182050/pubmed\" id=\"2182050\" target=\"_blank\">",
"        2182050",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pak CYS, Sakhaee K, Adams-Huet B, et al, &ldquo;Treatment of Postmenopausal Osteoporosis With Slow-Release Sodium Fluoride: Final Report of a Randomized Controlled Trial,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1995, 123(6):401-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/33/4632/abstract-text/7639438/pubmed\" id=\"7639438\" target=\"_blank\">",
"        7639438",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pitt P and Berry H, &ldquo;Fluoride Treatment in Osteoporosis,&rdquo;",
"      <i>",
"       Postgrad Med J",
"      </i>",
"      , 1991, 67(786):323-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/33/4632/abstract-text/2068022/pubmed\" id=\"2068022\" target=\"_blank\">",
"        2068022",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Riggs BL, Hodgson SF, O'Fallon WM, et al, &ldquo;Effect of Fluoride Treatment on the Fracture Rate in Postmenopausal Women With Osteoporosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1990, 322(12):802-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/33/4632/abstract-text/2407957/pubmed\" id=\"2407957\" target=\"_blank\">",
"        2407957",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schuman AJ, &ldquo;How Much Fluoride Is Too Much? The New Guidelines,&rdquo;",
"      <i>",
"       Contemp Pediatr",
"      </i>",
"      , 1995, 12(6):65-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/33/4632/abstract-text/10161198/pubmed\" id=\"10161198\" target=\"_blank\">",
"        10161198",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      U.S. Department of Health and Human Services, &ldquo;Toxicological Profile for Fluorides, Hydrogen Fluoride, and Fluorine (F) TP-91/17,&rdquo; Agency for Toxic Substances and Diseases Registry, 1993.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8462 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-22DD962998-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_33_4632=[""].join("\n");
var outline_f4_33_4632=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172452\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172453\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172485\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172456\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172467\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172457\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172440\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172426\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172441\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172493\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172484\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172444\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172430\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299352\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172435\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172437\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13882220\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13882221\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172447\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172446\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038620\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172429\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172443\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8462\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8462|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/37/6741?source=related_link\">",
"      Fluoride: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/59/34742?source=related_link\">",
"      Fluoride: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_33_4633="Complications of scuba diving";
var content_f4_33_4633=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Complications of scuba diving",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/33/4633/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/33/4633/contributors\">",
"     Dipak Chandy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/33/4633/contributors\">",
"     Gerald L Weinhouse, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/33/4633/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/33/4633/contributors\">",
"     Daniel F Danzl, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/33/4633/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/33/4633/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/33/4633/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are more than 9 million recreational scuba divers in the United States, and another several hundred thousand new divers are trained annually [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/1\">",
"     1",
"    </a>",
"    ]. The incidence of diving-related disorders has increased in tandem with this increasing population at risk. The Divers Alert Network (",
"    <a class=\"external\" href=\"file://www.diversalertnetwork.org/\">",
"     www.diversalertnetwork.org",
"    </a>",
"    ) records more than 1000 diving-related injuries annually, of which almost 10 percent are fatal [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/2\">",
"     2",
"    </a>",
"    ]. Hypothermia, trauma, and submersion-related injuries are potential complications of diving. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15913?source=see_link\">",
"     \"Accidental hypothermia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26809?source=see_link\">",
"     \"Drowning (submersion injuries)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, a variety of emergencies specific to diving may occur. These include [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Barotrauma, including arterial air embolism",
"     </li>",
"     <li>",
"      Decompression sickness",
"     </li>",
"     <li>",
"      Nitrogen narcosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pathophysiology and treatment of complications of compressed gas diving are reviewed here. The imaging and management of pneumothorax, ear barotrauma, and an overview of air embolism are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/19/22838?source=see_link\">",
"     \"Imaging of pneumothorax\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24121?source=see_link\">",
"     \"Secondary spontaneous pneumothorax in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35397?source=see_link\">",
"     \"Ear barotrauma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38664?source=see_link\">",
"     \"Air embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1940068\">",
"    <span class=\"h1\">",
"     GAS LAWS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of diving-related medical conditions are related to the behavior of gases under varying pressures, which is governed by two basic gas laws:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Boyle's law",
"      </strong>",
"      states that at a constant temperature, the volume of a gas varies inversely with the pressure to which it is subjected. This law helps to explain the principles behind diving-related barotrauma and air embolism.",
"     </li>",
"     <li>",
"      <strong>",
"       Henry's law",
"      </strong>",
"      states that at a constant temperature, the amount of a gas that is dissolved in a liquid is directly proportional to the partial pressure of that gas. This law provides the explanation for decompression sickness and nitrogen narcosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BAROTRAUMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Barotrauma is the most common form of diving-related injury and develops when an air-filled body space fails to equilibrate its pressure with the environment following changes in ambient pressure. Barotrauma can occur due to under-pressurization (during descent) or over-pressurization (during ascent), with the latter generally causing more severe sequelae. During descent, decreasing air volume in a space that also contains tissue leads to mucosal edema, vascular engorgement, and hemorrhage. During ascent, increasing gas volume in a confined space can produce tissue disruption and rupture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pulmonary barotrauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following drowning, pulmonary barotrauma is the second leading cause of death among scuba divers [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/4\">",
"     4",
"    </a>",
"    ]. As a diver descends, the air in the lungs becomes compressed. Pulmonary edema and hemorrhage occur when lung volume decreases below residual volume. As a diver ascends and transalveolar pressure exceeds 20 to 80 mmHg, overexpansion injury in the form of alveolar rupture can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Divers who hold their breath as they ascend and those with obstructive airway diseases, such as asthma or chronic obstructive pulmonary disease, are at increased risk [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Pneumomediastinum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following alveolar rupture, gas can dissect along the perivascular sheath into the mediastinum to produce pneumomediastinum. Symptoms of pneumomediastinum include a sensation of fullness in the chest, pleuritic chest pain that may radiate to the shoulders, dyspnea, coughing, hoarseness, and dysphagia. Crepitation in the neck due to associated subcutaneous emphysema may be present, and a crackling sound heard over the heart during systole (Hamman's sign) may be appreciated upon auscultation (",
"    <a class=\"graphic graphic_figure graphicRef67176 \" href=\"UTD.htm?21/9/21649\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The diagnosis can be confirmed on the basis of chest and neck radiographs. Typically, a radiolucent band is seen along the cardiac border on the posteroanterior film and retrosternally on the lateral view. No specific treatment is required, but inhalation of 100 percent oxygen is recommended to hasten resorption of extraalveolar gas. Rarely, mediastinotomy may be required to relieve a tension pneumomediastinum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Pneumothorax",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumothorax is relatively uncommon, developing in only approximately 10 percent of episodes of pulmonary barotrauma. Patients with a history of spontaneous pneumothorax, bullae, or cystic lung disease are at increased risk of pneumothorax and should be cautioned against diving [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pneumothorax develops when gas ruptures from the lung parenchyma into the pleural space. If this occurs at a significant depth, the pleural gas expands as the diver ascends (as described by Boyle's law) and can result in a tension pneumothorax. Manifestations include dyspnea, chest pain, tachycardia, hypotension, cyanosis, distended neck veins, tracheal deviation, hyperresonance to percussion, unilateral decrease in breath sounds, and accompanying subcutaneous emphysema in approximately 25 percent of cases.",
"   </p>",
"   <p>",
"    If a pneumothorax results in severe hypoxemia or hemodynamic compromise, immediate pleural decompression is required. This is usually accomplished by inserting a large-bore needle into the second intercostal space in the mid-clavicular line of the affected hemithorax, followed by tube thoracostomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24121?source=see_link\">",
"     \"Secondary spontaneous pneumothorax in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1226?source=see_link\">",
"     \"Placement and management of thoracostomy tubes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Arterial gas embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arterial gas embolism is the most serious potential sequel of pulmonary barotrauma. Arterial gas emboli can result from any of three processes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Passage of gas bubbles into the pulmonary veins and from there into the systemic circulation",
"     </li>",
"     <li>",
"      Development of venous gas emboli (either from barotrauma or decompression sickness), which overwhelm the filtering capacity of the pulmonary capillaries to appear in the systemic arterial circulation",
"     </li>",
"     <li>",
"      Development of venous gas emboli that reach the arterial circulation \"paradoxically\" via a functional right-to-left shunt, such as a patent foramen ovale [",
"      <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/10-13\">",
"       10-13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After reaching the systemic arterial circulation, gas emboli typically break up as they reach vascular branch points and ultimately lodge in vessels with diameters ranging from 30 to 60 &micro;m, where they produce distal ischemia and local activation of inflammatory cascades. The specific symptoms and signs produced are dependent upon the final location of gas emboli; the most serious clinical consequences occur with embolization to the cerebral and coronary arteries. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38664?source=see_link\">",
"     \"Air embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As little as 0.5 mL of air in the coronary circulation can lead to dysrhythmias, myocardial infarction,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cardiac arrest [",
"      <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Manifestations of cerebral emboli range from focal motor, sensory, or visual deficits to seizures, loss of consciousness, apnea, and death.",
"     </li>",
"     <li>",
"      Mucocutaneous findings include a characteristic cyanotic marbling of the skin and focal pallor of the tongue.",
"     </li>",
"     <li>",
"      Embolization to the kidney can produce hematuria, proteinuria, and renal failure.",
"     </li>",
"     <li>",
"      Uterine and gastrointestinal bleeding and failure of other organs have occasionally been reported.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Emergency treatment of arterial gas embolism includes the immediate administration of 100 percent oxygen to widen the pressure gradient for nitrogen between the bubble and the circulation and thus accelerate reabsorption of gas bubbles, and hydration to decrease vascular obstruction and augment collateral flow. The Trendelenburg position decreases the risk of additional cerebral emboli, but may increase cerebral edema; thus, the supine position is the best compromise for transportation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients should be transferred to the nearest hyperbaric oxygen facility as soon as possible, the location of which can be obtained from the Divers Alert Network at (919) 684-9111. The prognosis is generally improved with early treatment of cerebral air emboli, with a sharp decrease in clinical efficacy after a four to five hour delay [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Patients with residual deficits should receive repetitive, intermittent hyperbaric treatments and may require several days to reach maximum improvement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5448?source=see_link\">",
"     \"Hyperbaric oxygen therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adjunctive treatment with glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    , or a combination of prostacyclin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    has been reported, but the efficacy of these interventions is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Based on the available data, we do not recommend any of these adjunctive forms of therapy at the present time.",
"   </p>",
"   <p>",
"    Some patients suffer neurologic deterioration after seemingly successful recompression treatment. This phenomenon may be due to the slow reexpansion of residual gas bubbles upon termination of hyperbaric therapy, postischemic reperfusion injury, or re-embolization from the underlying area of pulmonary abnormality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Ear barotrauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Involvement of the middle ear during descent (\"ear squeeze\") is the most common disorder among divers [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/3,20\">",
"     3,20",
"    </a>",
"    ]. Pressure in the middle ear normally equilibrates with ambient pressure via the eustachian tube. However, if upon descent this equalization is prevented by mucosal edema secondary to an upper respiratory infection, pregnancy, or anatomic variations [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/21\">",
"     21",
"    </a>",
"    ], the negative pressure in the middle ear can lead to its filling with serous fluid or blood or to inward rupture of the tympanic membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35397?source=see_link\">",
"     \"Ear barotrauma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptoms vary from a sensation of pressure to hearing loss and pain, which may suddenly be relieved with rupture of the tympanic membrane. Acute unilateral tympanic membrane rupture can also produce vertigo, nausea, and disorientation due to leakage of cold water into the middle ear and uneven caloric stimulation. Over-pressurization of the middle ear can occur during ascent, but tympanic membrane rupture is rare.",
"   </p>",
"   <p>",
"    Divers should attempt to prevent ear barotrauma by the use of maneuvers that open the Eustachian tubes and equalize pressure between the middle ear and the ambient environment (",
"    <a class=\"graphic graphic_table graphicRef61166 \" href=\"UTD.htm?21/34/22060\">",
"     table 1",
"    </a>",
"    ). Treatment of middle ear barotrauma consists of topical and systemic decongestants, analgesics, and antihistamines. Antibiotics should be used if purulent otorrhea is observed [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/22\">",
"     22",
"    </a>",
"    ]. Most tympanic membrane ruptures heal spontaneously if normal eustachian tube function is restored and infection is controlled.",
"   </p>",
"   <p>",
"    Inner ear barotrauma is a fairly uncommon injury but should be excluded in all cases of middle ear barotrauma [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/23\">",
"     23",
"    </a>",
"    ]. It can occur following the development of a sudden pressure differential between the inner and middle ear, leading to rupture of the round or oval window [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. The main symptoms are tinnitus, vertigo, and hearing loss, which in turn can cause disorientation and panic. The resulting labyrinthine fistula and leakage of perilymph can result in permanent inner ear damage. Long-term follow-up of a small cohort of divers who experienced inner ear barotrauma and inner ear decompression sickness treated with hyperbaric recompression noted that persistent vestibular deficits were common (though often asymptomatic) in this population [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The primary treatment of this complication is complete bed rest with head elevation to avoid increases in cerebrospinal fluid pressure, which can increase the leakage of perilymph [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/25,27\">",
"     25,27",
"    </a>",
"    ]. Deteriorating inner ear function generally requires tympanotomy and patching of the round or oval window [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Sinus barotrauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sinus barotrauma is the second most common disorder among divers, following ear barotrauma. During descent, increases in ambient environmental pressure can lead to mucosal engorgement, edema, and inflammation producing blockage of the sinus ostia; the frontal sinus is most commonly affected due to the relatively long and tortuous course of its duct [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/28\">",
"     28",
"    </a>",
"    ]. Common symptoms include headache, epistaxis, and localized sinus pain. Treatment includes the use of topical and systemic decongestants and antibiotics if purulent nasal discharge is seen.",
"   </p>",
"   <p>",
"    If a one-way valve blockage occurs at a sinus ostium, a sudden decrease in ambient pressure during ascent can lead to a pressure differential that may be sufficient to rupture the sinus and produce pneumocephalus. The treatment in such cases is careful observation and prophylactic antibiotics for meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/29\">",
"     29",
"    </a>",
"    ]. Antibiotic coverage should be directed at nasopharyngeal flora and traditionally has included agents in the penicillin or cephalosporin classes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Dental barotrauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;During ascent or descent, the volume of air spaces at the roots of infected teeth or adjacent to fillings can change rapidly, leading to toothache or breakdown of the tooth [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/30\">",
"     30",
"    </a>",
"    ]. Dental barotrauma is a common complication, reported in 66 of 709 (9 percent) of experienced divers in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/3\">",
"     3",
"    </a>",
"    ]. According to two reports, orofacial pain (including toothache, sinus, and jaw pain) occurs frequently in divers [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/3,31\">",
"     3,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DECOMPRESSION SICKNESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decompression sickness was originally described as \"caisson disease\" when it was first recognized in 1843 among tunnel workers following return from the compressed environment of the caisson to atmospheric pressure. The term \"the bends\" is frequently applied to this illness because laborers with decompression sickness sometimes walked with a slight stoop, a posture affected by female socialites around the time of construction of the Brooklyn Bridge in the late 19",
"    <sup>",
"     th",
"    </sup>",
"    century and also known as the Grecian Bend [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a diver descends and breathes air under increased pressure, the tissues become loaded with increased quantities of oxygen and nitrogen as predicted by Henry's law. As the diver returns to the surface, the sum of the gas tensions in the tissue may exceed the ambient pressure and lead to the liberation of free gas from the tissues in the form of bubbles; the location of bubble formation is somewhat dependent upon tissue characteristics. The liberated gas bubbles can alter organ function by blocking vessels, rupturing or compressing tissue, or activating clotting and inflammatory cascades. The volume and location of these bubbles determine if symptoms occur [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several factors can increase the risk of developing decompression sickness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Right-to-left shunt",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any intracardiac right-to-left shunt (eg, patent foramen ovale, atrial septal defect, ventricular septal defect, patent ductus arteriosus, and partially corrected tetralogy of Fallot) increases the risk of paradoxical air emboli, and is considered by many to be a contraindication to continued diving [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/9,12,34\">",
"     9,12,34",
"    </a>",
"    ]. As an example, the presence of a patent foramen ovale (PFO) is associated with a two- to fivefold increase in the odds ratio for developing serious (type II) decompression sickness, although the overall incidence of this complication is low (4 to 6 per 10,000 dives) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/35-39\">",
"     35-39",
"    </a>",
"    ]. Among patients with a patent foramen ovale, the risk is increased with larger PFOs and increased atrial septal mobility [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been suggested that, during decompression, gaseous pulmonary emboli may increase right heart pressures, leading to right-to-left shunting and paradoxical arterial embolism. Support for this view comes from a longitudinal study performed on divers with known PFO, which noted progressive patency of these lesions over time [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/40\">",
"     40",
"    </a>",
"    ]. This finding contrasts with the presumed natural history of PFO based upon autopsy studies, which suggest decreased patency and gradual closure over time [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/32/3593?source=see_link\">",
"     \"Patent foramen ovale\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Right-to-left shunting increases with exposure to high altitude, since altitude-induced hypoxia raises pulmonary vascular resistance and right-sided pressures [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/42\">",
"     42",
"    </a>",
"    ]. The extent to which arterial oxygen desaturation occurs depends upon many factors, including the size of the communication, baseline right-sided pressures, and the extent of altitude-induced pulmonary hypertension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16042?source=see_link&amp;anchor=H15#H15\">",
"     \"High altitude, air travel, and heart disease\", section on 'Congenital heart disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Air travel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who travel by air soon after scuba diving are at increased risk for developing decompression sickness (DCS) in-flight [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/43\">",
"     43",
"    </a>",
"    ]. Such a passenger should be advised to wait 12 hours before flying if he or she has been making only one dive per day. Individuals who have participated in multiple dives, or those requiring decompression stops, should consider waiting up to 48 hours before flying [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/26/13737?source=see_link\">",
"     \"Patient assessment for air travel\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Gender",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men appear to be at greater risk of decompression sickness than women. However, this difference may be related to specific aspects of diving, including maximum depth, rate of descent and ascent, and number of dives undertaken per day, rather than gender [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Additional factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inexperienced divers are at greater risk of decompression sickness [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 75 percent of patients with decompression sickness develop symptoms within one hour and 90 percent within 12 hours of surfacing; only a small number become symptomatic more than 24 hours after diving. Scuba divers should wait 12 to 48 hours before flying on a commercial airliner, depending upon the length of their diving exposures, to avoid decompression sickness in a diver who has subclinical gas bubbles [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prodromal manifestations of decompression sickness include malaise, fatigue, and a sense of foreboding. Other constitutional symptoms include anorexia and headache. Decompression sickness is classified into two types based on the clinical manifestations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Type I decompression sickness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type I decompression sickness involves mild insults and typically affects the following organ systems:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Musculoskeletal &ndash; Localized joint pain is the most common manifestation of decompression sickness [",
"      <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/48,49\">",
"       48,49",
"      </a>",
"      ]. Joints appear particularly vulnerable to the development of gas bubbles because local regions of negative pressure are created during the movement of lubricated articular surfaces. Symptoms are believed to result from the presence of bubbles in the periarticular tissues, which impair blood flow and stretch noncompliant tissues. Pain generally develops within an hour of surfacing and gradually increases over the next one to two days. The elbow and shoulder are affected three times more commonly than the knee and hip. Motion of the joint usually does not worsen the pain, and localized tenderness or signs of inflammation are rarely seen.",
"     </li>",
"     <li>",
"      Cutaneous &ndash; Pruritus, usually over the upper torso, is relatively common and thought to result from the presence of small bubbles in the skin. It generally resolves within 30 minutes, even without treatment. Localized erythema, potentially evolving into mottled areas of cyanosis, can also be seen. It likely is due to vasospasm or obstruction of venous drainage by the bubbles and resolves without treatment.",
"     </li>",
"     <li>",
"      Lymphatic &ndash; Lymphatic obstruction by bubbles, although rare, can lead to pain, lymphadenopathy, and localized edema, usually with follicular depressions and a peau d'orange effect [",
"      <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/50\">",
"       50",
"      </a>",
"      ]. These lesions are mainly seen on the chest and torso.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Type II decompression sickness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type II decompression sickness is more severe and can lead to permanent injury and death. The following systems are typically affected:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neurologic &ndash; Approximately 60 percent of divers with decompression sickness have signs and symptoms of nervous system involvement. The vast majority of these cases are characterized by damage to the spinal cord, usually in the upper lumbar or lower thoracic regions. Paresthesias and weakness may progress to paraplegia, and loss of sphincter control, particularly of the bladder, may occur [",
"      <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/51\">",
"       51",
"      </a>",
"      ]. Cerebral manifestations can also occur and include memory loss, ataxia (\"the staggers\"), visual disturbances, and changes in personality, speech, and affect [",
"      <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/52\">",
"       52",
"      </a>",
"      ]. Most of these manifestations are believed to result from the formation and coalescence of gas bubbles within low pressure venous plexi and consequent venous obstruction. However, microvascular arterial embolization or bubble formation within nervous tissue may also play a role [",
"      <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pulmonary &ndash; In about 5 percent of cases of decompression sickness, the burden of venous air bubbles is sufficient to precipitate symptomatic venous gas embolism. Gas bubbles can occlude portions of the pulmonary circulation and produce chest pain, wheezing, dyspnea, and pharyngeal irritation (\"the chokes\"). Embarrassment of right ventricular outflow with acute right-sided cardiac failure (\"air lock\"), circulatory collapse, and death may ensue, or some gas bubbles may traverse the pulmonary capillary bed or a patent foramen ovale to produce arterial gas emboli. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38664?source=see_link\">",
"       \"Air embolism\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of significant decompression sickness includes hydration, administration of 100 percent oxygen, and positioning the patient in the left lateral decubitus (Durant's maneuver) and mild Trendelenburg (bed angled downward toward head) position in an effort to restore forward blood flow by placing the right ventricular outflow tract inferior to the right ventricular cavity, permitting air to migrate superiorly to a nonobstructing position [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although randomized trials are lacking, definitive treatment includes hyperbaric oxygen therapy in a recompression chamber initiated as quickly as possible, since the time to initiation of treatment is one of the main determinants of outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. Hyperbaric oxygen therapy decreases the volume of air bubbles according to Boyle's law and also provides oxygenation to hypoxic tissue by increasing the dissolved oxygen content of arterial blood. In addition, plasma nitrogen concentration decreases, increasing the gradient of nitrogen from bubble to plasma, thus accelerating the absorption of bubbles. Hyperbaric therapy should be undertaken for at least four hours, since bubble elimination may be poor in areas of reduced flow where edema and sludging are present [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5448?source=see_link\">",
"     \"Hyperbaric oxygen therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Complete resolution of symptoms in Type II decompression sickness is seen in almost 75 percent of cases, while approximately 16 percent of patients may have residual symptoms for up to three months. Delayed treatment has an adverse effect, with one study reporting a decrease in successful outcomes from 75 to 57 percent when treatment was delayed beyond 12 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/48\">",
"     48",
"    </a>",
"    ]. However, recompression treatment should never be withheld even after a long delay because favorable results can still occur in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/57,58\">",
"     57,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adverse effects due to hyperbaric therapy are relatively rare. A dry cough associated with carinal irritation and decrements in pulmonary function occur when divers undergo extended recompression therapy; these phenomena are due to hyperoxic bronchial injury and absorptive atelectasis, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/59\">",
"     59",
"    </a>",
"    ]. Oxygen toxicity involving the central nervous system can lead to seizures, and older patients undergoing repeated treatments can develop myopia due to an alteration in the lens structure, which reverses in about six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28407?source=see_link\">",
"     \"Oxygen toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As in the case of arterial gas embolism, several adjunctive therapies for decompression sickness have been utilized, including non-steroidal anti-inflammatory agents (NSAID), anticoagulants, and glucocorticoids, but none has been shown to improve outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/61\">",
"     61",
"    </a>",
"    ]. One randomized trial suggests NSAIDs may reduce the number of recompression treatments required [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     NITROGEN NARCOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nitrogen narcosis is caused by the raised partial pressure of nitrogen in nervous system tissue, and usually occurs at depths greater than 100 feet. It has been called \"rapture of the depths\" because it induces signs and symptoms similar to alcohol or benzodiazepine intoxication, such as impairment of intellectual and neuromuscular performance and changes in behavior and personality. Hallucinations and loss of consciousness can occur at depths greater than 300 feet.",
"   </p>",
"   <p>",
"    A diver's susceptibility to nitrogen narcosis is increased by other factors that have an opioid effect on the central nervous system, such as, hypercarbia, fatigue, alcohol, and hypothermia (core temperature less than 35&ordm;C) induced by cold water. Divers recover rapidly upon ascent to a shallower depth. The main danger of this condition stems from impairment of the diver's judgment, which can lead to drowning accidents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     DIVING AND COEXISTING CONDITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physiologic changes engendered by diving are generally well tolerated, but a number of medical conditions can increase the potential for complications. The British Thoracic Society published guidelines for the respiratory evaluation of potential divers in 2003 (",
"    <a class=\"graphic graphic_table graphicRef73880 graphicRef54026 \" href=\"UTD.htm?31/56/32654\">",
"     table 2A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/9\">",
"     9",
"    </a>",
"    ]. The key points essential to clinical assessment before diving are outlined in an algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef74826 \" href=\"UTD.htm?42/62/44014\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy is not an absolute contraindication to diving, although all pregnant women should probably be discouraged from undertaking the sport [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/63\">",
"     63",
"    </a>",
"    ]. The fetus is not protected from decompression sickness and is at greater risk of malformations and arterial gas emboli due to the lack of an effective pulmonary capillary filter [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. In addition, changes in blood flow during pregnancy and abnormal temperature regulation in the mother can increase the risk of decompression sickness, while congested mucous membranes can lead to sinus and ear barotrauma. However, termination of pregnancy is not recommended in women who have dived early in pregnancy, and normal infants have been born to women who continued diving throughout gestation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Lung disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of chronic obstructive lung disease, cystic fibrosis, bronchiectasis, interstitial lung disease, or a history of thoracic surgery or prior pneumothorax due to any cause should be considered",
"    <strong>",
"     absolute contraindications",
"    </strong>",
"    to diving.",
"   </p>",
"   <p>",
"    A patient with active asthma should also be strongly discouraged from diving even if they have normal pulmonary function tests, because individual lung units may have prolonged time constants, exhibit gas trapping, and rupture upon ascent. However, asthmatics at their baseline status with normal pulmonary function and easily controlled airway reactivity during exercise are probably at only a minimally increased risk of diving-related barotrauma [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/66-68\">",
"     66-68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute coronary syndrome can occur in association with diving [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/69\">",
"     69",
"    </a>",
"    ]. However, there is little evidence to guide decisions about which patients should be screened for ischemic heart disease (IHD). We believe that patients with active, untreated IHD should not dive. Screening recommendations among medical organizations vary [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/70\">",
"     70",
"    </a>",
"    ]. Some (eg, Divers Alert Network, Undersea and Hyperbaric Medical Society) recommend exercise stress testing for all potential divers older than 40 years, while others (eg, South Pacific Underwater Medicine Society) reserve such testing for divers over 45 years or anyone with significant risk factors for coronary artery disease. Given the dearth of evidence, either approach is reasonable.",
"   </p>",
"   <p>",
"    The presence of a patent foramen ovale increases the risk of both arterial gas embolization and decompression sickness, and patients with a known right-to-left intracardiac shunt should be instructed not to dive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16825?source=see_link\">",
"     \"Pathophysiology and clinical features of atrial septal defects in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39689?source=see_link\">",
"     \"Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A patient with a history of significant ventricular arrhythmias or exercise-induced arrhythmias should undergo cardiac stress testing before being permitted to dive. Among patients with congenital long QT syndrome (LQTS), swimming or diving can induce potentially fatal ventricular arrhythmias; this association is relatively specific for LQTS type 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical features of congenital long QT syndrome\", section on 'Triggers of arrhythmia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Other conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diving has been successfully undertaken in the presence of a variety of medical conditions, including sickle trait and Crohn's disease (with or without an ostomy). Diving is generally contraindicated in persons with an unrepaired inguinal hernia, and those",
"    <span class=\"nowrap\">",
"     panic/phobic",
"    </span>",
"    disorders or insulin dependent diabetes mellitus, unless their conditions are mild and well-controlled [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4633/abstract/74\">",
"     74",
"    </a>",
"    ]. Decisions about the safety of diving must be individualized within the context of the individual's overall health (",
"    <a class=\"graphic graphic_algorithm graphicRef74826 \" href=\"UTD.htm?42/62/44014\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1940060\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recreational SCUBA diving continues to increase in popularity, and diving-related injuries have increased proportionally. Potential complications include hypothermia, trauma, and submersion-related injuries. Barotrauma, decompression sickness, and nitrogen narcosis are complications more specific to diving.",
"     </li>",
"     <li>",
"      Barotrauma is the most common form of diving-related injury and develops when an air-filled body space fails to equilibrate its pressure with the environment. Barotrauma can manifest as lung injury (including pneumothorax), arterial gas embolism, and ear or sinus injury. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Barotrauma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Decompression sickness occurs when a diver returns to the surface and gas tensions in the tissue exceed the ambient pressure, leading to the liberation of free gas from the tissues in the form of bubbles. The liberated gas bubbles can alter organ function by blocking blood vessels, rupturing or compressing tissue, or activating clotting and inflammatory cascades. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Decompression sickness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of significant decompression sickness includes hydration, administration of 100 percent oxygen, positioning the patient to improve forward blood flow, and hyperbaric oxygen therapy. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nitrogen narcosis is caused by the raised partial pressure of nitrogen in nervous system tissue, and usually occurs at depths greater than 100 feet. It induces signs and symptoms similar to alcohol or benzodiazepine intoxication. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Nitrogen narcosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/1\">",
"      DeGorordo A, Vallejo-Manzur F, Chanin K, Varon J. Diving emergencies. Resuscitation 2003; 59:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/2\">",
"      Newton HB. Neurologic complications of scuba diving. Am Fam Physician 2001; 63:2211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/3\">",
"      Taylor DM, O'Toole KS, Ryan CM. Experienced scuba divers in Australia and the United States suffer considerable injury and morbidity. Wilderness Environ Med 2003; 14:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/4\">",
"      Braun R, Krishel S. Environmental emergencies. Emerg Med Clin North Am 1997; 15:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/5\">",
"      Hardy KR. Diving-related emergencies. Emerg Med Clin North Am 1997; 15:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/6\">",
"      Balk M, Goldman JM. Alveolar hemorrhage as a manifestation of pulmonary barotrauma after scuba diving. Ann Emerg Med 1990; 19:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/7\">",
"      Slade JB Jr, Hattori T, Ray CS, et al. Pulmonary edema associated with scuba diving : case reports and review. Chest 2001; 120:1686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/8\">",
"      Colebatch HJ, Smith MM, Ng CK. Increased elastic recoil as a determinant of pulmonary barotrauma in divers. Respir Physiol 1976; 26:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/9\">",
"      British Thoracic Society Fitness to Dive Group, Subgroup of the British Thoracic Society Standards of Care Committee. British Thoracic Society guidelines on respiratory aspects of fitness for diving. Thorax 2003; 58:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/10\">",
"      Gerriets T, Tetzlaff K, Liceni T, et al. Arteriovenous bubbles following cold water sport dives: relation to right-to-left shunting. Neurology 2000; 55:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/11\">",
"      Schwerzmann M, Seiler C, Lipp E, et al. Relation between directly detected patent foramen ovale and ischemic brain lesions in sport divers. Ann Intern Med 2001; 134:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/12\">",
"      Gerriets T, Tetzlaff K, Hutzelmann A, et al. Association between right-to-left shunts and brain lesions in sport divers. Aviat Space Environ Med 2003; 74:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/13\">",
"      Knauth M, Ries S, Pohimann S, et al. Cohort study of multiple brain lesions in sport divers: role of a patent foramen ovale. BMJ 1997; 314:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/14\">",
"      SPENCER FC, ROSSI NP, YU SC, KOEPKE JA. THE SIGNIFICANCE OF AIR EMBOLISM DURING CARDIOPULMONARY BYPASS. J Thorac Cardiovasc Surg 1965; 49:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/15\">",
"      Arthur DC, Margulies RA. A short course in diving medicine. Ann Emerg Med 1987; 16:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/16\">",
"      Leitch DR, Green RD. Pulmonary barotrauma in divers and the treatment of cerebral arterial gas embolism. Aviat Space Environ Med 1986; 57:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/17\">",
"      Murphy BP, Harford FJ, Cramer FS. Cerebral air embolism resulting from invasive medical procedures. Treatment with hyperbaric oxygen. Ann Surg 1985; 201:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/18\">",
"      Evans DE, Catron PW, McDermott JJ, et al. Effect of lidocaine after experimental cerebral ischemia induced by air embolism. J Neurosurg 1989; 70:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/19\">",
"      Hallenbeck JM, Leitch DR, Dutka AJ, et al. Prostaglandin I2, indomethacin, and heparin promote postischemic neuronal recovery in dogs. Ann Neurol 1982; 12:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/20\">",
"      Neblett LM. Otolaryngology and sport scuba diving. Update and guidelines. Ann Otol Rhinol Laryngol Suppl 1985; 115:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/21\">",
"      Uzun C, Adali MK, Koten M, et al. Relationship between mastoid pneumatization and middle ear barotrauma in divers. Laryngoscope 2002; 112:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/22\">",
"      Melamed Y, Shupak A, Bitterman H. Medical problems associated with underwater diving. N Engl J Med 1992; 326:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/23\">",
"      Moon RE. Treatment of diving emergencies. Crit Care Clin 1999; 15:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/24\">",
"      Farmer, JC, Jr. Eustachian tube function and otologic barotrauma. Ann Otol Rhinol Laryngol 1985; 120:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/25\">",
"      Klingmann C, Benton P, Schellinger P, Knauth M. A safe treatment concept for divers with acute inner ear disorders. Laryngoscope 2004; 114:2048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/26\">",
"      Shupak A, Gil A, Nachum Z, et al. Inner ear decompression sickness and inner ear barotrauma in recreational divers: a long-term follow-up. Laryngoscope 2003; 113:2141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/27\">",
"      Parell GJ, Becker GD. Conservative management of inner ear barotrauma resulting from scuba diving. Otolaryngol Head Neck Surg 1985; 93:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/28\">",
"      Fagan P, McKenzie B, Edmonds C. Sinus barotrauma in divers. Ann Otol Rhinol Laryngol 1976; 85:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/29\">",
"      Brodie HA. Prophylactic antibiotics for posttraumatic cerebrospinal fluid fistulae. A meta-analysis. Arch Otolaryngol Head Neck Surg 1997; 123:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/30\">",
"      Edmonds C, Thomas RL. Medical aspects of diving--3. Med J Aust 1972; 2:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/31\">",
"      Jagger RG, Shah CA, Weerapperuma ID, Jagger DC. The prevalence of orofacial pain and tooth fracture (odontocrexis) associated with SCUBA diving. Prim Dent Care 2009; 16:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/32\">",
"      Moon RE, Vann RD, Bennett PB. The physiology of decompression illness. Sci Am 1995; 273:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/33\">",
"      Barratt DM, Harch PG, Van Meter K. Decompression illness in divers: a review of the literature. Neurologist 2002; 8:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/34\">",
"      Wilmshurst PT, Byrne JC, Webb-Peploe MM. Relation between interatrial shunts and decompression sickness in divers. Lancet 1989; 2:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/35\">",
"      Bove AA. Risk of decompression sickness with patent foramen ovale. Undersea Hyperb Med 1998; 25:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/36\">",
"      Kerut EK, Norfleet WT, Plotnick GD, Giles TD. Patent foramen ovale: a review of associated conditions and the impact of physiological size. J Am Coll Cardiol 2001; 38:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/37\">",
"      Cartoni D, De Castro S, Valente G, et al. Identification of professional scuba divers with patent foramen ovale at risk for decompression illness. Am J Cardiol 2004; 94:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/38\">",
"      Torti SR, Billinger M, Schwerzmann M, et al. Risk of decompression illness among 230 divers in relation to the presence and size of patent foramen ovale. Eur Heart J 2004; 25:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/39\">",
"      Moon RE, Camporesi EM, Kisslo JA. Patent foramen ovale and decompression sickness in divers. Lancet 1989; 1:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/40\">",
"      Germonpre P, Hastir F, Dendale P, et al. Evidence for increasing patency of the foramen ovale in divers. Am J Cardiol 2005; 95:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/41\">",
"      Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc 1984; 59:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/42\">",
"      Maggiorini M, M&eacute;lot C, Pierre S, et al. High-altitude pulmonary edema is initially caused by an increase in capillary pressure. Circulation 2001; 103:2078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/43\">",
"      Gendreau MA, DeJohn C. Responding to medical events during commercial airline flights. N Engl J Med 2002; 346:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/44\">",
"      Sheffield PJ. Flying after diving guidelines: a review. Aviat Space Environ Med 1990; 61:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/45\">",
"      Freiberger JJ, Denoble PJ, Pieper CF, et al. The relative risk of decompression sickness during and after air travel following diving. Aviat Space Environ Med 2002; 73:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/46\">",
"      St Leger Dowse M, Bryson P, Gunby A, Fife W. Comparative data from 2250 male and female sports divers: diving patterns and decompression sickness. Aviat Space Environ Med 2002; 73:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/47\">",
"      Klingmann C, Gonnermann A, Dreyhaupt J, et al. Decompression illness reported in a survey of 429 recreational divers. Aviat Space Environ Med 2008; 79:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/48\">",
"      Green RD, Leitch DR. Twenty years of treating decompression sickness. Aviat Space Environ Med 1987; 58:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/49\">",
"      Rivera, JC. Decompression sickness among divers: An analysis of 935 cases. Milit Med 1964; 129:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/50\">",
"      Edmonds C, Thomas RL. Medical aspects of diving. 4. Med J Aust 1972; 2:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/51\">",
"      Erde A, Edmonds C. Decompression sickness: a clinical series. J Occup Med 1975; 17:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/52\">",
"      Dick AP, Massey EW. Neurologic presentation of decompression sickness and air embolism in sport divers. Neurology 1985; 35:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/53\">",
"      Hallenbeck JM. Cinephotomicrography of dog spinal vessels during cord-damaging decompression sickness. Neurology 1976; 26:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/54\">",
"      Tetzlaff K, Shank ES, Muth CM. Evaluation and management of decompression illness--an intensivist's perspective. Intensive Care Med 2003; 29:2128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/55\">",
"      Melamed Y, Sherman D, Wiler-Ravell D, Kerem D. The transportable recompression rescue chamber as an alternative to delayed treatment in serious diving accidents. Aviat Space Environ Med 1981; 52:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/56\">",
"      Bennett MH, Lehm JP, Mitchell SJ, Wasiak J. Recompression and adjunctive therapy for decompression illness. Cochrane Database Syst Rev 2012; 5:CD005277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/57\">",
"      Halpern P, Greenstein A, Melamed Y, et al. Spinal decompression sickness with delayed onset, delayed treatment, and full recovery. Br Med J (Clin Res Ed) 1982; 284:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/58\">",
"      Myers RA, Bray P. Delayed treatment of serious decompression sickness. Ann Emerg Med 1985; 14:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/59\">",
"      Clark JM, Lambertsen CJ. Pulmonary oxygen toxicity: a review. Pharmacol Rev 1971; 23:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/60\">",
"      Lyne AJ. Ocular effects of hyperbaric oxygen. Trans Ophthalmol Soc U K 1978; 98:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/61\">",
"      Farmer JC, Thomas WG, Youngblood DG, Bennett PB. Inner ear decompression sickness. Laryngoscope 1976; 86:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/62\">",
"      Bennett M, Mitchell S, Dominguez A. Adjunctive treatment of decompression illness with a non-steroidal anti-inflammatory drug (tenoxicam) reduces compression requirement. Undersea Hyperb Med 2003; 30:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/63\">",
"      Camporesi EM. Diving and pregnancy. Semin Perinatol 1996; 20:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/64\">",
"      Bolton ME. Scuba diving and fetal well-being: a survey of 208 women. Undersea Biomed Res 1980; 7:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/65\">",
"      Turner G, Unsworth I. Intrauterine bends? Lancet 1982; 1:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/66\">",
"      Bove AA. Pulmonary barotrauma in divers: can prospective pulmonary function testing identify those at risk? Chest 1997; 112:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/67\">",
"      Tetzlaff K, Muth CM, Waldhauser LK. A review of asthma and scuba diving. J Asthma 2002; 39:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/68\">",
"      Krieger BP. Diving: what to tell the patient with asthma and why? Curr Opin Pulm Med 2001; 7:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/69\">",
"      Kanter AS, Stewart BF, Costello JA, Hampson NB. Myocardial infarction during scuba diving: a case report and review. Am Heart J 1995; 130:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/70\">",
"      Harrison D, Lloyd-Smith R, Khazei A, et al. Controversies in the medical clearance of recreational scuba divers: updates on asthma, diabetes mellitus, coronary artery disease, and patent foramen ovale. Curr Sports Med Rep 2005; 4:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/71\">",
"      Moss AJ, Robinson JL, Gessman L, et al. Comparison of clinical and genetic variables of cardiac events associated with loud noise versus swimming among subjects with the long QT syndrome. Am J Cardiol 1999; 84:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/72\">",
"      Ackerman MJ, Tester DJ, Porter CJ. Swimming, a gene-specific arrhythmogenic trigger for inherited long QT syndrome. Mayo Clin Proc 1999; 74:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/73\">",
"      Batra AS, Silka MJ. Mechanism of sudden cardiac arrest while swimming in a child with the prolonged QT syndrome. J Pediatr 2002; 141:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4633/abstract/74\">",
"      Dear Gde L, Pollock NW, Uguccioni DM, et al. Plasma glucose responses in recreational divers with insulin-requiring diabetes. Undersea Hyperb Med 2004; 31:291.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 177 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-202.43.93.2-77D3A94D3A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_33_4633=[""].join("\n");
var outline_f4_33_4633=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1940060\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1940068\">",
"      GAS LAWS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BAROTRAUMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pulmonary barotrauma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Pneumomediastinum",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Pneumothorax",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Arterial gas embolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Ear barotrauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Sinus barotrauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Dental barotrauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DECOMPRESSION SICKNESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Right-to-left shunt",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Air travel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Gender",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Additional factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Type I decompression sickness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Type II decompression sickness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      NITROGEN NARCOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      DIVING AND COEXISTING CONDITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Lung disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Other conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1940060\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/177\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/177|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?42/62/44014\" title=\"algorithm 1\">",
"      Respiratory assessment of potential divers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/177|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/9/21649\" title=\"figure 1\">",
"      Soft tissue emphysema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/177|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/34/22060\" title=\"table 1\">",
"      Ear pressurization techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/35/30269\" title=\"table 2A\">",
"      BTS diving guidelines a",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/34/14893\" title=\"table 2B\">",
"      BTS diving guidelines b",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15913?source=related_link\">",
"      Accidental hypothermia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38664?source=related_link\">",
"      Air embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39689?source=related_link\">",
"      Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=related_link\">",
"      Clinical features of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26809?source=related_link\">",
"      Drowning (submersion injuries)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35397?source=related_link\">",
"      Ear barotrauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16042?source=related_link\">",
"      High altitude, air travel, and heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5448?source=related_link\">",
"      Hyperbaric oxygen therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/19/22838?source=related_link\">",
"      Imaging of pneumothorax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28407?source=related_link\">",
"      Oxygen toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/32/3593?source=related_link\">",
"      Patent foramen ovale",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16825?source=related_link\">",
"      Pathophysiology and clinical features of atrial septal defects in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/26/13737?source=related_link\">",
"      Patient assessment for air travel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1226?source=related_link\">",
"      Placement and management of thoracostomy tubes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24121?source=related_link\">",
"      Secondary spontaneous pneumothorax in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_33_4634="Septic shock: Rapid recognition and initial resuscitation in children";
var content_f4_33_4634=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Septic shock: Rapid recognition and initial resuscitation in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/33/4634/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/33/4634/contributors\">",
"     Scott L Weiss, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/33/4634/contributors\">",
"     Wendy J Pomerantz, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/33/4634/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/33/4634/contributors\">",
"     Adrienne G Randolph, MD, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/33/4634/contributors\">",
"     Susan B Torrey, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/33/4634/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/33/4634/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/33/4634/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/33/4634/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H19451388\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sepsis is a clinical syndrome complicating severe infection that is characterized by systemic inflammation, immune dysregulation, microcirculatory derangements, and end-organ dysfunction. There is a continuity of severity ranging from sepsis to severe sepsis and septic shock. Severe sepsis and septic shock are characterized by dysfunction of &ge;2 organ systems and cardiovascular dysfunction, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4634/abstract/1\">",
"     1",
"    </a>",
"    ]. With increased attention to rapid recognition, aggressive fluid administration, and early administration of vasoactive agents and antibiotics, pediatric mortality from severe sepsis and septic shock has decreased markedly [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4634/abstract/2-7\">",
"     2-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The early recognition and initial management of severe sepsis and septic shock in children during the first hour of resuscitation are reviewed here. The definitions, epidemiology, and clinical manifestations of sepsis in children and ongoing management of children with septic shock are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10346?source=see_link\">",
"     \"Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13354?source=see_link\">",
"     \"Septic shock: Ongoing management after resuscitation in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25706214\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Septic shock refers to sepsis with cardiovascular dysfunction (ie, hypotension, reliance on vasoactive drug administration to maintain a normal blood pressure, or two of the following: prolonged capillary refill, oliguria, metabolic acidosis, or elevated arterial lactate) that persists despite the administration of &ge;40",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of isotonic fluid in one hour. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10346?source=see_link&amp;anchor=H61670172#H61670172\">",
"     \"Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis\", section on 'Severity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19451395\">",
"    <span class=\"h1\">",
"     RAPID RECOGNITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clinical diagnosis of septic shock is made in children who have signs of inadequate tissue perfusion, two or more criteria for the systemic inflammatory response syndrome (",
"    <a class=\"graphic graphic_table graphicRef86087 \" href=\"UTD.htm?26/36/27212\">",
"     table 1",
"    </a>",
"    ), and suspected or proven infection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4634/abstract/8\">",
"     8",
"    </a>",
"    ]. Rapid recognition of hemodynamic abnormalities and early suspicion of infection are essential to achieve favorable outcomes. As an example, in a prospective cohort study of 91 infants and children presenting to community hospitals with septic shock (defined by hypotension or delayed capillary refill), each hour delay in initiation of appropriate resuscitation or persistence of hemodynamic abnormalities was associated with a clinically significant increased risk of death (OR 1.5 and 2.3, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4634/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10346?source=see_link&amp;anchor=H2#H2\">",
"     \"Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis\", section on 'Definitions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10346?source=see_link&amp;anchor=H61670172#H61670172\">",
"     \"Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis\", section on 'Severity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19451408\">",
"    <span class=\"h2\">",
"     Inadequate tissue perfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seriously ill patients should undergo urgent evaluation for the following signs of impaired perfusion or shock [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4634/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fever",
"     </li>",
"     <li>",
"      Tachycardia or bradycardia",
"     </li>",
"     <li>",
"      Decreased peripheral pulses compared with central pulses",
"     </li>",
"     <li>",
"      Mottled or cool extremities",
"     </li>",
"     <li>",
"      &ldquo;Flash&rdquo; or &gt;3 second capillary refill",
"     </li>",
"     <li>",
"      Dry mucus membranes, sunken eyes, and decreased urine output",
"     </li>",
"     <li>",
"      Tachypnea, bradypnea, or apnea",
"     </li>",
"     <li>",
"      Hypotension",
"     </li>",
"     <li>",
"      Altered mental status (irritability, anxiety, confusion, lethargy, somnolence, apnea)",
"     </li>",
"     <li>",
"      Hypothermia (especially neonates)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Tachycardia and tachypnea are common and non-specific findings in young pediatric patients and may be due to fever, anxiety, dehydration,",
"    <span class=\"nowrap\">",
"     pain/discomfort,",
"    </span>",
"    anemia, or agitation. However, persistent tachycardia is a sensitive indicator of circulatory dysfunction and should not be overlooked. If a question exists as to whether tachycardia is due to circulatory impairment, a fluid bolus is recommended unless there is evidence for cardiac dysfunction (eg, hepatomegaly, jugular venous distention, S3 gallop, cardiomegaly).",
"   </p>",
"   <p>",
"    Hypotension is a late sign of cardiovascular dysfunction and shock in pediatric patients and is",
"    <strong>",
"     not",
"    </strong>",
"    necessary to diagnose septic shock. Infants and children with sepsis often maintain blood pressure despite the presence of septic shock through an increase in heart rate, systemic vascular resistance, and venous tone but have a limited capacity to augment myocardial stroke volume. As a result, infants and children are also more likely to exhibit &ldquo;cold&rdquo; shock in sepsis compared to the classic presentation of &ldquo;warm&rdquo; (or hyperdynamic or vasodilated) shock in adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10346?source=see_link&amp;anchor=H1374189#H1374189\">",
"     \"Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis\", section on 'Shock'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19451420\">",
"    <span class=\"h2\">",
"     Signs of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be simultaneously evaluated for an infectious source to distinguish non-infectious from septic shock. Fever, cough or congestion, dyspnea, hypoxemia, rash, abdominal pain, myalgias, immunocompromising condition (eg, chemotherapy, sickle cell disease, or other known conditions associated with splenic dysfunction or primary immune deficiency), leukocytosis, or leukopenia with thrombocytopenia should raise suspicion for infection (",
"    <a class=\"graphic graphic_table graphicRef59769 \" href=\"UTD.htm?2/26/2477\">",
"     table 2",
"    </a>",
"    ). Other factors concerning for specific infections, such as dysuria (urinary tract infection), hematochezia (gastroenteritis), headache and neck stiffness (meningitis), bone or joint inflammation (",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    ), conjunctival",
"    <span class=\"nowrap\">",
"     suffusion/injection",
"    </span>",
"    (toxic shock syndrome), ecthyma (Pseudomonas species) and",
"    <span class=\"nowrap\">",
"     petechiae/purpura",
"    </span>",
"    (meningococcemia), should also be quickly ascertained. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10346?source=see_link&amp;anchor=H61670563#H61670563\">",
"     \"Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis\", section on 'Infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If an infection is suspected or a non-infectious etiology of shock is not clear, current guidelines recommend obtaining blood, urine, and, as indicated, other cultures and administering empiric broad-spectrum antibiotics within one hour of presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4634/abstract/10\">",
"     10",
"    </a>",
"    ]. Antibiotic therapy should not be delayed beyond one hour in order to obtain cultures if there is a concern for severe sepsis or septic shock. Patients with a recent history of an immunocompromising condition (eg, neutropenia, chemotherapy, sickle cell disease, or primary immune deficiency) are at highest risk for sepsis and severe complications and their outcome is highly dependent on rapid antimicrobial treatment. (See",
"    <a class=\"local\" href=\"#H9034264\">",
"     'Initial antimicrobial therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19451427\">",
"    <span class=\"h2\">",
"     Suggestive laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suggested laboratory studies for children with sepsis and septic shock are discussed in detail separately and include (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10346?source=see_link&amp;anchor=H14817539#H14817539\">",
"     \"Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis\", section on 'Laboratory studies'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Rapid blood glucose",
"     </li>",
"     <li>",
"      Arterial or venous blood gas",
"     </li>",
"     <li>",
"      Complete blood count with differential",
"     </li>",
"     <li>",
"      Blood lactate",
"     </li>",
"     <li>",
"      Serum electrolytes",
"     </li>",
"     <li>",
"      Blood urea nitrogen and serum creatinine",
"     </li>",
"     <li>",
"      Ionized blood calcium",
"     </li>",
"     <li>",
"      Serum total bilirubin and alanine aminotransferase",
"     </li>",
"     <li>",
"      Prothrombin and partial thromboplastin times (PT and PTT)",
"     </li>",
"     <li>",
"      International normalized ratio (INR)",
"     </li>",
"     <li>",
"      Fibrinogen and D-dimer",
"     </li>",
"     <li>",
"      Blood culture",
"     </li>",
"     <li>",
"      Urinalysis",
"     </li>",
"     <li>",
"      Urine culture",
"     </li>",
"     <li>",
"      Other cultures as indicated by clinical findings",
"     </li>",
"     <li>",
"      Diagnostic serologic testing as indicated to identify suspected sources of infection",
"     </li>",
"     <li>",
"      Inflammatory biomarkers (eg, C-reactive protein, procalcitonin) in selected cases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following laboratory findings support the diagnosis of septic shock:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lactic acidosis indicated by metabolic acidosis on blood gases and elevation of arterial blood lactate (&gt;3.5",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10346?source=see_link&amp;anchor=H14817539#H14817539\">",
"       \"Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis\", section on 'Laboratory studies'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Age-specific leukocytosis or leukopenia (",
"      <a class=\"graphic graphic_table graphicRef86087 \" href=\"UTD.htm?26/36/27212\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Platelet count",
"      <span class=\"nowrap\">",
"       &lt;80,000/microL",
"      </span>",
"      or a decline of 50 percent from highest value recorded over the past three days",
"     </li>",
"     <li>",
"      Disseminated intravascular coagulopathy (decreased fibrinogen with increased D-dimer, international normalized ratio, prothrombin time, or partial thromboplastin time) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8697?source=see_link&amp;anchor=H20#H20\">",
"       \"Disseminated intravascular coagulation in infants and children\", section on 'Diagnosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Renal insufficiency suggested by a serum creatinine &ge;2 times upper limit of normal for age or twofold increase in baseline creatinine",
"     </li>",
"     <li>",
"      Liver dysfunction implied by a total bilirubin &ge;4",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (not applicable to newborn) or alanine aminotransferase (ALT) &gt;2 times upper limit of normal for age",
"     </li>",
"     <li>",
"      Pyuria indicating an urinary tract infection",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6411955\">",
"    <span class=\"h1\">",
"     PHYSIOLOGIC INDICATORS AND TARGET GOALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Restoration of tissue perfusion, such as reversal of shock, should be targeted to the following therapeutic endpoints (goals in parentheses) (",
"    <a class=\"graphic graphic_algorithm graphicRef80923 \" href=\"UTD.htm?28/36/29255\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4634/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Quality of central and peripheral pulses (strong, distal pulses equal to central pulses)",
"     </li>",
"     <li>",
"      Skin perfusion (warm, with capillary refill &lt;2 seconds)",
"     </li>",
"     <li>",
"      Mental status (normal mental status)",
"     </li>",
"     <li>",
"      Urine output (&ge;1",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour, up to 40 mL per hour, once effective circulating volume is restored)",
"     </li>",
"     <li>",
"      Blood pressure (systolic pressure at least fifth percentile for age: 60 mmHg &lt;1 month of age, 70 mmHg + [2 x age in years] in children 1 month to 10 years of age, 90 mmHg in children 10 years of age or older); however, blood pressure by itself is not a reliable end point for assessing the adequacy of resuscitation",
"     </li>",
"     <li>",
"      Lactate (&lt;4",
"      <span class=\"nowrap\">",
"       mmol/L",
"      </span>",
"      or &ge;10 percent decrease per hour until normal)",
"     </li>",
"     <li>",
"      Central venous oxygen saturation (ScvO",
"      <sub>",
"       2",
"      </sub>",
"      ), (&ge;70 percent), if available",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Heart rate is an important physiologic indicator of circulatory status that should also be monitored closely (",
"    <a class=\"graphic graphic_table graphicRef78097 \" href=\"UTD.htm?27/37/28252\">",
"     table 3",
"    </a>",
"    ). However, many other factors (ie, fever, drugs, anxiety) influence heart rate. Although trends in response to treatment should be carefully monitored, specific target goals for heart rate are difficult to define and may not be useful. Children with persistently elevated heart rate unresponsive to repeated fluid boluses should be evaluated for cardiac dysfunction. (See",
"    <a class=\"local\" href=\"#H19451408\">",
"     'Inadequate tissue perfusion'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Several studies have demonstrated that lactate and ScvO",
"    <sub>",
"     2",
"    </sub>",
"    can correlate with severity of shock and prognosis in sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4634/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Persistently elevated lactate &gt;4",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    or failure to decrease by at least 10 percent every one to two hours and ScvO2 &lt;70 percent may indicate persistence of abnormal end-organ perfusion. However, an ScvO2 &ge;70 percent can also be falsely reassuring in sepsis due to hyperdynamic cardiac function, microcirculatory shunting, or mitochondrial dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4634/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Blood lactate can be obtained by bedside testing. When measuring ScvO",
"    <sub>",
"     2",
"    </sub>",
"    in pediatric patients, pulmonary artery catheters are rarely used. Instead, changes in central venous oxygen saturation (ScvO2) are obtained from a catheter with its tip in the superior vena cava (ScvO2) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4634/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Identifying physiologic indicators to monitor the effectiveness of resuscitation for children with septic shock is challenging. Noninvasive ultrasonic determination of cardiac index, cardiac output, systemic vascular resistance, and stroke volume is feasible in healthy children, and age-based normative values have been published. Although not widely available, bedside Doppler ultrasound shows promise as a noninvasive method to guide vasoactive therapy by calculating cardiac output (CO) and systemic vascular resistance (SVR) from measurements of blood flow over the pulmonary artery or aorta. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=see_link&amp;anchor=H4#H4\">",
"     \"Initial management of shock in children\", section on 'Physiologic indicators and target goals'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regardless of the method used to measure vascular pressures, clinical signs of end organ perfusion must also be monitored in order to accurately determine the severity of shock and response to treatment. These indicators can be readily monitored noninvasively during the initial management of shock and, since many children in shock respond well, invasive monitoring can often be avoided. Mean arterial pressure can be measured with a blood pressure cuff. Clinical experience suggests that quality of central and peripheral pulses, skin perfusion, mental status, and urine output are useful signs for assessing response to therapy. Limited observational evidence suggests that capillary refill time may correlate with ScvO2. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=see_link&amp;anchor=H4#H4\">",
"     \"Initial management of shock in children\", section on 'Physiologic indicators and target goals'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19450185\">",
"    <span class=\"h1\">",
"     RESUSCITATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6411279\">",
"    <span class=\"h2\">",
"     Early goal-directed therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Goal-directed therapy for septic shock refers to an aggressive systematic approach to resuscitation targeted to improvements in physiologic indicators of perfusion and vital organ function within the first six hours. Effective treatment of septic shock requires rapid correction of circulatory dysfunction with continuous monitoring and re-evaluation at frequent intervals and early administration of empiric broad-spectrum antimicrobial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4634/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest that children with septic shock receive treatment according to the 2007 American College of Critical Care Medicine (ACCM) guidelines with emphasis on early goal-directed therapy (",
"    <a class=\"graphic graphic_algorithm graphicRef80923 \" href=\"UTD.htm?28/36/29255\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4634/abstract/8\">",
"     8",
"    </a>",
"    ]. These guidelines are also largely compatible with the algorithm for pediatric septic shock promoted in the Pediatric Advanced Life Support (PALS) course (",
"    <a class=\"graphic graphic_algorithm graphicRef65304 \" href=\"UTD.htm?14/27/14770\">",
"     algorithm 2",
"    </a>",
"    ). However, the ACCM guidelines provide a tighter time frame for optimal delivery of initial intravenous fluid boluses. The timing of therapeutic actions in the ACCM guidelines should be viewed as best practices for resuscitation of a child with septic shock. However, meeting the time targets may not always be possible within the first hour of illness depending upon patient factors and available pediatric expertise.",
"   </p>",
"   <p>",
"    This recommendation is supported by one trial and observational studies that show a marked reduction in mortality among children with severe sepsis after wide dissemination of the 2002 ACCM guidelines on which the 2007 guidelines are based as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a trial of goal-directed therapy in 102 children with severe sepsis or fluid-refractory septic shock treated in two pediatric intensive care units, 28-day mortality was lower in patients who received goal-directed therapy versus therapy guided by blood pressure (12 versus 39 percent, respectively) primarily due to the marked benefit of goal-directed therapy among the children with central venous oxygen saturation (ScvO",
"      <sub>",
"       2",
"      </sub>",
"      ) &lt;70 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?4/33/4634/abstract/17\">",
"       17",
"      </a>",
"      ]. Patients managed according to goal-directed therapy received a clinically significantly greater volume of crystalloid, more blood transfusions, and more vasoactive drug therapy. Although patients with ScvO",
"      <sub>",
"       2",
"      </sub>",
"      &gt;70 who received goal-directed therapy also had lower mortality than controls (12 versus 22 percent), this difference was not statistically significant.",
"     </li>",
"     <li>",
"      Institution of timely goal directed interventions by a mobile intensive care team compatible with the ACCM 2002 guidelines, including early and aggressive bolus colloid administration, endotracheal intubation and mechanical ventilation, and vasoactive therapy in conjunction with regionalization of care for 331 children with meningococcemia in the United Kingdom was associated with a decrease in the case fatality rate from 23 to 2 percent over five years (annual reduction in the odds of death 0.41, 95% CI: 0.27-0.62) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/33/4634/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Analysis of the case fatality rate among children treated for sepsis and purpura (primarily caused by Neisseria meningitidis, serogroup C) over 20 years in a children&rsquo;s hospital demonstrated a drop in annual mortality from approximately 20 to 1 percent with no deaths after 2002, corresponding to release of the ACCM guidelines and a nation-wide meningococcal C vaccination campaign [",
"      <a class=\"abstract\" href=\"UTD.htm?4/33/4634/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the United States, the annual death rate from severe sepsis was estimated as 4 percent (2 percent in healthy children and 8 percent in children with prior chronic illness) in 2003 compared with 9 percent in 1999 [",
"      <a class=\"abstract\" href=\"UTD.htm?4/33/4634/abstract/2,3\">",
"       2,3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19450192\">",
"    <span class=\"h2\">",
"     Airway and breathing",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with septic shock should initially receive 100 percent supplemental oxygen to optimize blood oxygen content and, thus, oxygen delivery to tissues. Oxygenation should be monitored using continuous pulse oximetry (SpO2). Once adequate perfusion has been restored, supplemental oxygen should be titrated to avoid SpO2 &gt;97 percent to prevent the adverse effects (eg, lung injury and microcirculatory vasoconstriction) associated with hyperoxia and free radical generation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4634/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27014?source=see_link\">",
"     \"Continuous oxygen delivery systems for infants, children, and adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=see_link\">",
"     \"Basic airway management in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endotracheal intubation using rapid sequence intubation (RSI) is frequently necessary in children with septic shock to protect the airway, assist with ventilation,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    promote oxygenation. In addition, endotracheal intubation and sedation reduces the work of breathing which may avoid diversion of cardiac output to the muscles of respiration and may improve perfusion to other organs. A rapid overview of RSI in children is provided in the table (",
"    <a class=\"graphic graphic_table graphicRef51456 \" href=\"UTD.htm?17/26/17837\">",
"     table 4",
"    </a>",
"    ). Emergent endotracheal intubation in children and pediatric rapid sequence intubation (RSI) are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"     \"Emergent endotracheal intubation in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=see_link\">",
"     \"Rapid sequence intubation (RSI) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Key actions when performing RSI in children with septic shock include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with hemodynamic instability should receive appropriate support with fluid",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      catecholamines (see below) prior to or during intubation.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"       Ketamine",
"      </a>",
"      , if available and",
"      <strong>",
"       not",
"      </strong>",
"      contraindicated, is preferable for sedation prior to endotracheal intubation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/30/11754?source=see_link&amp;anchor=H10#H10\">",
"       \"Sedation or induction agents for rapid sequence intubation in adults\", section on 'Ketamine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"       Etomidate",
"      </a>",
"      inhibits cortisol formation and should",
"      <strong>",
"       not",
"      </strong>",
"      be used routinely. If etomidate is used, we suggest the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      It is important to evaluate for signs of adrenal insufficiency sometimes evidenced by refractory shock [",
"      <a class=\"abstract\" href=\"UTD.htm?4/33/4634/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=see_link&amp;anchor=H18#H18\">",
"       \"Rapid sequence intubation (RSI) in children\", section on 'Etomidate'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13354?source=see_link&amp;anchor=H18270403#H18270403\">",
"       \"Septic shock: Ongoing management after resuscitation in children\", section on 'Address adrenal insufficiency'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Emergency clinicians should inform the physicians assuming care for the patient in the intensive care unit when",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"       etomidate",
"      </a>",
"      has been used for induction.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"       Etomidate",
"      </a>",
"      should",
"      <strong>",
"       not",
"      </strong>",
"      be used as an infusion or in repeated bolus doses for maintenance of sedation after intubation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/13/11478?source=see_link\">",
"       Thiopental",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/48/12039?source=see_link\">",
"       propofol",
"      </a>",
"      are associated with hypotension and should be avoided in children with septic shock.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When performing rapid sequence intubation in a child with septic shock, it is important to choose agents that do not worsen cardiovascular status. Previously,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"     etomidate",
"    </a>",
"    was a common choice because it typically does not compromise hemodynamic stability. However, small observational studies in children with sepsis and septic shock undergoing intubation with or without etomidate indicate that one dose of etomidate is associated with lower levels of serum cortisol, cortisol to 11-deoxycortisol ratios, and higher adrenocortical hormone levels for up to 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4634/abstract/21,23\">",
"     21,23",
"    </a>",
"    ]. In one case series of 31 children with meningococcal sepsis who required endotracheal intubation, of the eight children who died, seven received etomidate [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4634/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2007 update to the Clinical Guidelines for Hemodynamic Support of Neonates and Children with Septic Shock from the American College of Critical Care Medicine states that",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"     etomidate",
"    </a>",
"    is",
"    <strong>",
"     no",
"    </strong>",
"    longer recommended to sedate children with septic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4634/abstract/8\">",
"     8",
"    </a>",
"    ]. The 2010 advanced life support recommendations provided by the American Heart Association and the International Liaison Committee on Resuscitation on which the Pediatric Advanced Life Support course is based also suggest that etomidate",
"    <strong>",
"     not",
"    </strong>",
"    be used routinely in children with septic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4634/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2984154\">",
"    <span class=\"h2\">",
"     Treat hypoglycemia and hypocalcemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with septic shock are at risk for hypoglycemia and hypocalcemia Rapid blood glucose and ionized calcium should be measured as intravenous access is obtained.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Hypoglycemia",
"      </strong>",
"      &ndash; Hypoglycemia should be corrected by rapid intravenous infusion of dextrose as described in the rapid overview (",
"      <a class=\"graphic graphic_table graphicRef83485 \" href=\"UTD.htm?31/43/32446\">",
"       table 5",
"      </a>",
"      ). After initial hypoglycemia is reversed, the clinician should provide a continuous infusion of dextrose to maintain blood glucose in a safe range (70 to 150",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [3.89 to 8.33",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      for children whose condition does not permit oral intake. Hypoglycemia may also be an indicator of adrenal insufficiency in predisposed children and those with refractory septic shock. (See",
"      <a class=\"local\" href=\"#H6282460\">",
"       'Corticosteroids'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13354?source=see_link&amp;anchor=H18270403#H18270403\">",
"       \"Septic shock: Ongoing management after resuscitation in children\", section on 'Address adrenal insufficiency'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In normoglycemic young children, a continuous maintenance infusion of dextrose 10 percent is a reasonable option to prevent the occurrence of hypoglycemia and is suggested by the American College of Critical Care Medicine [",
"      <a class=\"abstract\" href=\"UTD.htm?4/33/4634/abstract/8\">",
"       8",
"      </a>",
"      ]. Hyperglycemia should be avoided.",
"     </li>",
"     <li>",
"      <strong>",
"       Hypocalcemia",
"      </strong>",
"      &ndash; Children with persistent shock in association with an ionized calcium &lt;1.1",
"      <span class=\"nowrap\">",
"       mmol/L",
"      </span>",
"      (4.8",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      or symptomatic hypocalcemia (eg, positive Chvostek or Trousseau signs, seizures, prolonged QT interval on EKG, or cardiac arrhythmias) should undergo correction with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/13/41175?source=see_link\">",
"       calcium gluconate",
"      </a>",
"      10 percent solution in a dose of 50 to 100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (0.5 to 1",
"      <span class=\"nowrap\">",
"       mL/kg),",
"      </span>",
"      up to 2 g (20 mL) by slow intravenous or intraosseous infusion over five minutes. This suggested dose is equivalent to elemental calcium 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (0.15",
"      <span class=\"nowrap\">",
"       mmol/kg),",
"      </span>",
"      up to 180 mg elemental (4.5 mmol) per single dose.",
"      <br/>",
"      <br/>",
"      Calcium should be administered in a larger vein or, preferably, a central line.",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/56/41862?source=see_link\">",
"       Sodium bicarbonate",
"      </a>",
"      should",
"      <strong>",
"       not",
"      </strong>",
"      be introduced into an intravenous or intraosseous cannula without flushing before and after administration because of potential precipitation.",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/63/19446?source=see_link\">",
"       Calcium chloride",
"      </a>",
"      10 percent in a dose of 10 to 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (0.1 to 0.2",
"      <span class=\"nowrap\">",
"       mL/kg),",
"      </span>",
"      maximum dose 1 g (10 mL) provides an equivalent dose but should",
"      <strong>",
"       only",
"      </strong>",
"      be administered through a central line. Patients receiving a calcium infusion warrant continuous cardiac monitoring.",
"      <br/>",
"      <br/>",
"      Hypocalcemia is a common finding in critically ill patients with sepsis likely due to changes in the hormonal milieu, though the exact pathophysiology remains unclear [",
"      <a class=\"abstract\" href=\"UTD.htm?4/33/4634/abstract/24-26\">",
"       24-26",
"      </a>",
"      ]. Intracellular calcium is necessary for cardiac and smooth muscle contraction.&nbsp;Infants under 12 months of age may rely more heavily on extracellular calcium to maintain adequate cardiac contractility than older patients. Animal models and observational studies have suggested improved physiologic outcomes when hypocalcemia is treated [",
"      <a class=\"abstract\" href=\"UTD.htm?4/33/4634/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]. Although definitive evidence to support improved clinical outcomes in humans receiving intravenous calcium for low ionized calcium levels is lacking [",
"      <a class=\"abstract\" href=\"UTD.htm?4/33/4634/abstract/29\">",
"       29",
"      </a>",
"      ], current guidelines recommend correcting ionized hypocalcemia in patients with septic shock even in the absence of clinical manifestations of hypocalcemia (eg, seizures, cardiac arrhythmias) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/33/4634/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19450206\">",
"    <span class=\"h2\">",
"     Intravenous fluid therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relative intravascular hypovolemia is common in septic shock (due to vasodilation and capillary leak) and may be severe. Observational evidence suggests that vigorous fluid resuscitation may have a major role in preventing end-organ damage and improving survival. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=see_link&amp;anchor=H1783287#H1783287\">",
"     \"Initial management of shock in children\", section on 'Benefits'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, guidelines emphasize rapid restoration of intravascular volume when treating children with septic shock as follows (",
"    <a class=\"graphic graphic_algorithm graphicRef80923 \" href=\"UTD.htm?28/36/29255\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef65304 \" href=\"UTD.htm?14/27/14770\">",
"     algorithm 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4634/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Rapid intravenous (IV) access",
"      </strong>",
"      &ndash; IV access (preferably two sites and of the largest caliber that can be reliably inserted) should be established within five minutes. If a peripheral IV cannot be obtained in this time, guidelines advise placement of an intraosseous needle. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8057?source=see_link&amp;anchor=H4#H4\">",
"       \"Vascular (venous) access for pediatric resuscitation and other pediatric emergencies\", section on 'Peripheral access'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40761?source=see_link&amp;anchor=H3#H3\">",
"       \"Intraosseous infusion\", section on 'Indications'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40761?source=see_link&amp;anchor=H17935746#H17935746\">",
"       \"Intraosseous infusion\", section on 'Fluid and drug administration'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Initial IV fluid bolus",
"      </strong>",
"      &ndash; In resource-rich settings and when not contraindicated by comorbidities (eg, severe anemia, diabetic ketoacidosis, heart failure, severe malnutrition), initial therapy should begin with a bolus of 20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of isotonic crystalloid solution (ie, 0.9 percent normal saline or lactated Ringer solution) infused over five minutes or as rapidly as possible, preferably with a manual &ldquo;push-pull&rdquo; technique or rapid infuser. After the initial infusion, the child should be quickly reassessed for signs of inadequate end-organ perfusion to determine if additional fluid is needed (see",
"      <a class=\"local\" href=\"#H19451408\">",
"       'Inadequate tissue perfusion'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=see_link&amp;anchor=H1783323#H1783323\">",
"       \"Initial management of shock in children\", section on 'Risks'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Repeated IV fluid bolus",
"      </strong>",
"      &ndash; Repeated 20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      fluid boluses should be given until tissue perfusion, oxygen delivery, and blood pressure are adequate, or signs of fluid overload (rales, gallop rhythm, enlarged liver) develop. Experience suggests that patients may require volumes of 60",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      or more in the first hour and up to",
"      <span class=\"nowrap\">",
"       120mL/kg",
"      </span>",
"      or more during the first several hours of fluid administration [",
"      <a class=\"abstract\" href=\"UTD.htm?4/33/4634/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Establish ongoing monitoring of tissue perfusion",
"      </strong>",
"      &ndash; Once effective circulating volume has been restored, ongoing fluid requirements are guided by monitoring of tissue perfusion, including capillary refill time; urine output; serial blood lactate levels; and, if available and appropriate, measurement of radial arterial blood pressure, central venous pressure, and central venous oxygen saturation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13354?source=see_link&amp;anchor=H18270340#H18270340\">",
"       \"Septic shock: Ongoing management after resuscitation in children\", section on 'Ongoing and invasive monitoring'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Other fluids",
"      </strong>",
"      &ndash; The use of colloid for fluid resuscitation for children with septic shock is controversial. Nevertheless, colloid infusion with albumin 5 percent is a reasonable option for children who have not improved following &gt;60",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of crystalloid fluid, have hypoalbuminemia (albumin &lt;3",
"      <span class=\"nowrap\">",
"       g/dL),",
"      </span>",
"      or who develop a hyperchloremic metabolic acidosis. Although the findings are not consistent and multiple preparations are available, synthetic colloids, such as hydroxethylstarch solutions, have been shown to increase the risk of acute kidney injury, coagulopathy, and death in adults with severe sepsis or septic shock, especially with administered volumes &gt;15",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      and should be",
"      <strong>",
"       avoided",
"      </strong>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=see_link&amp;anchor=H5#H5\">",
"       \"Treatment of hypovolemia (dehydration) in children\", section on 'Crystalloid versus colloid'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=see_link&amp;anchor=H10#H10\">",
"       \"Evaluation and management of severe sepsis and septic shock in adults\", section on 'Intravenous fluids'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Preliminary evidence in one small pediatric trial suggests that administration of hypertonic saline may achieve hemodynamic stability with a lower volume of fluid, but its impact on other outcomes relative to normal saline are uncertain [",
"      <a class=\"abstract\" href=\"UTD.htm?4/33/4634/abstract/31\">",
"       31",
"      </a>",
"      ]; thus, we do",
"      <strong>",
"       not",
"      </strong>",
"      advocate use of hypertonic saline outside of an experimental protocol.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7455743\">",
"    <span class=\"h3\">",
"     Resource-limited settings",
"    </span>",
"    &nbsp;&mdash;&nbsp;In resource-limited settings, fluid resuscitation according to emergency triage assessment and treatment guidelines developed by the World Health organization is suggested for children with signs of shock. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=see_link&amp;anchor=H12495758#H12495758\">",
"     \"Initial management of shock in children\", section on 'Resource limited settings'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In resource-limited settings that cannot provide advanced airway and circulatory support, children with signs of shock and severe febrile illness but",
"    <strong>",
"     without",
"    </strong>",
"    dehydration or hemorrhage who receive rapid bolus administration of albumin or normal saline may have increased mortality. Thus, rapid fluid infusion according to the American College of Critical Care Medicine as described above should be",
"    <strong>",
"     avoided",
"    </strong>",
"    in this special population of patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=see_link&amp;anchor=H1783323#H1783323\">",
"     \"Initial management of shock in children\", section on 'Risks'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9034264\">",
"    <span class=\"h2\">",
"     Initial antimicrobial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous antimicrobial therapy should be initiated immediately after obtaining appropriate cultures with the goal of completing administration within one hour of presentation. Each hour delay in antibiotic administration has been associated with an approximately 8 percent increase in mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4634/abstract/32\">",
"     32",
"    </a>",
"    ]. In patients in septic shock, effective delivery of antimicrobials usually requires two ports or sites for intravenous access: one devoted to fluid resuscitation and one for antimicrobial delivery. Antimicrobials should",
"    <strong>",
"     not",
"    </strong>",
"    be withheld for children in whom lumbar puncture cannot be performed safely due to hemodynamic instability or coagulopathy (",
"    <a class=\"graphic graphic_algorithm graphicRef74865 \" href=\"UTD.htm?34/44/35521\">",
"     algorithm 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The choice of antimicrobials can be complex and should consider the child's age, history, comorbidities, clinical syndrome, Gram stain data, and local resistance patterns. Consultation with an expert in pediatric infectious disease is strongly encouraged for all children with septic shock.",
"   </p>",
"   <p>",
"    General principles for initial antimicrobial coverage for children who are critically ill with sepsis include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All children with septic shock should receive coverage for methicillin-resistant Staphylococcus aureus (MRSA).",
"     </li>",
"     <li>",
"      Coverage for enteric organisms should be added whenever clinical features suggest genitourinary (GU)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      gastrointestinal (GI) sources (eg, perforated appendicitis or bacterial overgrowth in a child with short gut syndrome).",
"     </li>",
"     <li>",
"      Treatment for Pseudomonas species should be included for children who are immunosuppressed or at risk for infection with these organisms (ie, those with cystic fibrosis).",
"     </li>",
"     <li>",
"      Listeria monocytogenes and herpes simplex virus are important pathogens in infants &le;28 days of age.",
"     </li>",
"     <li>",
"      When treating empirically, antibiotics which can be given by rapid intravenous bolus (eg, beta-lactam agents or cephalosporins) should be administered first followed by infusions of antibiotics, such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"       vancomycin",
"      </a>",
"      , that must be delivered more slowly.",
"     </li>",
"     <li>",
"      Ongoing antimicrobial therapy should be modified based upon culture results, including antimicrobial susceptibility and the patient&rsquo;s clinical course.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Suggested initial empiric antimicrobial regimens based upon patient age, level of immunocompetence, and previous antibiotic administration include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Children &gt;28 days of age who are normal hosts",
"      </strong>",
"      :",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"       Vancomycin",
"      </a>",
"      (15",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      maximum 1 to 2 g, for the initial dose)",
"     </li>",
"     <li>",
"      PLUS",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/23/40310?source=see_link\">",
"       cefotaxime",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      maximum 2 g, for the initial dose) OR",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      (75",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      maximum 2 g, for the initial dose)",
"     </li>",
"     <li>",
"      Consider adding an aminoglycoside (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/48/37632?source=see_link\">",
"       gentamicin",
"      </a>",
"      ) for possible GU source",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/10/33956?source=see_link\">",
"       piperacillin",
"      </a>",
"      with tazobactam,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"       clindamycin",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/59/21425?source=see_link\">",
"       metronidazole",
"      </a>",
"      for possible GI source",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Children &gt;28 days who are immunosuppressed or at risk for infection with Pseudomonas species",
"      </strong>",
"      :",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"       Vancomycin",
"      </a>",
"      (15",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      maximum 1 to 2 g, for the initial dose)",
"     </li>",
"     <li>",
"      PLUS",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/9/12438?source=see_link\">",
"       cefepime",
"      </a>",
"      (50",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      maximum 2 g, for the initial dose) OR",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/4/14405?source=see_link\">",
"       ceftazidime",
"      </a>",
"      (50",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      maximum 2 g, for the initial dose)",
"     </li>",
"     <li>",
"      PLUS an aminoglycoside (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/48/37632?source=see_link\">",
"       gentamicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/43/12984?source=see_link\">",
"       amikacin",
"      </a>",
"      ) or carbapenem (eg, imipenem,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/24/2439?source=see_link\">",
"       meropenem",
"      </a>",
"      ) in settings where bacterial organisms with extended-spectrum beta-lactamase (ESBL) resistance are prevalent. For patients who have been recently (within two weeks) treated broad-spectrum antibiotics (eg, third-generation cephalosporin, aminoglycoside, or fluoroquinolone), the addition of a carbapenem is favored over an aminoglycoside.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Children who cannot receive penicillin or who have recently received broad-spectrum antibiotics",
"      </strong>",
"      :",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"       Vancomycin",
"      </a>",
"      (age appropriate dose)",
"     </li>",
"     <li>",
"      PLUS",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/24/2439?source=see_link\">",
"       Meropenem",
"      </a>",
"      (&lt;3 months: 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      for the initial dose, &ge;3 months: 20",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      maximum 2 g, for the initial dose)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/25/1430?source=see_link\">",
"       Aztreonam",
"      </a>",
"      OR",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/15/38128?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      PLUS",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"       clindamycin",
"      </a>",
"      may be used instead of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/24/2439?source=see_link\">",
"       meropenem",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Patients at increased risk of fungal infection",
"      </strong>",
"      (eg, identified fungal source, immunocompromised with persistent fever on broad spectrum antibiotics)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Add",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/3/31799?source=see_link\">",
"       liposomal Amphotericin B",
"      </a>",
"      or an echinocandin (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/47/21237?source=see_link\">",
"       caspofungin",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/29/9686?source=see_link\">",
"       micafungin",
"      </a>",
"      ) to the antimicrobial regimen [",
"      <a class=\"abstract\" href=\"UTD.htm?4/33/4634/abstract/33\">",
"       33",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Patients with risk factors for rickettsial infection",
"      </strong>",
"      (eg, travel to or reside in an endemic region):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Add a",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/38/28262?source=see_link\">",
"       tetracycline",
"      </a>",
"      antibiotic (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/54/12136?source=see_link\">",
"       doxycycline",
"      </a>",
"      ) to the antimicrobial regimen",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Infants 0 to 28 days of age",
"      </strong>",
"      :",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"       Vancomycin",
"      </a>",
"      (15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      for the initial dose)",
"     </li>",
"     <li>",
"      PLUS",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/23/40310?source=see_link\">",
"       cefotaxime",
"      </a>",
"      (50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      for the initial dose)",
"     </li>",
"     <li>",
"      PLUS",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/48/37632?source=see_link\">",
"       gentamicin",
"      </a>",
"      (2.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      for the initial dose)",
"     </li>",
"     <li>",
"      PLUS",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"       ampicillin",
"      </a>",
"      (50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      for the initial dose)",
"     </li>",
"     <li>",
"      Add",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/38/34400?source=see_link\">",
"       acyclovir",
"      </a>",
"      (20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per dose) for suspicion of HSV infection",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For neonates with clinical features concerning for herpes simplex virus (HSV) infection who may receive",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    , viral cultures of vesicles if present, cerebrospinal fluid and surface (mouth, nasopharynx, eye, and anus can be obtained from one swab ending with the anal swab) and polymerase chain reaction testing (from cerebrospinal fluid and blood) for HSV should be obtained whenever possible. Concerning clinical features include family members with HSV infection, respiratory collapse, elevated transaminases, thrombocytopenia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    abnormal cerebrospinal fluid suggestive of HSV infection (",
"    <a class=\"graphic graphic_table graphicRef66525 \" href=\"UTD.htm?18/25/18845\">",
"     table 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/31/35321?source=see_link&amp;anchor=H4#H4\">",
"     \"Neonatal herpes simplex virus infection: Clinical features and diagnosis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19450213\">",
"    <span class=\"h2\">",
"     Fluid-refractory shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasoactive agents are frequently necessary in the initial resuscitation of children with septic shock to sustain perfusion pressure while hypovolemia is corrected. Based upon expert opinion, the American College of Critical Care Medicine guidelines suggest the initiation of vasoactive therapy in children with septic shock who have not improved after 40 to 60",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of isotonic crystalloid along with continued fluid administration [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4634/abstract/8\">",
"     8",
"    </a>",
"    ]. Although central venous access is preferred for vasopressor administration (eg, dopamine, epinephrine,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/48/25348?source=see_link\">",
"     dobutamine",
"    </a>",
"    , or norepinephrine), peripheral intravenous (IV) access or intraosseous needle is acceptable while central venous access is being obtained. The initial choice of vasoactive agents is guided by physical findings [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4634/abstract/8,34\">",
"     8,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6410106\">",
"    <span class=\"h3\">",
"     Cold shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American College of Critical Care Medicine (ACCM) guidelines suggest that patients with cold shock (eg, poor perfusion, cold extremities) that do not respond to initial boluses of 40 to 60",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of fluid receive dopamine infusions (starting dose 5",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per minute, titrate to response up to 10",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per minute) (",
"    <a class=\"graphic graphic_algorithm graphicRef80923 \" href=\"UTD.htm?28/36/29255\">",
"     algorithm 1",
"    </a>",
"    )[",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4634/abstract/8\">",
"     8",
"    </a>",
"    ]. At lower doses, dopamine improves splanchnic and renal blood flow and, at higher doses, it provides both inotropic and vasopressor support. Unlike adults, dopamine is still a first-line agent in children because of its wide availability and practitioner familiarity, and no evidence has correlated dopamine use with increased mortality in children with septic shock. However, infants younger than one year of age may be less responsive to dopamine [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4634/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of note, in the Pediatric Advanced Life Support guidelines, low-dose dopamine is suggested for patients with septic shock but normal blood pressures and epinephrine is suggested for patients with cold shock (",
"    <a class=\"graphic graphic_algorithm graphicRef65304 \" href=\"UTD.htm?14/27/14770\">",
"     algorithm 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4634/abstract/9\">",
"     9",
"    </a>",
"    ]. No trials have directly compared dopamine to epinephrine for the treatment of cold shock in children. Thus, the optimal approach is debated and awaits further study.",
"   </p>",
"   <p>",
"    If cold shock is resistant to dopamine infusion at a dose of 10",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per minute, epinephrine infusion at a rate between 0.05 to 0.3",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per minute may be added [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4634/abstract/8\">",
"     8",
"    </a>",
"    ]. At doses exceeding 0.1",
"    <span class=\"nowrap\">",
"     mcg/kg/minute",
"    </span>",
"    (and possibly lower in some patients), alpha-adrenergic effects of epinephrine are more pronounced and systemic vasoconstriction may be more evident. Examples of how to prepare an epinephrine infusion for a 10 kg or 20 kg child are provided in the tables (",
"    <a class=\"graphic graphic_table graphicRef56049 \" href=\"UTD.htm?2/18/2350\">",
"     table 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef66791 \" href=\"UTD.htm?39/39/40573\">",
"     table 8",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6410114\">",
"    <span class=\"h3\">",
"     Warm shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with warm shock (eg, bounding pulses, pink extremities, and &ldquo;flash&rdquo; capillary refill) the American College of Critical Care Medicine and Pediatric Advanced Life Support guidelines suggest norepinephrine infusion starting at 0.03 to 0.05",
"    <span class=\"nowrap\">",
"     mcg/kg/minute",
"    </span>",
"    as the first-line drug (",
"    <a class=\"graphic graphic_algorithm graphicRef80923 \" href=\"UTD.htm?28/36/29255\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef65304 \" href=\"UTD.htm?14/27/14770\">",
"     algorithm 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4634/abstract/8\">",
"     8",
"    </a>",
"    ]. If dopamine infusion has already been started then norepinephrine can be added to dopamine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6282460\">",
"    <span class=\"h2\">",
"     Corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who persist with shock in spite of rapid fluid administration and continuous infusions of epinephrine or norepinephrine may have adrenal insufficiency. Risk factors include purpura fulminans, recent or chronic treatment with corticosteroids, hypothalamic or pituitary abnormalities, or adrenal insufficiency (congenital or acquired). When adrenal insufficiency is suspected, administration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    in stress doses",
"    <span class=\"nowrap\">",
"     (50mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"    </span>",
"    or 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, intermittent or continuous infusion, maximum dose 50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) is suggested [",
"    <a class=\"abstract\" href=\"UTD.htm?4/33/4634/abstract/8\">",
"     8",
"    </a>",
"    ]. Although evidence is lacking regarding the best method to identify adrenal insufficiency in children with refractory septic shock, assessment of adrenal status (either baseline serum cortisol or adrenocorticotropin hormone stimulation testing) is advised prior to corticosteroid administration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13354?source=see_link&amp;anchor=H18270403#H18270403\">",
"     \"Septic shock: Ongoing management after resuscitation in children\", section on 'Address adrenal insufficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10636681\">",
"    <span class=\"h2\">",
"     Transfer to definitive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;After resuscitation, children with septic shock should be managed by clinicians with pediatric critical care expertise in a setting that has the necessary resources to provide pediatric intensive care. Children with septic shock who present to facilities without the necessary clinical expertise or resources should undergo timely transfer to an appropriate facility. Use of a pediatric specialized team is associated with improved patient survival and fewer adverse effects during transport. Thus, the use of pediatric specialized teams for transport of children with septic shock is recommended whenever it is available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/59/26553?source=see_link&amp;anchor=H10751377#H10751377\">",
"     \"Prehospital pediatrics and emergency medical services (EMS)\", section on 'Inter-facility transport'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19450291\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A clinical diagnosis of septic shock is made in children who have signs of inadequate tissue perfusion, two or more criteria for the systemic inflammatory response syndrome (",
"      <a class=\"graphic graphic_table graphicRef86087 \" href=\"UTD.htm?26/36/27212\">",
"       table 1",
"      </a>",
"      ), and suspected or proven infection. (See",
"      <a class=\"local\" href=\"#H19451395\">",
"       'Rapid recognition'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10346?source=see_link&amp;anchor=H1374240#H1374240\">",
"       \"Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      All patients with septic shock should initially receive 100 percent supplemental oxygen to optimize blood oxygen content and, thus, oxygen delivery to tissues. Once adequate perfusion has been restored, supplemental oxygen should be titrated to avoid oxygen saturation by pulse oximetry of greater than 97 percent to prevent the adverse effects associated with hyperoxia and free radical generation (eg, lung injury and microcirculatory vasoconstriction). (See",
"      <a class=\"local\" href=\"#H19450192\">",
"       'Airway and breathing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endotracheal intubation using rapid sequence intubation (RSI) is frequently necessary in children with septic shock to protect the airway, assist with ventilation,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      promote oxygenation. When performing RSI in children with septic shock,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"       ketamine",
"      </a>",
"      , if available and",
"      <strong>",
"       not",
"      </strong>",
"      contraindicated, is preferable for sedation prior to endotracheal intubation.",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"       Etomidate",
"      </a>",
"      should",
"      <strong>",
"       not",
"      </strong>",
"      be used routinely in patients with septic shock. A rapid overview of RSI in children is provided in the table (",
"      <a class=\"graphic graphic_table graphicRef51456 \" href=\"UTD.htm?17/26/17837\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19450192\">",
"       'Airway and breathing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that children with septic shock receive treatment according to the American College of Critical Care Medicine (ACCM) guidelines including goal-directed therapy which provides a systematic approach to resuscitation of septic shock targeted to specific improvements in physiologic indicators of perfusion and vital organ function (",
"      <a class=\"graphic graphic_algorithm graphicRef80923 \" href=\"UTD.htm?28/36/29255\">",
"       algorithm 1",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For children in resource-rich settings, rapid infusion of isotonic fluid (eg, normal saline) and early administration of empiric broad-spectrum antimicrobial therapy are essential actions. (See",
"      <a class=\"local\" href=\"#H6411279\">",
"       'Early goal-directed therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6411955\">",
"       'Physiologic indicators and target goals'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19450185\">",
"       'Resuscitation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The American College of Critical Care Medicine guidelines suggest the initiation of vasoactive therapy in children with septic shock who have not improved after 40 to 60",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of isotonic crystalloid along with continued fluid administration. Specific vasopressor agents (eg, dopamine, epinephrine, or norepinephrine) are given based upon whether the patient has clinical findings of cold or warm shock. (See",
"      <a class=\"local\" href=\"#H19450213\">",
"       'Fluid-refractory shock'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who persist with shock in spite of rapid fluid administration and continuous infusions of epinephrine or norepinephrine may have adrenal insufficiency. When adrenal insufficiency is suspected, administration of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      in stress doses (50 to 100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       /day",
"      </span>",
"      or 1 to 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, intermittent or continuous infusion, maximum dose 50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) is suggested [",
"      <a class=\"abstract\" href=\"UTD.htm?4/33/4634/abstract/8\">",
"       8",
"      </a>",
"      ]. Assessment of adrenal status (either baseline serum cortisol or adrenocorticotropin hormone stimulation testing) is advised prior to corticosteroid administration. (See",
"      <a class=\"local\" href=\"#H6282460\">",
"       'Corticosteroids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After initial resuscitation, ongoing aggressive management of septic shock should continue according to the principles of goal-directed therapy for children in whom adequate circulation has not been restored (",
"      <a class=\"graphic graphic_algorithm graphicRef80923 \" href=\"UTD.htm?28/36/29255\">",
"       algorithm 1",
"      </a>",
"      ). This care should be provided by clinicians with pediatric critical care expertise in a setting that has the necessary resources to provide pediatric intensive care. (See",
"      <a class=\"local\" href=\"#H10636681\">",
"       'Transfer to definitive care'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13354?source=see_link\">",
"       \"Septic shock: Ongoing management after resuscitation in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4634/abstract/1\">",
"      Goldstein B, Giroir B, Randolph A, International Consensus Conference on Pediatric Sepsis. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 2005; 6:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4634/abstract/2\">",
"      Odetola FO, Gebremariam A, Freed GL. Patient and hospital correlates of clinical outcomes and resource utilization in severe pediatric sepsis. Pediatrics 2007; 119:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4634/abstract/3\">",
"      Watson RS, Carcillo JA, Linde-Zwirble WT, et al. The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med 2003; 167:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4634/abstract/4\">",
"      Han YY, Carcillo JA, Dragotta MA, et al. Early reversal of pediatric-neonatal septic shock by community physicians is associated with improved outcome. Pediatrics 2003; 112:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4634/abstract/5\">",
"      Weiss SL, Parker B, Bullock ME, et al. Defining pediatric sepsis by different criteria: discrepancies in populations and implications for clinical practice. Pediatr Crit Care Med 2012; 13:e219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4634/abstract/6\">",
"      Jaramillo-Bustamante JC, Mar&iacute;n-Agudelo A, Fern&aacute;ndez-Laverde M, Bare&ntilde;o-Silva J. Epidemiology of sepsis in pediatric intensive care units: first Colombian multicenter study. Pediatr Crit Care Med 2012; 13:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4634/abstract/7\">",
"      Kutko MC, Glick RD, Butler LM, et al. Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro. Clin Cancer Res 2003; 9:5749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4634/abstract/8\">",
"      Brierley J, Carcillo JA, Choong K, et al. Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine. Crit Care Med 2009; 37:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4634/abstract/9\">",
"      Kleinman ME, de Caen AR, Chameides L, et al. Pediatric basic and advanced life support: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations. Pediatrics 2010; 126:e1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4634/abstract/10\">",
"      Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4634/abstract/11\">",
"      Dugas MA, Proulx F, de Jaeger A, et al. Markers of tissue hypoperfusion in pediatric septic shock. Intensive Care Med 2000; 26:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4634/abstract/12\">",
"      Nguyen HB, Rivers EP, Knoblich BP, et al. Early lactate clearance is associated with improved outcome in severe sepsis and septic shock. Crit Care Med 2004; 32:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4634/abstract/13\">",
"      Arnold RC, Shapiro NI, Jones AE, et al. Multicenter study of early lactate clearance as a determinant of survival in patients with presumed sepsis. Shock 2009; 32:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4634/abstract/14\">",
"      Velissaris D, Pierrakos C, Scolletta S, et al. High mixed venous oxygen saturation levels do not exclude fluid responsiveness in critically ill septic patients. Crit Care 2011; 15:R177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4634/abstract/15\">",
"      Fink MP. Bench-to-bedside review: Cytopathic hypoxia. Crit Care 2002; 6:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4634/abstract/16\">",
"      Dueck MH, Klimek M, Appenrodt S, et al. Trends but not individual values of central venous oxygen saturation agree with mixed venous oxygen saturation during varying hemodynamic conditions. Anesthesiology 2005; 103:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4634/abstract/17\">",
"      de Oliveira CF, de Oliveira DS, Gottschald AF, et al. ACCM/PALS haemodynamic support guidelines for paediatric septic shock: an outcomes comparison with and without monitoring central venous oxygen saturation. Intensive Care Med 2008; 34:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4634/abstract/18\">",
"      Booy R, Habibi P, Nadel S, et al. Reduction in case fatality rate from meningococcal disease associated with improved healthcare delivery. Arch Dis Child 2001; 85:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4634/abstract/19\">",
"      Maat M, Buysse CM, Emonts M, et al. Improved survival of children with sepsis and purpura: effects of age, gender, and era. Crit Care 2007; 11:R112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4634/abstract/20\">",
"      Asfar P, Calzia E, Huber-Lang M, et al. Hyperoxia during septic shock--Dr. Jekyll or Mr. Hyde? Shock 2012; 37:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4634/abstract/21\">",
"      den Brinker M, Joosten KF, Liem O, et al. Adrenal insufficiency in meningococcal sepsis: bioavailable cortisol levels and impact of interleukin-6 levels and intubation with etomidate on adrenal function and mortality. J Clin Endocrinol Metab 2005; 90:5110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4634/abstract/22\">",
"      Menon K, Ward RE, Lawson ML, et al. A prospective multicenter study of adrenal function in critically ill children. Am J Respir Crit Care Med 2010; 182:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4634/abstract/23\">",
"      den Brinker M, Hokken-Koelega AC, Hazelzet JA, et al. One single dose of etomidate negatively influences adrenocortical performance for at least 24h in children with meningococcal sepsis. Intensive Care Med 2008; 34:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4634/abstract/24\">",
"      Sanchez GJ, Venkataraman PS, Pryor RW, et al. Hypercalcitoninemia and hypocalcemia in acutely ill children: studies in serum calcium, blood ionized calcium, and calcium-regulating hormones. J Pediatr 1989; 114:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4634/abstract/25\">",
"      Zaloga GP, Chernow B. The multifactorial basis for hypocalcemia during sepsis. Studies of the parathyroid hormone-vitamin D axis. Ann Intern Med 1987; 107:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4634/abstract/26\">",
"      M&uuml;ller B, Becker KL, Kr&auml;nzlin M, et al. Disordered calcium homeostasis of sepsis: association with calcitonin precursors. Eur J Clin Invest 2000; 30:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4634/abstract/27\">",
"      Kovacs A, Courtois MR, Barzilai B, et al. Reversal of hypocalcemia and decreased afterload in sepsis. Effect on myocardial systolic and diastolic function. Am J Respir Crit Care Med 1998; 158:1990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4634/abstract/28\">",
"      Porcelli PJ Jr, Oh W. Effects of single dose calcium gluconate infusion in hypocalcemic preterm infants. Am J Perinatol 1995; 12:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4634/abstract/29\">",
"      Forsythe RM, Wessel CB, Billiar TR, et al. Parenteral calcium for intensive care unit patients. Cochrane Database Syst Rev 2008; :CD006163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4634/abstract/30\">",
"      Carcillo JA, Davis AL, Zaritsky A. Role of early fluid resuscitation in pediatric septic shock. JAMA 1991; 266:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4634/abstract/31\">",
"      Chopra A, Kumar V, Dutta A. Hypertonic versus normal saline as initial fluid bolus in pediatric septic shock. Indian J Pediatr 2011; 78:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4634/abstract/32\">",
"      Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/33/4634/abstract/33\">",
"      Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503.",
"     </a>",
"    </li>",
"    <li>",
"     Pediatric Advanced Life Support Provider Manual, Ralston M.  (Ed), American Heart Association, Subcommittee on Pediatric Resuscitation, Dallas 2006. p.102.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 85767 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.172.26-C9598D4138-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_33_4634=[""].join("\n");
var outline_f4_33_4634=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19450291\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19451388\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25706214\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19451395\">",
"      RAPID RECOGNITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19451408\">",
"      Inadequate tissue perfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19451420\">",
"      Signs of infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19451427\">",
"      Suggestive laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6411955\">",
"      PHYSIOLOGIC INDICATORS AND TARGET GOALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19450185\">",
"      RESUSCITATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6411279\">",
"      Early goal-directed therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19450192\">",
"      Airway and breathing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2984154\">",
"      Treat hypoglycemia and hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19450206\">",
"      Intravenous fluid therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7455743\">",
"      - Resource-limited settings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9034264\">",
"      Initial antimicrobial therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19450213\">",
"      Fluid-refractory shock",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6410106\">",
"      - Cold shock",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6410114\">",
"      - Warm shock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6282460\">",
"      Corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10636681\">",
"      Transfer to definitive care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19450291\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/85767\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/85767|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?28/36/29255\" title=\"algorithm 1\">",
"      Pediatric sepsis management guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?14/27/14770\" title=\"algorithm 2\">",
"      Pediatric algorithm for septic shock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?34/44/35521\" title=\"algorithm 3\">",
"      Management of suspected meningitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/85767|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/36/27212\" title=\"table 1\">",
"      Pediatric systemic inflammatory response syndrome criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/26/2477\" title=\"table 2\">",
"      Evaluation of sources of sepsis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/37/28252\" title=\"table 3\">",
"      Normal respiratory rate and heart rate in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/26/17837\" title=\"table 4\">",
"      Rapid overview of rapid sequence intubation in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/43/32446\" title=\"table 5\">",
"      Rapid overview for hypoglycemia in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/25/18845\" title=\"table 6\">",
"      CSF patterns viral meningitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/18/2350\" title=\"table 7\">",
"      Example of epinephrine infusion - pediatric 10 kg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/39/40573\" title=\"table 8\">",
"      Example of epinephrine infusion - pediatric 20 kg",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=related_link\">",
"      Basic airway management in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27014?source=related_link\">",
"      Continuous oxygen delivery systems for infants, children, and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8697?source=related_link\">",
"      Disseminated intravascular coagulation in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=related_link\">",
"      Emergent endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=related_link\">",
"      Initial management of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40761?source=related_link\">",
"      Intraosseous infusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/31/35321?source=related_link\">",
"      Neonatal herpes simplex virus infection: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/59/26553?source=related_link\">",
"      Prehospital pediatrics and emergency medical services (EMS)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=related_link\">",
"      Rapid sequence intubation (RSI) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/30/11754?source=related_link\">",
"      Sedation or induction agents for rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13354?source=related_link\">",
"      Septic shock: Ongoing management after resuscitation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10346?source=related_link\">",
"      Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=related_link\">",
"      Treatment of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8057?source=related_link\">",
"      Vascular (venous) access for pediatric resuscitation and other pediatric emergencies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_33_4635="Potency of treatment for GERD";
var content_f4_33_4635=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F72132&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F72132&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Therapeutic regimens for GERD in order of increasing potency*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Over-the-counter antacids and/or H2 receptor blockers",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Prescription H2-blockers (twice daily)&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Intermittent (2 weeks) use of a PPI",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Omeprazole (20 mg daily) or equivalent dose of the other PPIs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Omeprazole (20 mg twice daily or 40 mg daily) or equivalent doses of the other PPIs",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Regardless of the potency of pharmacologic therapy, the patient should be counseled on lifestyle and dietary modifications.",
"     <br>",
"      &bull; Prescription H2 blockers should be prescribed in the ulcer dose; doubling the dose in a BID regimen has not been shown to be superior in the treatment of GERD.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_33_4635=[""].join("\n");
var outline_f4_33_4635=null;
var title_f4_33_4636="Differential diagnosis of PID";
var content_f4_33_4636=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F59205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F59205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of pelvic inflammatory disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Adenomyosis uteri",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adnexal torsion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Appendicitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cervicitis (herpetic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Crohn's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cystitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Degenerating myoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diverticulitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ectopic pregnancy*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endometriosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extruding myoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Functional pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Genital trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infectious proctitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Irritable bowel syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lead intoxication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lupus serositis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meckel's diverticulum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mesenteric lymphadenitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mesenteric vascular disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ovarian tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ovulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pelvic adhesive disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rupture of teratoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sickle crisis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ulcerative colitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urolithiasis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Ectopic pregnancy must be excluded with a pregnancy test in any woman suspected of having pelvic inflammatory disease.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_33_4636=[""].join("\n");
var outline_f4_33_4636=null;
var title_f4_33_4637="Domains of development";
var content_f4_33_4637=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77685&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77685&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Domains of development*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Domain",
"       </td>",
"       <td class=\"subtitle1\">",
"        Description",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        <strong>",
"         Cognitive",
"        </strong>",
"        (intellectual)",
"       </td>",
"       <td>",
"        Problem solving skills",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rate of learning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Short- and long-term memory for what a child has seen, heard, and learned, including sequences required to complete tasks (including executive functioning skills, such as organization, attention, and processing speed)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Language",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Expressive language",
"       </td>",
"       <td>",
"        Ability to communicate and be understood by others, including facility with articulation of sounds and the pragmatic skills of maintaining a conversation that embraces the listener's perspective and interests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ability to speak using correct grammar",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Receptive language",
"       </td>",
"       <td>",
"        Ability to understand words, commands, sentences, and passages when heard",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Motor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gross motor",
"       </td>",
"       <td>",
"        Use of large muscles in the neck, arms, legs, back, and torso to move around effectively",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fine motor",
"       </td>",
"       <td>",
"        Use of hands, fingers, and wrists to execute refined tasks, such as eating with utensils, drawing, writing, and eventually using tools like scissors, keyboards, etc",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        <strong>",
"         Pre-academic/academic",
"        </strong>",
"       </td>",
"       <td>",
"        Knowledge of shapes, colors, and eventually numbers and letter names, words in print, comprehension of written words and passages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ability to write and spell words independently; understand time and money concepts and complete mathematical calculations; and eventually to express thoughts in writing",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Self-help",
"        </strong>",
"        (adaptive behavior or personal-social)",
"       </td>",
"       <td>",
"        Skills necessary for hygiene, dressing, and eventually household maintenance, cooking, cleaning, navigating neighborhoods, etc",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        <strong>",
"         Behavior",
"        </strong>",
"       </td>",
"       <td>",
"        Willingness to comply with rules when asked and eventually to understand why complying with rules is wise",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age-appropriate ability to be still long enough to attend to the tasks at hand",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age-appropriate attention span to facilitate the ability to take in new information",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"6\">",
"        <strong>",
"         Social-emotional/mental health",
"        </strong>",
"       </td>",
"       <td>",
"        Sense of well-being and self-esteem (eg, a positive outlook on life with an increasingly realistic sense of own strengths and weaknesses)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Relating to siblings, parents, friends, and close relatives, ideally with joy and affection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Emerging respect for others, including their well-being and property",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Awareness and empathy for others",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adjusting to life's challenges and learning to regulate and cope with difficult emotions like anger, disappointment, sadness, etc",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Incorporating social-emotional understanding into behavior so as to develop increasingly age-appropriate self-discipline",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Development is a series of domains, each capturing different kinds of skills.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_33_4637=[""].join("\n");
var outline_f4_33_4637=null;
var title_f4_33_4638="Contents: Psychotic disorders";
var content_f4_33_4638=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Psychotic disorders",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Psychotic disorders",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Antipsychotic medications",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/24/7562\">",
"           First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/40/6793\">",
"           Guidelines for prescribing clozapine in schizophrenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/9/30871\">",
"           Pharmacotherapy for schizophrenia: Long-acting injectable antipsychotic drugs",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/10/15530\">",
"           Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/4/3145\">",
"           Delusional parasitosis: Epidemiology, clinical presentation, assessment and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/58/28583\">",
"           Overview of psychosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/39/17014\">",
"           Postpartum psychosis: Epidemiology, clinical manifestations, and assessment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/34/1575\">",
"           Treatment of delusional parasitosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/62/29670\">",
"           Treatment of postpartum psychosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Schizophrenia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/3/2105\">",
"           Anxiety in schizophrenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/21/25944\">",
"           Depression in schizophrenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/35/29241\">",
"           Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/45/44760\">",
"           Pharmacotherapy for schizophrenia: Side effect management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/44/8904\">",
"           Psychosocial interventions for schizophrenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/15/1270\">",
"           Psychosocial interventions for severe mental illness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/47/34552\">",
"           Schizophrenia: Clinical manifestations, course, assessment, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/37/20057\">",
"           Schizophrenia: Epidemiology and pathogenesis",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-636855AA96-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f4_33_4638=[""].join("\n");
var outline_f4_33_4638=null;
var title_f4_33_4639="Grade III nipple inversion";
var content_f4_33_4639=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F76984&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F76984&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Grade III nipple inversion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In Grade III nipple inversion, there is no projection of the nipple and the papilla is buried below the level of the skin. Despite maximal manipulation, the nipple cannot be pulled out and would be described as invaginated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_33_4639=[""].join("\n");
var outline_f4_33_4639=null;
